Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0042981 regulation of apoptotic process	IBA GO_REF:0000033	ACCEPT	Summary: CLU is well-established as a regulator of apoptosis. The secreted form inhibits apoptosis via complement MAC inhibition (PMID:9200695), the intracellular form inhibits apoptosis by interacting with activated BAX at mitochondria (PMID:16113678), and isoform 4 (nCLU) promotes apoptosis via BCL2L1 interaction (UniProt). The IBA annotation to the broad term "regulation of apoptotic process" is appropriate given the dual pro- and anti-apoptotic roles of different CLU isoforms. Reason: CLU has well-documented roles in both inhibiting and promoting apoptosis depending on isoform and context. The IBA term at this level of specificity is appropriate for the phylogenetically conserved function. Supporting Evidence: PMID:16113678 intracellular clusterin inhibits apoptosis by interfering with Bax activation in mitochondria
GO:0005634 nucleus	IBA GO_REF:0000033	KEEP AS NON CORE	Summary: Nuclear localization of CLU has been reported for intracellular isoforms (isoform 4/nCLU) and under stress conditions (PMID:19137541, PMID:25051234). The predominant secreted form (isoform 1) is not nuclear. The IBA annotation is reasonable given nuclear isoforms exist across species. Multiple IDA annotations also support nuclear localization. Reason: Nuclear localization is real but represents a minor isoform (nCLU/isoform 4) or stress-related redistribution, not the predominant subcellular localization of the main secreted form. Keep as non-core. Supporting Evidence: PMID:19137541 proteasome inhibition by MG132 caused stabilization and accumulation of all CLU protein products, including the nuclear form of CLU (nCLU)
GO:0005615 extracellular space	IBA GO_REF:0000033	ACCEPT	Summary: CLU is a secreted glycoprotein that is a major constituent of the extracellular space, present in plasma, CSF, and other body fluids (PMID:2387851, PMID:11123922). This is the core localization of the predominant secreted isoform. Reason: Extracellular space is the primary site of CLU function as an extracellular chaperone and complement regulator. Well-supported by extensive literature. Supporting Evidence: PMID:11123922 Clusterin represents the first identified secreted mammalian chaperone.
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process	IBA GO_REF:0000033	KEEP AS NON CORE	Summary: PMID:20068069 demonstrated that sCLU acts as a ubiquitin-binding protein that enhances COMMD1 and I-kappaB proteasomal degradation by interacting with members of the SCF-betaTrCP E3 ligase family in prostate cancer cells. This is supported by IMP evidence from the same publication. The IBA annotation reflects a conserved intracellular function. Reason: This function is demonstrated for intracellular CLU in cancer cell context (PMID:20068069) and is not the core extracellular chaperone function. The annotation is valid but represents a secondary/intracellular activity. Supporting Evidence: PMID:20068069 sCLU increases NF-kappaB nuclear translocation and transcriptional activity by serving as a ubiquitin-binding protein that enhances COMMD1 and I-kappaB proteasomal degradation by interacting with members of the SCF-betaTrCP E3 ligase family.
GO:0051787 misfolded protein binding	IBA GO_REF:0000033	ACCEPT	Summary: Misfolded protein binding is the core molecular function of CLU as an extracellular holdase chaperone. CLU binds stressed/misfolded proteins to form soluble high molecular weight complexes and prevents their aggregation (PMID:11123922, PMID:19996109). This is the most appropriate MF term for CLU's chaperone activity. Reason: This is the most informative and accurate MF term for CLU's core function. CLU binds misfolded/stressed proteins via exposed hydrophobic surfaces, maintaining them in a soluble state. Well-supported by multiple IDA studies (PMID:11123922, PMID:19996109). Supporting Evidence: PMID:11123922 clusterin (i) inhibits stress-induced precipitation of a very broad range of structurally divergent protein substrates, (ii) binds irreversibly via an ATP-independent mechanism to stressed proteins to form solubilized high molecular weight complexes
GO:0002376 immune system process	IEA GO_REF:0000043	ACCEPT	Summary: CLU participates in immune system processes primarily through complement regulation (inhibition of MAC assembly) and immune complex clearance. The IEA term is very broad but not incorrect. Reason: CLU is a complement regulator that inhibits MAC assembly (PMID:9200695, PMID:34667172). The broad IEA annotation to "immune system process" is acceptable as a high-level summary, though more specific terms are also annotated.
GO:0005576 extracellular region	IEA GO_REF:0000044	ACCEPT	Summary: CLU is a secreted protein found in the extracellular region. This is well-established. The IEA maps correctly from UniProt subcellular location. Reason: Extracellular region is the primary localization of the predominant secreted CLU isoform. Confirmed by multiple experimental methods.
GO:0005634 nucleus	IEA GO_REF:0000120	KEEP AS NON CORE	Summary: Nuclear localization is documented for the nCLU isoform (isoform 4) and under stress/proteasome inhibition (PMID:19137541). IEA is consistent with IDA and IBA annotations to nucleus. Reason: Nuclear localization is real for minor intracellular isoforms but not the predominant secreted form.
GO:0005737 cytoplasm	IEA GO_REF:0000120	KEEP AS NON CORE	Summary: Cytoplasmic localization of CLU occurs via retrotranslocation from the ER under stress (PMID:22689054) and for intracellular isoforms. IEA is consistent with multiple IDA annotations. Reason: Cytoplasmic localization is documented but represents stress-induced or isoform-specific behavior, not the primary localization.
GO:0005739 mitochondrion	IEA GO_REF:0000120	KEEP AS NON CORE	Summary: Mitochondrial localization occurs under ER stress conditions where CLU retrotranslocates to the cytosol and redistributes to mitochondria to inhibit apoptosis (PMID:22689054, PMID:16113678). IEA is consistent with IDA evidence. Reason: Mitochondrial localization is stress-induced and relates to anti-apoptotic function of intracellular CLU, not the primary extracellular chaperone function.
GO:0005783 endoplasmic reticulum	IEA GO_REF:0000044	ACCEPT	Summary: CLU transits through the ER as part of the secretory pathway. The precursor is glycosylated in the ER. IEA mapping from UniProt is appropriate as CLU does transiently reside in the ER. Reason: CLU passes through the ER during biosynthesis. Under stress conditions, ER-resident CLU can retrotranslocate. The annotation is valid.
GO:0005829 cytosol	IEA GO_REF:0000120	KEEP AS NON CORE	Summary: Cytosolic CLU has been detected by IDA (PMID:22689054) and is associated with stress-induced retrotranslocation. IEA is consistent. Reason: Cytosolic localization is secondary, occurring under stress conditions. Not the primary localization.
GO:0006915 apoptotic process	IEA GO_REF:0000043	ACCEPT	Summary: CLU is involved in apoptotic process regulation. IEA from UniProt keyword "Apoptosis" is appropriate. CLU both inhibits (via BAX interaction, PMID:16113678) and promotes (nCLU isoform) apoptosis. Reason: IEA to the broad term "apoptotic process" is acceptable given CLU's well-documented roles in apoptosis regulation.
GO:0006958 complement activation, classical pathway	IEA GO_REF:0000043	MODIFY	Summary: CLU is a complement regulator but specifically inhibits the terminal pathway (MAC assembly) rather than activating the classical pathway. CLU inhibits C9 polymerization on C5b-8 and C5b-9 complexes (PMID:9200695). The term "complement activation, classical pathway" is misleading for CLU's function, which is inhibitory and acts on the terminal pathway. Reason: CLU does not activate the classical complement pathway. It inhibits terminal complement assembly (MAC). More appropriate terms are already annotated (GO:0001971, GO:0045916). This IEA mapping is inaccurate. Proposed replacements: negative regulation of complement activation Supporting Evidence: PMID:9200695 Clusterin inhibited at three sites and by two modes of action. Clusterin inhibited C9 assembly on C5b-8 and C5b-9 and also bound to C5b-7 to prevent membrane attachment.
GO:0031410 cytoplasmic vesicle	IEA GO_REF:0000043	ACCEPT	Summary: CLU is found in cytoplasmic vesicles (secretory granules, chromaffin granules, platelet alpha granules). IEA from UniProt keyword is reasonable. Reason: CLU transits through the secretory pathway and is found in various vesicular compartments including platelet alpha granules and secretory granules.
GO:0031966 mitochondrial membrane	IEA GO_REF:0000044	KEEP AS NON CORE	Summary: Under stress, intracellular CLU redistributes to mitochondria and stabilizes mitochondrial membrane integrity (PMID:22689054, PMID:17689225). CLU interacts with conformation-altered BAX at the mitochondrial membrane (PMID:16113678). Reason: Mitochondrial membrane localization is stress-induced and related to anti-apoptotic function of intracellular CLU, not the primary function.
GO:0042583 chromaffin granule	IEA GO_REF:0000044	KEEP AS NON CORE	Summary: CLU has been detected in chromaffin granules as noted in UniProt subcellular location. The early literature described CLU in endocrine and neuronal granules (PMID:1585460). Reason: Chromaffin granule localization is a minor specialized localization consistent with CLU's role as a secreted glycoprotein in neuroendocrine cells.
GO:0045087 innate immune response	IEA GO_REF:0000043	ACCEPT	Summary: CLU inhibits MAC assembly, a key effector of innate immunity. The IEA annotation to innate immune response is appropriate. Reason: CLU regulates complement, which is a core component of innate immunity. This broad term is acceptable alongside the more specific complement annotations.
GO:0048471 perinuclear region of cytoplasm	IEA GO_REF:0000044	KEEP AS NON CORE	Summary: Perinuclear localization has been observed for intracellular CLU (PMID:20068069). IEA from UniProt mapping is consistent with IDA data. Reason: Perinuclear localization is documented for intracellular CLU but is not the primary localization.
GO:0005515 protein binding	IPI PMID:17043677 Disrupted in Schizophrenia 1 Interactome: evidence for the c...	MARK AS OVER ANNOTATED	Summary: PMID:17043677 reports CLU interaction with DISC1 in a schizophrenia interactome study. "Protein binding" is uninformative for CLU given its known chaperone function; more specific terms like misfolded protein binding already capture this. Reason: Protein binding is too vague. CLU interacts with many proteins via its chaperone activity. More specific MF terms are already annotated.
GO:0005515 protein binding	IPI PMID:17170699 ERp57 is essential for efficient folding of glycoproteins sh...	MARK AS OVER ANNOTATED	Summary: PMID:17170699 identifies CLU as an endogenous substrate of ERp57 (PDIA3), an ER oxidoreductase required for disulfide bond formation in glycoproteins. This reflects CLU being a client of the ER folding machinery, not a function of CLU itself. Reason: Protein binding is uninformative. CLU is a substrate of ERp57, not a binding partner in a functional sense relevant to CLU's molecular function.
GO:0005515 protein binding	IPI PMID:20195357 A comprehensive resource of interacting protein regions for ...	MARK AS OVER ANNOTATED	Summary: PMID:20195357 is a large-scale interacting protein region resource. Protein binding is uninformative for a known chaperone. Reason: Generic protein binding from a high-throughput study; uninformative for CLU which has more specific MF annotations.
GO:0005515 protein binding	IPI PMID:22179788 The extracellular chaperone clusterin sequesters oligomeric ...	MARK AS OVER ANNOTATED	Summary: PMID:22179788 shows CLU sequesters oligomeric Abeta(1-40). This is better captured by the amyloid-beta binding (GO:0001540) annotation from the same publication. Reason: More specific terms (amyloid-beta binding, misfolded protein binding) already capture this interaction.
GO:0005515 protein binding	IPI PMID:22528093 Search for amyloid-binding proteins by affinity chromatograp...	MARK AS OVER ANNOTATED	Summary: PMID:22528093 identifies CLU as an amyloid-binding protein by affinity chromatography. Better captured by GO:0001540 amyloid-beta binding. Reason: Uninformative. CLU's binding to amyloid proteins is captured by more specific annotations.
GO:0005515 protein binding	IPI PMID:25451228 PACAP inhibits tumor growth and interferes with clusterin in...	MARK AS OVER ANNOTATED	Summary: PMID:25451228 shows PACAP interacts with CLU and downregulates CLU expression in cervical cancer cells. Protein binding is uninformative. Reason: PACAP-CLU interaction in cancer context. Protein binding is too vague.
GO:0005515 protein binding	IPI PMID:26496610 A human interactome in three quantitative dimensions organiz...	MARK AS OVER ANNOTATED	Summary: PMID:26496610 is a large-scale human interactome study. Protein binding from high-throughput data is uninformative for CLU. Reason: Generic high-throughput protein binding; uninformative.
GO:0005515 protein binding	IPI PMID:28887769 α-Synuclein Interacts with Lipoproteins in Plasma.	MARK AS OVER ANNOTATED	Summary: PMID:28887769 shows alpha-synuclein co-immunoprecipitates with ApoJ from plasma, suggesting association on lipoprotein particles. This reflects CLU's apolipoprotein role rather than direct protein binding. Reason: The interaction is likely indirect, mediated through shared lipoprotein particles. Protein binding is uninformative; CLU's chaperone function already covers its protein-binding activity.
GO:0005515 protein binding	IPI PMID:31270237 α-synuclein-lipoprotein interactions and elevated ApoE level...	MARK AS OVER ANNOTATED	Summary: PMID:31270237 shows alpha-synuclein colocalizes with apolipoproteins including ApoJ on lipoprotein vesicles in CSF. Likely an indirect association on lipoproteins. Reason: Indirect association on lipoproteins; protein binding is uninformative.
GO:0005515 protein binding	IPI PMID:31413325 HENA, heterogeneous network-based data set for Alzheimer's d...	MARK AS OVER ANNOTATED	Summary: PMID:31413325 is a heterogeneous network-based data set for AD. Protein binding from a data-mining resource is uninformative. Reason: Computational dataset; protein binding is uninformative for CLU.
GO:0005515 protein binding	IPI PMID:32814053 Interactome Mapping Provides a Network of Neurodegenerative ...	MARK AS OVER ANNOTATED	Summary: PMID:32814053 is interactome mapping of neurodegenerative disease proteins. Protein binding is uninformative for CLU which has specific MF annotations. Reason: High-throughput interactome study; uninformative protein binding.
GO:0002434 immune complex clearance	IEA GO_REF:0000107	ACCEPT	Summary: CLU facilitates clearance of immune complexes via receptor-mediated endocytosis through LRP2/megalin and other receptors. This IEA from Ensembl Compara is consistent with ISS evidence also annotated. Reason: Immune complex clearance is a documented function of CLU, consistent with its role as an extracellular chaperone that facilitates clearance of protein complexes via receptor-mediated endocytosis.
GO:0043065 positive regulation of apoptotic process	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: The nCLU isoform (isoform 4) promotes apoptosis by interacting with BCL2L1 (UniProt). The IEA from Ensembl Compara is consistent with orthologue data. Reason: Positive regulation of apoptosis is real but specific to the nuclear isoform (nCLU). The predominant secreted form is anti-apoptotic.
GO:0045202 synapse	IEA GO_REF:0000107	MARK AS OVER ANNOTATED	Summary: CLU is found at synapses in the brain and has been implicated in synaptic biology through its interactions with amyloid-beta and its association with neurodegeneration. However, CLU is not a synaptic protein per se; it is an extracellular chaperone that is present in the extracellular space including at synapses. Reason: CLU is an extracellular chaperone found throughout the extracellular space. Its presence at synapses reflects general extracellular localization rather than synaptic-specific localization.
GO:1902004 positive regulation of amyloid-beta formation	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: Under certain conditions (low CLU:Abeta ratio), CLU can promote amyloid formation (PMID:17412999). However, at physiological ratios CLU primarily inhibits amyloid formation. The IEA annotation is technically valid but context-dependent. Reason: CLU can promote amyloid-beta formation at very low CLU:substrate ratios (PMID:17412999), but its primary function is inhibitory. This annotation captures a secondary, dose-dependent effect. Supporting Evidence: PMID:17412999 Proamyloidogenic effects of clusterin appear to be restricted to conditions in which the substrate protein is present at a very large molar excess
GO:1905907 negative regulation of amyloid fibril formation	IEA GO_REF:0000107	ACCEPT	Summary: CLU potently inhibits amyloid fibril formation by multiple substrates (PMID:17412999, PMID:12047389, PMID:22179788). This is a core function. IEA is consistent with extensive experimental evidence. Reason: Negative regulation of amyloid fibril formation is a well-established core function of CLU as an extracellular holdase chaperone.
GO:0005829 cytosol	IDA GO_REF:0000052	KEEP AS NON CORE	Summary: Cytosolic CLU detected by immunofluorescence curation. Consistent with retrotranslocation under stress (PMID:22689054). Reason: Cytosolic localization is stress-induced, not the primary localization.
GO:0005576 extracellular region	HDA PMID:20551380 Proteomics characterization of extracellular space component...	ACCEPT	Summary: PMID:20551380 is a proteomics characterization of extracellular space components in human aorta that detected CLU. Confirms core extracellular localization. Reason: Proteomic detection of CLU in extracellular space of human aorta. Consistent with core localization.
GO:0005576 extracellular region	HDA PMID:27559042 Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin...	ACCEPT	Summary: PMID:27559042 is a glycoproteomics study of human atrial fibrillation tissue that detected CLU extracellularly. Confirms core localization. Reason: High-throughput proteomic detection confirming CLU in extracellular region.
GO:0001971 negative regulation of activation of membrane attack complex	IDA PMID:34667172 Structural basis of soluble membrane attack complex packagin...	ACCEPT	Summary: PMID:34667172 provides structural basis showing how clusterin binds sMAC and inhibits C9 polymerization by obstructing the polymerizing face of C9. This is a core function of CLU. Reason: Cryo-EM structure of sMAC shows how CLU recognizes and inhibits polymerizing complement proteins. Core complement regulatory function. Supporting Evidence: PMID:34667172 clusterin recognizes and inhibits polymerizing complement proteins by binding a negatively charged surface of sMAC
GO:0001971 negative regulation of activation of membrane attack complex	IDA PMID:9200695 Potent inhibition of terminal complement assembly by cluster...	ACCEPT	Summary: PMID:9200695 demonstrates CLU is a potent inhibitor of terminal complement assembly, binding to C5b-8 and C5b-9 to prevent C9 polymerization with high affinity. Reason: Definitive biochemical characterization of CLU as a MAC inhibitor. Core function. Supporting Evidence: PMID:9200695 Clusterin inhibited C9 assembly on C5b-8 and C5b-9 and also bound to C5b-7 to prevent membrane attachment
GO:0045916 negative regulation of complement activation	IDA PMID:34667172 Structural basis of soluble membrane attack complex packagin...	ACCEPT	Summary: Same study as above, CLU negatively regulates complement by inhibiting MAC. Core function. Reason: Core complement regulatory function demonstrated structurally.
GO:0045916 negative regulation of complement activation	IDA PMID:9200695 Potent inhibition of terminal complement assembly by cluster...	ACCEPT	Summary: CLU inhibits terminal complement at multiple steps (PMID:9200695). Core function. Reason: Biochemically validated complement inhibition. Core function.
GO:0140311 protein sequestering activity	IDA PMID:34667172 Structural basis of soluble membrane attack complex packagin...	ACCEPT	Summary: PMID:34667172 shows CLU sequesters soluble MAC precursors to prevent bystander damage. CLU traps C9 in an intermediate conformation. This is consistent with CLU's broader role as a protein sequestering agent. Reason: Protein sequestering is a core MF of CLU -- it captures misfolded proteins and complement intermediates to prevent aggregation and inappropriate activity. Structurally demonstrated.
GO:0140311 protein sequestering activity	IDA PMID:9200695 Potent inhibition of terminal complement assembly by cluster...	ACCEPT	Summary: PMID:9200695 shows CLU binds C5b-8 and C5b-9 complexes, sequestering them. Consistent with protein sequestering activity. Reason: Core MF of CLU to sequester complement intermediates and misfolded proteins.
GO:1903660 negative regulation of complement-dependent cytotoxicity	IDA PMID:34667172 Structural basis of soluble membrane attack complex packagin...	ACCEPT	Summary: CLU prevents complement-dependent cytotoxicity by inhibiting MAC assembly (PMID:34667172). Core function. Reason: Direct consequence of MAC inhibition. Well-supported.
GO:1903660 negative regulation of complement-dependent cytotoxicity	IDA PMID:9200695 Potent inhibition of terminal complement assembly by cluster...	ACCEPT	Summary: PMID:9200695 estimates that CLU can reduce complement cytolysis of nucleated cells by 10-fold or more. Core function. Reason: Direct biochemical demonstration of CLU protecting against complement-dependent cytotoxicity. Supporting Evidence: PMID:9200695 the presence of <10% of the circulating clusterin in its heterodimeric, active form could reduce the rate of complement cytolysis of nucleated cells by 10-fold, and under some conditions by 100-fold or more
GO:0005886 plasma membrane	IDA PMID:30333625 LILRB4 signalling in leukaemia cells mediates T cell suppres...	KEEP AS NON CORE	Summary: PMID:30333625 reports CLU at the plasma membrane in the context of LILRB4 signaling in leukemia. CLU can bind cell surface receptors. Reason: CLU can associate with the plasma membrane via receptor binding, but it is not an intrinsic membrane protein. This is a minor localization.
GO:0010628 positive regulation of gene expression	ISS GO_REF:0000024	MARK AS OVER ANNOTATED	Summary: ISS from orthologue data. CLU has been shown to modulate NF-kB transcriptional activity (PMID:20068069), which indirectly regulates gene expression. However, this is very broad. Reason: Very broad term. CLU modulates NF-kB via ubiquitin-mediated degradation of inhibitors, but "positive regulation of gene expression" is too general and nonspecific.
GO:0051087 protein-folding chaperone binding	ISS GO_REF:0000024	ACCEPT	Summary: CLU interacts with ATP-dependent chaperones including HSPA8/HSC70 (PMID:11123922) and HSPA5/GRP78 (PMID:22689054). CLU-client complexes are substrates for refolding by HSP70. The ISS annotation is valid. Reason: CLU stabilizes stressed proteins in a state competent for refolding by HSP70. This functional cooperation requires interaction with protein-folding chaperones. Supporting Evidence: PMID:11123922 stabilizes stressed proteins in a state competent for refolding by heat shock protein 70 (HSP70)
GO:0005615 extracellular space	IDA PMID:30333625 LILRB4 signalling in leukaemia cells mediates T cell suppres...	ACCEPT	Summary: PMID:30333625 detects CLU in the extracellular space. Confirms core localization. Reason: Extracellular space is the core localization.
GO:0048018 receptor ligand activity	IDA PMID:27477018 TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ,...	ACCEPT	Summary: PMID:27477018 shows CLU is a ligand for TREM2, a microglial receptor. CLU binding to TREM2 facilitates uptake of amyloid-beta by microglia. CLU is also a ligand for LRP2/megalin and VLDLR. Receptor ligand activity is appropriate. Reason: CLU functions as a ligand for multiple receptors (TREM2, LRP2, VLDLR) to mediate clearance of misfolded proteins and lipoproteins. This is a core functional aspect. Supporting Evidence: PMID:27477018 identified a set of lipoprotein particles (including LDL) and apolipoproteins (including CLU/APOJ and APOE) as ligands of TREM2
GO:0097242 amyloid-beta clearance	IDA PMID:27477018 TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ,...	ACCEPT	Summary: PMID:27477018 shows CLU facilitates Abeta uptake by microglia via TREM2 binding. CLU-Abeta complexes are taken up by microglia in a TREM2-dependent manner. This is a key function in AD pathobiology. Reason: Amyloid-beta clearance is a well-supported function of CLU, mediated via receptor binding and endocytosis. Core function in brain proteostasis. Supporting Evidence: PMID:27477018 β-amyloid (Aβ) binds to lipoproteins and this complex is efficiently taken up by microglia in a TREM2-dependent fashion
GO:0005576 extracellular region	TAS PMID:23164821 Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven...	ACCEPT	Summary: PMID:23164821 discusses CLU in the context of beta-amyloid toxicity regulation. Confirms extracellular localization. Reason: Consistent with core extracellular localization.
GO:0005737 cytoplasm	TAS PMID:23164821 Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven...	KEEP AS NON CORE	Summary: PMID:23164821 mentions cytoplasmic CLU. Consistent with intracellular forms documented elsewhere. Reason: Cytoplasmic localization is secondary, representing intracellular isoforms or stress-induced redistribution.
GO:0043524 negative regulation of neuron apoptotic process	ISS GO_REF:0000024	KEEP AS NON CORE	Summary: CLU protects neurons from apoptosis, consistent with its anti-apoptotic function via BAX interaction (PMID:16113678) and neuroprotective roles documented in AD context (PMID:9560017). Reason: Neuroprotection is a well-supported secondary function of CLU but reflects the general anti-apoptotic activity applied to neurons rather than a neuron-specific mechanism.
GO:0061740 protein targeting to lysosome involved in chaperone-mediated autophagy	IDA PMID:9228033 Interaction of apolipoprotein J-amyloid beta-peptide complex...	ACCEPT	Summary: PMID:9228033 shows CLU-Abeta complexes are internalized via LRP2/megalin and targeted to lysosomes for degradation. This is receptor-mediated endocytosis leading to lysosomal degradation, which is a core clearance function of CLU. Reason: CLU facilitates targeting of misfolded protein cargo to lysosomes for degradation via receptor-mediated endocytosis. Core clearance function.
GO:0140597 protein carrier chaperone	IDA PMID:9228033 Interaction of apolipoprotein J-amyloid beta-peptide complex...	ACCEPT	Summary: PMID:9228033 shows CLU acts as a carrier chaperone that binds Abeta and delivers it to LRP2/megalin for internalization and degradation. This is an excellent MF term for CLU's carrier function. Reason: Protein carrier chaperone accurately captures CLU's function of binding misfolded proteins and delivering them to receptors for clearance. Core MF.
GO:0016887 ATP hydrolysis activity	IDA NOT PMID:11123922 Clusterin is an ATP-independent chaperone with very broad su...	ACCEPT	Summary: PMID:11123922 explicitly demonstrated that CLU lacks detectable ATPase activity. This is a NOT annotation confirming CLU is an ATP-independent chaperone. Reason: Important negative annotation. CLU is definitively established as an ATP-independent chaperone, distinguishing it from classical chaperones like HSP70. Supporting Evidence: PMID:11123922 lacks detectable ATPase activity
GO:0048156 tau protein binding	IPI PMID:25051234 Intracellular clusterin interacts with brain isoforms of the...	ACCEPT	Summary: PMID:25051234 shows intracellular CLU (iCLU) interacts with tau in AD. Co-immunoprecipitation from human brain tissue confirmed iCLU association with modified tau species found in AD. Reason: Tau binding is well-supported by co-IP from human brain. Relevant to CLU's role in AD pathobiology and consistent with its broader misfolded protein binding activity. Supporting Evidence: PMID:25051234 By overexpressing iCLU and Tau in cell culture systems we discovered that iCLU was a Tau-interacting protein and that iCLU associated with brain-specific isoforms of BIN1, also recently identified as a Tau-binding protein
GO:0001836 release of cytochrome c from mitochondria	IC PMID:16113678 Clusterin inhibits apoptosis by interacting with activated B...	KEEP AS NON CORE	Summary: PMID:16113678 shows intracellular CLU inhibits BAX oligomerization, which leads to release of cytochrome c. The IC annotation infers CLU involvement in cytochrome c release (by inhibiting it). The annotation term itself describes the process, while CLU is a negative regulator. Reason: CLU inhibits cytochrome c release by blocking BAX activation at mitochondria. This is an intracellular anti-apoptotic function, not the primary extracellular chaperone function.
GO:0032760 positive regulation of tumor necrosis factor production	IDA PMID:15857407 Apolipoprotein J (clusterin) activates rodent microglia in v...	KEEP AS NON CORE	Summary: PMID:15857407 shows exogenous CLU activates rodent microglia and increases TNF-alpha secretion with EC50 of 55 nM. This is a pro-inflammatory effect in the CNS context. Reason: Microglial activation and TNF induction by CLU is a secondary, context-dependent effect in the CNS, not the core molecular function. Supporting Evidence: PMID:15857407 ApoJ increased the secretion of reactive nitrogen intermediates in a dose-dependent manner (EC(50) 112 nm), which was completely blocked by aminoguanidine (AG), a nitric oxide synthase inhibitor. However, AG did not block the increased secretion of tumor necrosis factor-alpha by apoJ (EC(50) 55 nm).
GO:0045429 positive regulation of nitric oxide biosynthetic process	IDA PMID:15857407 Apolipoprotein J (clusterin) activates rodent microglia in v...	KEEP AS NON CORE	Summary: PMID:15857407 shows CLU increases reactive nitrogen intermediate secretion from microglia in a dose-dependent manner. Reason: Microglial NO induction is a secondary inflammatory response to CLU in the CNS, not the core function.
GO:0005102 signaling receptor binding	IPI PMID:27477018 TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ,...	ACCEPT	Summary: PMID:27477018 shows CLU binds TREM2 receptor on microglia. CLU also binds LRP2/megalin and VLDLR. Signaling receptor binding is an appropriate MF term. Reason: CLU is a ligand for multiple signaling receptors (TREM2, LRP2, VLDLR). This is integral to its clearance function and a core molecular activity.
GO:0031333 negative regulation of protein-containing complex assembly	IMP PMID:16113678 Clusterin inhibits apoptosis by interacting with activated B...	KEEP AS NON CORE	Summary: PMID:16113678 shows CLU impedes BAX oligomerization, preventing mitochondrial pore formation. This represents negative regulation of protein complex assembly (BAX oligomers). Reason: CLU inhibits BAX oligomerization as part of its anti-apoptotic function. This is a valid but secondary intracellular function.
GO:0031333 negative regulation of protein-containing complex assembly	IDA PMID:22179788 The extracellular chaperone clusterin sequesters oligomeric ...	ACCEPT	Summary: PMID:22179788 shows CLU sequesters oligomeric Abeta, preventing further aggregation/complex assembly. This reflects CLU's core holdase chaperone function preventing protein aggregation. Reason: Preventing protein complex/aggregate assembly is a direct consequence of CLU's core holdase chaperone activity.
GO:0031333 negative regulation of protein-containing complex assembly	IDA PMID:23106396 Amyloid-β oligomers are sequestered by both intracellular an...	ACCEPT	Summary: PMID:23106396 shows CLU sequesters Abeta oligomers, preventing further assembly. Same core chaperone function as above. Reason: Core chaperone function preventing misfolded protein complex assembly.
GO:0031334 positive regulation of protein-containing complex assembly	IDA PMID:22179788 The extracellular chaperone clusterin sequesters oligomeric ...	KEEP AS NON CORE	Summary: PMID:22179788 shows that at very low CLU:Abeta ratios, CLU can promote Abeta complex formation. This is a dose-dependent effect opposite to the primary inhibitory function. Reason: At substoichiometric levels, CLU can paradoxically promote protein complex assembly. This is a secondary, dose-dependent effect opposite to the core inhibitory function.
GO:0002434 immune complex clearance	ISS GO_REF:0000024	ACCEPT	Summary: ISS from orthologues. CLU facilitates clearance of immune complexes via receptor-mediated endocytosis. Consistent with the IEA annotation from Ensembl Compara. Reason: Immune complex clearance is a documented function of CLU, consistent with its chaperone-carrier function.
GO:0048260 positive regulation of receptor-mediated endocytosis	ISS GO_REF:0000024	ACCEPT	Summary: CLU-cargo complexes are internalized via receptor-mediated endocytosis through LRP2/megalin (PMID:9228033) and TREM2 (PMID:27477018). CLU promotes this process. ISS is consistent. Reason: CLU facilitates receptor-mediated endocytosis of its cargo complexes. Core clearance mechanism.
GO:0051082 unfolded protein binding	IMP PMID:25402950 The chaperone activity of clusterin is dependent on glycosyl...	MODIFY	Summary: GO:0051082 "unfolded protein binding" is being obsoleted (go-ontology#30962). The annotation is based on PMID:25402950 (Rohne et al. 2014), which investigated the chaperone activity of clusterin under different glycosylation and redox conditions. The paper demonstrates that CLU has chaperone-like holdase activity -- it prevents aggregation of stressed/unfolded target proteins and maintains them in a soluble state. Critically, CLU does not actively refold proteins (PMID:11123922) and does not require ATP (PMID:11123922). This is consistent with an extracellular holdase function rather than a classical folding chaperone. The best replacement from existing GO terms is GO:0044183 "protein folding chaperone" (defined as binding to a protein to assist the protein folding process), though this is an imperfect fit since CLU prevents aggregation rather than directly assisting folding. The existing IBA annotation to GO:0051787 "misfolded protein binding" and the IDA annotations to GO:0051787 (PMID:11123922, PMID:19996109) more accurately capture the binding aspect of CLU chaperone function. GO:0050821 "protein stabilization" (already annotated via IDA from PMID:11123922 and PMID:12176985) captures the biological process aspect. A holdase-specific MF term would be ideal but does not currently exist in GO. Reason: GO:0051082 "unfolded protein binding" is being obsoleted. CLU is an extracellular holdase chaperone that prevents protein aggregation rather than actively promoting folding. PMID:25402950 demonstrates that CLU chaperone activity depends on glycosylation and redox environment, confirming holdase function. PMID:11123922 established that CLU does not refold proteins by itself and does not require ATP. GO:0044183 "protein folding chaperone" is proposed as an interim replacement -- it is the closest available MF term for chaperone activity, though CLU functions as a holdase (preventing aggregation and maintaining proteins in a folding-competent state for downstream ATP-dependent chaperones) rather than a foldase. The existing annotations to GO:0051787 "misfolded protein binding" (IBA, IDA) already capture the binding specificity, and GO:0050821 "protein stabilization" (IDA) captures the biological process. A future holdase-specific term in GO would be more appropriate. Proposed replacements: protein folding chaperone Supporting Evidence: PMID:25402950 We show that the PC-cleavage is dispensable for sCLU chaperone activity. Moreover, our data demonstrate that while fully deglycosylated sCLU lacks chaperone activity, partially deglycosylated sCLU is still capable of solubilizing target proteins. PMID:11123922 clusterin (i) inhibits stress-induced precipitation of a very broad range of structurally divergent protein substrates, (ii) binds irreversibly via an ATP-independent mechanism to stressed proteins to form solubilized high molecular weight complexes, (iii) lacks detectable ATPase activity, (iv) when acting alone, does not effect refolding of stressed proteins in vitro, and (v) stabilizes stressed proteins in a state competent for refolding by heat shock protein 70 (HSP70).
GO:0005737 cytoplasm	IDA PMID:22689054 GRP78 regulates clusterin stability, retrotranslocation and ...	KEEP AS NON CORE	Summary: PMID:22689054 demonstrates that under ER stress, GRP78 facilitates CLU retrotranslocation from the ER to the cytoplasm in prostate cancer cells. Subcellular fractionation and confocal microscopy confirmed cytoplasmic CLU accumulation under stress. Reason: Cytoplasmic localization of CLU is well-documented under ER stress conditions (PMID:22689054). This is a secondary, stress-induced localization, not the primary extracellular localization. Supporting Evidence: PMID:22689054 ER stress increased association between GRP78 and CLU, which led to increased cytoplasmic CLU levels, while reducing sCLU levels secreted into the culture media.
GO:0043065 positive regulation of apoptotic process	ISS GO_REF:0000024	KEEP AS NON CORE	Summary: ISS from orthologue data. The nCLU isoform (isoform 4) promotes apoptosis by interacting with BCL2L1 (UniProt). Consistent with the IEA annotation from Ensembl Compara (already reviewed). Reason: Positive regulation of apoptosis is valid for the nuclear isoform (nCLU). The predominant secreted form is anti-apoptotic. This is a minor isoform-specific function.
GO:0005634 nucleus	IDA PMID:19137541 Clusterin is a short half-life, poly-ubiquitinated protein, ...	KEEP AS NON CORE	Summary: PMID:19137541 shows that proteasome inhibition by MG132 causes stabilization and accumulation of all CLU protein products including the nuclear form (nCLU). The nuclear localization was directly observed in prostate cancer cells under proteasome inhibition. Reason: Nuclear localization is real for the nCLU isoform and under proteasome inhibition, but is not the predominant localization of the main secreted form. Supporting Evidence: PMID:19137541 Proteasome inhibition by MG132 caused stabilization and accumulation of all CLU protein products, including the nuclear form of CLU (nCLU), and committing cells to caspase-dependent death.
GO:0005737 cytoplasm	IDA PMID:17689225 Multiple pathways regulating the anti-apoptotic protein clus...	KEEP AS NON CORE	Summary: PMID:17689225 reports that CLU overexpressed by HDI treatment localizes to cytoplasm and mitochondria in breast cancer cells. The hyper-expressed form localizes to mitochondria and inhibits cytochrome c release. Reason: Cytoplasmic CLU is documented in cancer cells under treatment conditions. This is a secondary localization related to the anti-apoptotic intracellular function. Supporting Evidence: PMID:17689225 The hyper-expressed form of clusterin localizes to mitochondria, inhibits cytochrome c release, and is inhibited by the proteasome.
GO:0005743 mitochondrial inner membrane	IDA PMID:17689225 Multiple pathways regulating the anti-apoptotic protein clus...	KEEP AS NON CORE	Summary: PMID:17689225 shows that CLU localizes to mitochondria in breast cancer cells treated with HDIs and inhibits cytochrome c release. UniProt annotates CLU at the mitochondrial membrane as a peripheral membrane protein on the cytoplasmic side. Reason: Mitochondrial inner membrane localization is stress/treatment-induced. CLU is not a constitutive mitochondrial protein. This relates to the anti-apoptotic function of intracellular CLU in cancer cells. Supporting Evidence: PMID:17689225 The hyper-expressed form of clusterin localizes to mitochondria, inhibits cytochrome c release, and is inhibited by the proteasome.
GO:0042127 regulation of cell population proliferation	IMP PMID:19137541 Clusterin is a short half-life, poly-ubiquitinated protein, ...	KEEP AS NON CORE	Summary: PMID:19137541 demonstrates that siRNA-mediated depletion of CLU in PC-3 prostate cancer cells induces cell cycle progression and higher expression of proliferation markers (H3, PCNA, cyclins A, B1, D), while CLU overexpression inhibits proliferation and induces apoptosis. Reason: Regulation of cell proliferation by CLU is documented in prostate cancer cells but represents a secondary, context-dependent role in cancer biology, not the core chaperone function. Supporting Evidence: PMID:19137541 Following siRNA targeting all CLU mRNA variants, all protein products quickly disappeared, inducing cell cycle progression and higher expression of specific proliferation markers (i.e., H3 mRNA, PCNA, and cyclins A, B1, and D) as detected by RT-qPCR and Western blot
GO:0050821 protein stabilization	IDA PMID:12176985 Mildly acidic pH activates the extracellular molecular chape...	ACCEPT	Summary: PMID:12176985 shows that CLU at mildly acidic pH has enhanced chaperone activity, stabilizing stressed proteins against aggregation. Low pH induces dissociation of CLU aggregates and increases solvent-exposed hydrophobicity, enhancing its ability to stabilize stressed proteins. Reason: Protein stabilization is a core biological process of CLU. The holdase chaperone activity of CLU directly prevents aggregation and maintains proteins in a stable, soluble state. Well-demonstrated by direct assay. Supporting Evidence: PMID:12176985 the chaperone action of clusterin is enhanced at mildly acidic pH. Clusterin is the first chaperone shown to be activated by reduced pH.
GO:0005739 mitochondrion	IDA PMID:22689054 GRP78 regulates clusterin stability, retrotranslocation and ...	KEEP AS NON CORE	Summary: PMID:22689054 shows that under ER stress in prostate cancer cells, GRP78 facilitates CLU retrotranslocation and co-localized redistribution to the mitochondria, reducing stress-induced apoptosis by stabilizing mitochondrial membrane integrity. Reason: Mitochondrial localization is stress-induced and occurs in cancer cells under treatment conditions. Not the primary localization of the predominant secreted form. Supporting Evidence: PMID:22689054 GRP78 increased stress-induced CLU retrotranslocation from the ER with co-localized redistribution to the mitochondria, thereby reducing stress-induced apoptosis by cooperatively stabilizing mitochondrial membrane integrity.
GO:0005829 cytosol	IDA PMID:22689054 GRP78 regulates clusterin stability, retrotranslocation and ...	KEEP AS NON CORE	Summary: PMID:22689054 demonstrates cytosolic CLU accumulation under ER stress via retrotranslocation from the ER in prostate cancer cells. Reason: Cytosolic localization is secondary and stress-induced, not the primary localization of the secreted form.
GO:0043231 intracellular membrane-bounded organelle	IDA PMID:22689054 GRP78 regulates clusterin stability, retrotranslocation and ...	KEEP AS NON CORE	Summary: PMID:22689054 shows CLU in intracellular membrane-bounded organelles (ER, mitochondria) during ER stress in prostate cancer cells. This is a very broad CC term. Reason: Very broad localization term. CLU transits through the ER as part of the secretory pathway and redistributes to mitochondria under stress. More specific CC terms are already annotated.
GO:0099020 perinuclear endoplasmic reticulum lumen	IDA PMID:22689054 GRP78 regulates clusterin stability, retrotranslocation and ...	KEEP AS NON CORE	Summary: PMID:22689054 shows CLU in the ER lumen prior to retrotranslocation in prostate cancer cells. CLU is synthesized and glycosylated in the ER as part of its normal secretory processing. Reason: Perinuclear ER lumen localization reflects CLU transit through the secretory pathway. CLU is normally processed through the ER but its functional site is extracellular.
GO:0005515 protein binding	IPI PMID:22689054 GRP78 regulates clusterin stability, retrotranslocation and ...	MARK AS OVER ANNOTATED	Summary: PMID:22689054 shows CLU associates with GRP78/BiP under ER stress. This interaction is between CLU as a client/substrate of the ER chaperone machinery and is better captured by the existing annotation to GO:0051087 protein-folding chaperone binding. Reason: Protein binding is uninformative. The CLU-GRP78 interaction is already better captured by the protein-folding chaperone binding annotation (GO:0051087).
GO:0005515 protein binding	IPI PMID:8555189 Interaction of transforming growth factor beta receptors wit...	MARK AS OVER ANNOTATED	Summary: PMID:8555189 demonstrates that CLU interacts directly with both type I (RI/ACVR1) and type II (RII/TGFBR2) TGF-beta receptors via yeast two-hybrid and co-precipitation experiments. The 60 kDa intracellular form of CLU was precipitated by RI and RII fusion proteins. Reason: While the CLU-TGFBR interaction is specific and validated, the generic term protein binding is uninformative. A more specific term such as signaling receptor binding (GO:0005102) would better capture this. The signaling receptor binding annotation is already present from PMID:27477018.
GO:0005576 extracellular region	HDA PMID:27068509 Extracellular matrix remodelling in response to venous hyper...	ACCEPT	Summary: PMID:27068509 is a proteomics study of varicose veins detecting CLU in extracellular matrix. Confirms core extracellular localization. Reason: Proteomic detection confirming CLU in the extracellular region, consistent with core localization as a secreted protein.
GO:0005615 extracellular space	HDA PMID:20551380 Proteomics characterization of extracellular space component...	ACCEPT	Summary: PMID:20551380 is a proteomics characterization of extracellular space components in human aorta that detected CLU. Confirms core localization. Reason: Proteomic detection in human aorta extracellular space. Consistent with core localization. Note this is a duplicate of the already-reviewed HDA annotation for extracellular region from same PMID but for the more specific extracellular space term.
GO:0050750 low-density lipoprotein particle receptor binding	IPI PMID:9228033 Interaction of apolipoprotein J-amyloid beta-peptide complex...	ACCEPT	Summary: PMID:9228033 demonstrates that CLU-Abeta complex binds LRP-2/megalin (a member of the LDL receptor family) with high affinity. The interaction was shown by ELISA, and CLU-mediated binding to LRP-2 promotes cellular uptake and degradation of Abeta. Reason: LDL receptor family binding is a core molecular function of CLU. CLU serves as a carrier chaperone that delivers misfolded protein cargo to LRP-2/megalin and other LDL receptor family members for receptor-mediated endocytosis and clearance. Supporting Evidence: PMID:9228033 Abeta alone did not bind directly to LRP-2; however, when Abeta1-40 was combined with apoJ to form a complex, binding to LRP-2 took place.
GO:0005515 protein binding	IPI PMID:25051234 Intracellular clusterin interacts with brain isoforms of the...	MARK AS OVER ANNOTATED	Summary: PMID:25051234 shows intracellular CLU (iCLU) interacts with tau and BIN1 by co-immunoprecipitation. The tau binding is already captured by the more specific GO:0048156 tau protein binding annotation. Reason: Protein binding is uninformative. The iCLU-tau interaction is better captured by the tau protein binding (GO:0048156) annotation from the same publication.
GO:0005634 nucleus	IDA PMID:25051234 Intracellular clusterin interacts with brain isoforms of the...	KEEP AS NON CORE	Summary: PMID:25051234 reports intracellular CLU (iCLU) localization including nuclear localization in cell culture systems overexpressing iCLU, and in human AD brain tissue. Reason: Nuclear localization is real for intracellular CLU isoforms, particularly in the context of AD pathology, but is not the primary localization of the predominant secreted form.
GO:0005737 cytoplasm	IDA PMID:25051234 Intracellular clusterin interacts with brain isoforms of the...	KEEP AS NON CORE	Summary: PMID:25051234 shows iCLU in the cytoplasm of cells and human brain tissue. The intracellular form interacts with tau and BIN1 in the cytoplasm. Reason: Cytoplasmic localization for the intracellular CLU form. Secondary to the core extracellular localization.
GO:0005856 cytoskeleton	IDA PMID:25051234 Intracellular clusterin interacts with brain isoforms of the...	KEEP AS NON CORE	Summary: PMID:25051234 shows iCLU associates with tau, a microtubule-associated protein. Cytoskeletal localization likely reflects iCLU interaction with tau on microtubules. Reason: Cytoskeletal localization of iCLU is secondary and likely reflects its interaction with tau on microtubules in the context of AD pathology.
GO:0016020 membrane	IDA PMID:25051234 Intracellular clusterin interacts with brain isoforms of the...	KEEP AS NON CORE	Summary: PMID:25051234 reports iCLU at membranes. This is a very broad CC term and likely reflects iCLU association with ER membranes or other intracellular membrane compartments. Reason: Very broad term. More specific membrane-associated localizations are already annotated (ER, mitochondrial membrane). This adds little information beyond existing annotations.
GO:0001540 amyloid-beta binding	IDA PMID:22179788 The extracellular chaperone clusterin sequesters oligomeric ...	ACCEPT	Summary: PMID:22179788 demonstrates that CLU sequesters oligomeric forms of Abeta(1-40) peptide. CLU binds Abeta oligomers with high efficiency, forming stable CLU-Abeta complexes that prevent further aggregation. Reason: Amyloid-beta binding is a well-established core molecular function of CLU, representing a specific instance of its broader misfolded protein binding chaperone activity. Directly demonstrated by biophysical assays.
GO:0001540 amyloid-beta binding	IPI PMID:23106396 Amyloid-β oligomers are sequestered by both intracellular an...	ACCEPT	Summary: PMID:23106396 shows CLU sequesters Abeta oligomers both extracellularly and intracellularly, demonstrating amyloid-beta binding activity. Reason: Additional evidence for amyloid-beta binding, a core MF of CLU. Consistent with the IDA evidence from PMID:22179788.
GO:0044877 protein-containing complex binding	IPI PMID:22179788 The extracellular chaperone clusterin sequesters oligomeric ...	ACCEPT	Summary: PMID:22179788 shows CLU binds to oligomeric Abeta complexes. CLU specifically targets prefibrillar oligomeric species rather than monomers, consistent with binding to protein-containing complexes. Reason: CLU preferentially binds oligomeric protein complexes (prefibrillar species) rather than monomers. This is mechanistically important for its holdase chaperone function and is distinct from simple protein binding.
GO:0044877 protein-containing complex binding	IPI PMID:23106396 Amyloid-β oligomers are sequestered by both intracellular an...	ACCEPT	Summary: PMID:23106396 confirms CLU binds Abeta oligomeric complexes. Consistent with the IPI evidence from PMID:22179788. Reason: Additional evidence for CLU binding to protein-containing complexes (Abeta oligomers). Core MF.
GO:0048260 positive regulation of receptor-mediated endocytosis	IGI PMID:9228033 Interaction of apolipoprotein J-amyloid beta-peptide complex...	ACCEPT	Summary: PMID:9228033 shows that CLU-Abeta complex is internalized and degraded by LRP-2-expressing cells. CLU promotes cellular uptake of Abeta via LRP-2/megalin, and this was blocked by LRP-2 antibodies. The IGI annotation reflects genetic interaction evidence. Reason: CLU promotes receptor-mediated endocytosis of its cargo through LRP-2. This is a core clearance mechanism and is well-supported by biochemical evidence. Supporting Evidence: PMID:9228033 When LRP-2-expressing cells were given 125I-Abeta1-40, cellular uptake of the radiolabeled peptide was promoted by co-incubation with apoJ.
GO:1905908 positive regulation of amyloid fibril formation	TAS PMID:20005821 Overexpression of low-density lipoprotein receptor in the br...	KEEP AS NON CORE	Summary: PMID:20005821 concerns LDLR overexpression and Abeta clearance in mice. CLU can promote amyloid formation at very low CLU:substrate ratios (PMID:17412999), but its primary function is inhibitory. Reason: CLU can paradoxically promote amyloid formation at substoichiometric concentrations (PMID:17412999). This is a secondary, dose-dependent effect opposite to the core inhibitory function. The TAS reference indirectly supports this.
GO:0001540 amyloid-beta binding	IPI PMID:9228033 Interaction of apolipoprotein J-amyloid beta-peptide complex...	ACCEPT	Summary: PMID:9228033 demonstrates that CLU (apoJ) binds Abeta1-40 with a dissociation constant (Kd) of 4.8 nM and forms CLU-Abeta complexes that can be taken up via LRP-2/megalin. Reason: Core MF of CLU. High-affinity amyloid-beta binding (Kd 4.8 nM) demonstrated by quantitative ELISA. Supporting Evidence: PMID:9228033 an estimated dissociation constant (Kd) of 4.8 nM was derived for the interaction between Abeta1-40 and apoJ.
GO:0032991 protein-containing complex	IDA PMID:9228033 Interaction of apolipoprotein J-amyloid beta-peptide complex...	ACCEPT	Summary: PMID:9228033 shows CLU forms complexes with Abeta peptide that are recognized by LRP-2/megalin. These CLU-Abeta complexes represent protein-containing complexes. Reason: CLU forms high-molecular-weight complexes with client proteins as part of its core chaperone function. The CLU-Abeta complex is a well-characterized example.
GO:1905907 negative regulation of amyloid fibril formation	TAS PMID:9228033 Interaction of apolipoprotein J-amyloid beta-peptide complex...	ACCEPT	Summary: PMID:9228033 shows CLU inhibits formation of Abeta1-40 aggregates when incubated together. CLU-Abeta complex formation prevents Abeta aggregation. Reason: Core function of CLU. Inhibition of amyloid fibril formation is a direct consequence of its holdase chaperone activity. Supporting Evidence: PMID:9228033 incubation of apoJ with Abeta1-40 resulted in the formation of Abeta1-40-apoJ complex and the inhibition of the formation of Abeta1-40 aggregates.
GO:1905907 negative regulation of amyloid fibril formation	IDA PMID:22179788 The extracellular chaperone clusterin sequesters oligomeric ...	ACCEPT	Summary: PMID:22179788 shows CLU sequesters oligomeric Abeta, preventing further fibril formation. Direct assay evidence. Reason: Core function. Additional IDA evidence supporting CLU-mediated inhibition of amyloid fibril formation.
GO:1905907 negative regulation of amyloid fibril formation	TAS PMID:23106396 Amyloid-β oligomers are sequestered by both intracellular an...	ACCEPT	Summary: PMID:23106396 demonstrates that both intracellular and extracellular chaperones including CLU sequester Abeta oligomers, preventing further fibril assembly. Reason: Core function. Consistent with multiple other lines of evidence supporting CLU inhibition of amyloid fibril formation.
GO:0071944 cell periphery	IDA PMID:21803450 The APP intracellular domain (AICD) potentiates ER stress-in...	KEEP AS NON CORE	Summary: PMID:21803450 studies the APP intracellular domain (AICD) and its effects on ER stress-induced apoptosis. CLU detected at cell periphery may reflect extracellular CLU bound to cell surface receptors or in the process of secretion. Reason: Cell periphery localization is minor and likely reflects CLU binding to cell surface receptors or being in the process of secretion. More specific localizations are already annotated.
GO:0090201 negative regulation of release of cytochrome c from mitochondria	TAS PMID:21803450 The APP intracellular domain (AICD) potentiates ER stress-in...	KEEP AS NON CORE	Summary: PMID:21803450 studies AICD-mediated ER stress and CLU's protective role. CLU inhibits cytochrome c release by interacting with activated BAX at mitochondria (PMID:16113678, PMID:17689225). Reason: Negative regulation of cytochrome c release is a consequence of intracellular CLU's anti-apoptotic function via BAX interaction. This is a secondary intracellular function, not the core extracellular chaperone activity. Supporting Evidence: PMID:16113678 intracellular clusterin inhibits apoptosis by interfering with Bax activation in mitochondria
GO:1903573 negative regulation of response to endoplasmic reticulum stress	IMP PMID:21803450 The APP intracellular domain (AICD) potentiates ER stress-in...	KEEP AS NON CORE	Summary: PMID:21803450 studies the role of CLU in mitigating ER stress-induced apoptosis. CLU upregulation under ER stress (PMID:22689054) and its protective effects suggest involvement in negative regulation of ER stress response. Reason: CLU mitigates ER stress-induced apoptosis, but this represents a secondary stress-protective function of intracellular CLU, not the primary extracellular chaperone activity.
GO:0005794 Golgi apparatus	ISS GO_REF:0000024	ACCEPT	Summary: ISS from orthologue data. CLU transits through the Golgi as part of the secretory pathway where it undergoes proteolytic cleavage into alpha and beta chains. This is expected for a secreted glycoprotein. Reason: CLU is processed in the Golgi where the precursor is cleaved into alpha and beta chains. Golgi transit is part of the normal biosynthetic pathway for this secreted protein.
GO:0005576 extracellular region	TAS Reactome:R-HSA-6810643	ACCEPT	Summary: Reactome R-HSA-6810643 describes the EPPIN protein complex binding bacteria. CLU is part of the EPPIN complex on spermatozoa (PMID:17567961). Extracellular region localization is consistent. Reason: Core extracellular localization confirmed by Reactome pathway annotation.
GO:0005576 extracellular region	TAS Reactome:R-HSA-8852580	ACCEPT	Summary: Reactome R-HSA-8852580 describes CLU binding C5b-C7, C8, C9 complement components. This is the core complement regulatory function occurring in the extracellular space. Reason: Core extracellular localization confirmed by Reactome pathway for complement regulation.
GO:0005515 protein binding	IPI PMID:17567961 Characterization of an eppin protein complex from human seme...	MARK AS OVER ANNOTATED	Summary: PMID:17567961 identifies CLU as a component of the EPPIN protein complex (EPC) on spermatozoa, also containing lactotransferrin and semenogelin. The interaction was confirmed by immunoprecipitation. Reason: Protein binding is uninformative. The EPPIN complex interaction is specific but protein binding is too vague. A more informative term would be needed, though no specific GO MF term exists for this complex.
GO:0005615 extracellular space	IDA PMID:17567961 Characterization of an eppin protein complex from human seme...	ACCEPT	Summary: PMID:17567961 detects CLU in seminal plasma and on spermatozoa surface. Confirms extracellular space localization in the male reproductive tract. Reason: Core extracellular localization confirmed in seminal plasma.
GO:0009986 cell surface	IDA PMID:17567961 Characterization of an eppin protein complex from human seme...	KEEP AS NON CORE	Summary: PMID:17567961 shows CLU localizes to the surface of ejaculate spermatozoa as part of the EPPIN protein complex. CLU, LTF, and EPPIN colocalize on the sperm tail. Reason: Cell surface localization on spermatozoa is a specialized localization as part of the EPPIN complex. Not the primary localization but demonstrates CLU's presence at cell surfaces in specific tissue contexts. Supporting Evidence: PMID:17567961 On ejaculate spermatozoa eppin, LTF, and CLU colocalize on the tail.
GO:0032991 protein-containing complex	IDA PMID:17567961 Characterization of an eppin protein complex from human seme...	ACCEPT	Summary: PMID:17567961 identifies CLU as part of the EPPIN protein complex (EPC) containing CLU, lactotransferrin, semenogelin, and EPPIN. Confirmed by immunoprecipitation and mass spectrometry. Reason: CLU forms protein-containing complexes both as part of the EPPIN complex on spermatozoa and as chaperone-client complexes with misfolded proteins. Valid CC annotation.
GO:0070062 extracellular exosome	HDA PMID:23533145 In-depth proteomic analyses of exosomes isolated from expres...	ACCEPT	Summary: PMID:23533145 is a proteomics study of exosomes from prostatic secretions in urine that detected CLU. High-throughput proteomic detection. Reason: CLU detection in extracellular exosomes is consistent with its secreted nature. CLU is found in various extracellular vesicle preparations.
GO:0005615 extracellular space	HDA PMID:16502470 Human colostrum: identification of minor proteins in the aqu...	ACCEPT	Summary: PMID:16502470 identifies CLU in human colostrum by proteomics. Confirms extracellular space localization in a body fluid. Reason: Core extracellular localization confirmed in human colostrum by proteomics.
GO:1902004 positive regulation of amyloid-beta formation	ISS GO_REF:0000024	KEEP AS NON CORE	Summary: ISS from orthologue data. CLU can promote amyloid-beta formation at very low CLU:substrate ratios (PMID:17412999). Consistent with the IEA annotation from Ensembl Compara already reviewed. Reason: Dose-dependent secondary effect. At substoichiometric levels, CLU can paradoxically promote amyloid formation, but its primary function is inhibitory.
GO:1902998 positive regulation of neurofibrillary tangle assembly	IMP PMID:15897157 Association of apolipoprotein J-positive beta-amyloid plaque...	KEEP AS NON CORE	Summary: PMID:15897157 shows that apoJ-containing conditioned media and hippocampal injection of apoJ increases levels of tau and phosphorylated tau, and apoJ immunopositivity correlates with neuritic dystrophy in AD brain. This suggests CLU facilitates the conversion of diffuse Abeta deposits into amyloid and enhances tau phosphorylation. Reason: This is an indirect, disease-associated effect in the AD brain. CLU promotes tangle assembly through complex mechanisms involving Abeta aggregation and tau phosphorylation. This is a pathological consequence, not a primary molecular function. Supporting Evidence: PMID:15897157 apoJ immunopositivity strongly correlates with the presence of amyloid and associated neuritic dystrophy in the neuropil of AD temporal cortex, and supports a model where extracellular apoJ facilitates the conversion of diffuse Abeta deposits into amyloid and enhances tau phosphorylation in neurites surrounding these of plaques.
GO:1902847 regulation of neuronal signal transduction	IMP PMID:21397462 Neural hyperactivation in carriers of the Alzheimer's risk v...	MARK AS OVER ANNOTATED	Summary: PMID:21397462 is an fMRI study showing that carriers of the CLU AD risk variant (rs11136000) have neural hyperactivation during working memory tasks. This is a GWAS variant association study, not a direct demonstration of CLU function in neuronal signal transduction. Reason: This is a GWAS variant association study showing altered brain activation patterns in CLU risk allele carriers. It does not demonstrate a direct molecular role for CLU in neuronal signal transduction. The neural hyperactivation may reflect indirect effects via CLU's roles in Abeta clearance, complement regulation, or lipid transport.
GO:0017038 protein import	IDA PMID:24446231 Apolipoproteins E and J interfere with amyloid-beta uptake b...	MODIFY	Summary: PMID:24446231 shows that ApoJ (CLU) interferes with Abeta uptake by primary human astrocytes and microglia. Specifically, ApoJ reduced Abeta oligomer uptake by astrocytes but not microglia. This is more about regulating protein import/clearance than performing the import itself. Reason: PMID:24446231 actually shows CLU reduces Abeta uptake by astrocytes, not promotes it. The term protein import is misleading. CLU regulates Abeta clearance by glial cells but the direction is inhibitory in this study. The annotation to GO:1900221 regulation of amyloid-beta clearance from the same publication is more appropriate. Proposed replacements: regulation of amyloid-beta clearance Supporting Evidence: PMID:24446231 Upon exposure to Aβ combined with ApoE, ApoJ, α1-antichymotrypsin (ACT) and a combination of serum amyloid P and complement C1q (SAP-C1q), a clear reduction in astrocytic but not microglial Aβoligo uptake, was observed
GO:1900221 regulation of amyloid-beta clearance	IDA PMID:24446231 Apolipoproteins E and J interfere with amyloid-beta uptake b...	ACCEPT	Summary: PMID:24446231 demonstrates that CLU modulates Abeta clearance by glial cells. ApoJ reduces astrocytic Abeta oligomer uptake but fibrillar Abeta clearance by microglia is reduced in the presence of AAPs including ApoJ. This demonstrates CLU regulation of Abeta clearance. Reason: Regulation of amyloid-beta clearance is a well-established function of CLU. While PMID:24446231 shows the relationship is complex (CLU can both promote and interfere with clearance depending on cell type and aggregation state), regulation of Abeta clearance is a core function consistent with CLU's chaperone-carrier role. Supporting Evidence: PMID:24446231 Abeta clearance by glial cells is negatively affected by AAPs like ApoE and ApoJ. Thus, targeting the association of Abeta with AAPs, such as ApoE and ApoJ, could serve as a therapeutic strategy to increase Abeta clearance by glial cells.
GO:0000902 cell morphogenesis	IDA PMID:15857407 Apolipoprotein J (clusterin) activates rodent microglia in v...	MARK AS OVER ANNOTATED	Summary: PMID:15857407 shows that exogenous CLU activates rodent microglia with changes in morphology, including enlarged cell bodies and processes. Microglial morphological changes are a consequence of activation, not a primary CLU function in cell morphogenesis. Reason: Cell morphogenesis is an over-annotation. The microglial morphological changes observed are secondary to CLU-mediated microglial activation, not a primary function of CLU in cell morphogenesis. CLU is not a morphogen.
GO:0001774 microglial cell activation	IDA PMID:15857407 Apolipoprotein J (clusterin) activates rodent microglia in v...	KEEP AS NON CORE	Summary: PMID:15857407 demonstrates that exogenous CLU activates rodent microglia both in vivo (ICV infusion) and in vitro, with enlarged cell bodies, MHCII induction, and increased secretion of NO and TNF-alpha. Reason: Microglial activation by CLU is a well-demonstrated secondary function in the CNS. While not the core chaperone function, it is relevant to CLU's role in neuroinflammation and AD pathobiology. Supporting Evidence: PMID:15857407 exogenous apoJ activates rodent microglia in vivo and in vitro
GO:0005737 cytoplasm	IDA PMID:9560017 Possible neuroprotective role of clusterin in Alzheimer's di...	KEEP AS NON CORE	Summary: PMID:9560017 is an immunocytochemical study of CLU in AD brain showing clusterin immunoreactivity in NFT-free neurons of affected cortical areas. Cytoplasmic localization in neurons was observed by immunohistochemistry. Reason: Cytoplasmic CLU immunoreactivity in AD brain neurons. This is a secondary localization, likely reflecting internalized extracellular CLU or intracellular isoforms.
GO:0061518 microglial cell proliferation	IDA PMID:15857407 Apolipoprotein J (clusterin) activates rodent microglia in v...	KEEP AS NON CORE	Summary: PMID:15857407 shows CLU activates microglia with morphological changes and inflammatory responses. While activation can include proliferation, the paper primarily demonstrates activation phenotype rather than proliferation specifically. Reason: Microglial proliferation induced by CLU is a secondary effect related to its role in neuroinflammation. Not the core molecular function.
GO:0097418 neurofibrillary tangle	IDA PMID:9560017 Possible neuroprotective role of clusterin in Alzheimer's di...	KEEP AS NON CORE	Summary: PMID:9560017 shows clusterin immunoreactivity in neuropil threads and neurofibrillary tangles (NFTs) in AD brain by immunocytochemistry. CLU was detected in NFT-containing neurons and in neuropil threads. Reason: CLU localization to neurofibrillary tangles is a disease-associated pathological finding in AD brain, not a normal functional localization. Reflects CLU's association with aggregated tau.
GO:0097440 apical dendrite	IDA PMID:9560017 Possible neuroprotective role of clusterin in Alzheimer's di...	KEEP AS NON CORE	Summary: PMID:9560017 is an immunocytochemical study in AD brain. Clusterin immunoreactivity was observed in neurons of affected cortical areas including apical dendrites. This likely reflects CLU association with degenerating neuronal processes. Reason: Apical dendrite localization is a disease-associated finding in AD brain. CLU is not normally a dendritic protein; this reflects its association with degenerating neuronal compartments in AD.
GO:1902430 negative regulation of amyloid-beta formation	IDA PMID:12047389 Suppression of apolipoprotein C-II amyloid formation by the ...	ACCEPT	Summary: PMID:12047389 demonstrates that substoichiometric levels of CLU potently inhibit amyloid formation by apolipoprotein C-II. CLU inhibits fibril growth by interacting with transient amyloid nuclei. While the substrate is apoC-II rather than Abeta, the mechanism is analogous. Reason: While PMID:12047389 specifically studies apoC-II amyloid, CLU inhibits amyloid formation by diverse substrates including Abeta. Negative regulation of amyloid-beta formation is a core function. Supporting Evidence: PMID:12047389 Sub-stoichiometric levels of clusterin, derived from either plasma or semen, potently inhibit amyloid formation by apoC-II.
GO:1902430 negative regulation of amyloid-beta formation	IDA PMID:17412999 The extracellular chaperone clusterin influences amyloid for...	ACCEPT	Summary: PMID:17412999 directly demonstrates that CLU at substoichiometric levels (e.g., CLU:substrate=1:10) potently inhibits amyloid formation by Abeta peptide and provides cytoprotection. Reason: Core function of CLU. Direct demonstration that CLU inhibits Abeta amyloid formation at physiologically relevant ratios. Supporting Evidence: PMID:17412999 when clusterin is present at much higher but still substoichiometric levels (e.g., a molar ratio of clusterin:substrate=1:10), it potently inhibits amyloid formation and provides substantial cytoprotection.
GO:0032286 central nervous system myelin maintenance	IMP PMID:21543606 Common Alzheimer's disease risk variant within the CLU gene ...	MARK AS OVER ANNOTATED	Summary: PMID:21543606 is an imaging genetics study showing that the CLU AD risk variant (rs11136000 C allele) is associated with lower white matter integrity (fractional anisotropy) in young healthy adults. This is a genetic association, not a direct demonstration of CLU function in myelin maintenance. Reason: This is a GWAS variant association with brain imaging measures, not a direct demonstration of CLU function in CNS myelin maintenance. The association between CLU genotype and white matter integrity may reflect indirect effects through lipid transport, complement regulation, or other mechanisms.
GO:0051131 chaperone-mediated protein complex assembly	IDA PMID:17412999 The extracellular chaperone clusterin influences amyloid for...	KEEP AS NON CORE	Summary: PMID:17412999 shows that CLU interacts with prefibrillar species and can co-incorporate into insoluble aggregates at low CLU:substrate ratios. At very low ratios, CLU can promote complex assembly, but this is a secondary dose-dependent effect. The term chaperone-mediated protein complex assembly could also reflect CLU forming HMW complexes with client proteins as part of its holdase function. Reason: CLU forms high-molecular-weight complexes with client proteins as part of its holdase chaperone function. At substoichiometric ratios it can also promote assembly of amyloid complexes. This annotation captures a secondary aspect of CLU chaperone activity.
GO:0097418 neurofibrillary tangle	IDA PMID:15897157 Association of apolipoprotein J-positive beta-amyloid plaque...	KEEP AS NON CORE	Summary: PMID:15897157 shows apoJ immunoreactivity at the core of beta-amyloid plaques associated with dystrophic neurites in AD brain. ApoJ co-localizes with thioflavine-S-positive amyloid cores and phospho-tau-positive neuritic deposits. Reason: CLU localization to neurofibrillary tangles is a disease-associated pathological finding. Reflects CLU's co-localization with amyloid and tau pathology in AD, consistent with its chaperone function but not a normal subcellular localization. Supporting Evidence: PMID:15897157 Of Abeta deposits with apoJ immunopositivity, 71% were associated with phospho-tau-positive dystrophic neurites in the surrounding tissue.
GO:0072562 blood microparticle	HDA PMID:22516433 Proteomic analysis of microvesicles from plasma of healthy d...	ACCEPT	Summary: PMID:22516433 is a proteomic analysis of microvesicles from healthy donor plasma that detected CLU. High-throughput proteomic detection. Reason: CLU is found in blood microparticles, consistent with its presence in various extracellular compartments as a secreted glycoprotein.
GO:0070062 extracellular exosome	HDA PMID:19199708 Proteomic analysis of human parotid gland exosomes by multid...	ACCEPT	Summary: PMID:19199708 is a proteomic analysis of human parotid gland exosomes that detected CLU. High-throughput proteomic detection. Reason: CLU detection in exosomes is consistent with its secreted nature and broad extracellular distribution.
GO:0070062 extracellular exosome	HDA PMID:19056867 Large-scale proteomics and phosphoproteomics of urinary exos...	ACCEPT	Summary: PMID:19056867 is a proteomics study of urinary exosomes that detected CLU. High-throughput proteomic detection. Reason: CLU detection in urinary exosomes is consistent with its presence in body fluids and extracellular vesicles.
GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage	IMP PMID:16113678 Clusterin inhibits apoptosis by interacting with activated B...	KEEP AS NON CORE	Summary: PMID:16113678 shows that intracellular CLU inhibits apoptosis by interacting with activated BAX in mitochondria, preventing BAX oligomerization and cytochrome c release. CLU inhibits chemotherapeutic drug-mediated and c-Myc-mediated apoptosis. Reason: Negative regulation of intrinsic apoptotic signaling is a well-supported secondary function of intracellular CLU, but represents the cancer-related anti-apoptotic activity, not the core extracellular chaperone function. Supporting Evidence: PMID:16113678 intracellular clusterin inhibits apoptosis by interfering with Bax activation in mitochondria
GO:0005576 extracellular region	TAS Reactome:R-HSA-481007	ACCEPT	Summary: Reactome R-HSA-481007 describes exocytosis of platelet alpha granule contents. CLU is released from platelet alpha granules into the extracellular space upon platelet activation. Reason: Core extracellular localization confirmed by Reactome pathway for platelet alpha granule exocytosis.
GO:0031093 platelet alpha granule lumen	TAS Reactome:R-HSA-481007	KEEP AS NON CORE	Summary: Reactome R-HSA-481007 describes CLU as a component of platelet alpha granule contents that are released upon platelet activation. Reason: Platelet alpha granule lumen is a specialized storage localization for CLU prior to secretion upon platelet activation. Valid but specialized localization, not the primary functional site.
GO:0031625 ubiquitin protein ligase binding	IDA PMID:20068069 Clusterin facilitates COMMD1 and I-kappaB degradation to enh...	KEEP AS NON CORE	Summary: PMID:20068069 demonstrates that sCLU interacts with members of the SCF-betaTrCP E3 ubiquitin ligase family to enhance COMMD1 and I-kappaB proteasomal degradation. CLU acts as a ubiquitin-binding protein that bridges substrates to the E3 ligase complex. Reason: Ubiquitin protein ligase binding is a validated MF for intracellular CLU in the cancer context. This is a secondary intracellular function demonstrated in prostate cancer cells, not the core extracellular chaperone activity. Supporting Evidence: PMID:20068069 sCLU increases NF-kappaB nuclear translocation and transcriptional activity by serving as a ubiquitin-binding protein that enhances COMMD1 and I-kappaB proteasomal degradation by interacting with members of the SCF-betaTrCP E3 ligase family.
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process	IMP PMID:20068069 Clusterin facilitates COMMD1 and I-kappaB degradation to enh...	KEEP AS NON CORE	Summary: PMID:20068069 demonstrates that sCLU enhances COMMD1 and I-kappaB proteasomal degradation. Knockdown of sCLU stabilizes COMMD1 and I-kappaB, confirming CLU promotes proteasomal degradation. Reason: This function is demonstrated for intracellular CLU in prostate cancer cells. Consistent with the IBA annotation already reviewed. Secondary intracellular activity.
GO:0048471 perinuclear region of cytoplasm	IDA PMID:20068069 Clusterin facilitates COMMD1 and I-kappaB degradation to enh...	KEEP AS NON CORE	Summary: PMID:20068069 detects CLU in perinuclear foci in prostate cancer cells, potentially representing aggresomes containing misfolded ubiquitinated proteins. UniProt notes perinuclear foci that may be aggresomes. Reason: Perinuclear localization in cancer cells is documented but represents a secondary intracellular localization, not the primary extracellular site.
GO:2000060 positive regulation of ubiquitin-dependent protein catabolic process	IMP PMID:20068069 Clusterin facilitates COMMD1 and I-kappaB degradation to enh...	KEEP AS NON CORE	Summary: PMID:20068069 shows CLU promotes ubiquitin-dependent degradation of COMMD1 and I-kappaB. This is the parent term of GO:0032436. Both annotations from the same paper are valid. Reason: Broader term covering the same intracellular function as GO:0032436. Valid but secondary to the core extracellular chaperone function.
GO:0005615 extracellular space	IDA PMID:11123922 Clusterin is an ATP-independent chaperone with very broad su...	ACCEPT	Summary: PMID:11123922 is the landmark study establishing CLU as the first identified secreted mammalian chaperone. CLU inhibits stress-induced precipitation of proteins in undiluted human serum, confirming extracellular space as the primary functional site. Reason: Core localization. This is the definitive study establishing CLU as an extracellular chaperone functioning in the extracellular space. Supporting Evidence: PMID:11123922 at physiological levels, clusterin inhibits stress-induced precipitation of proteins in undiluted human serum. Clusterin represents the first identified secreted mammalian chaperone.
GO:0006457 protein folding	IDA PMID:11123922 Clusterin is an ATP-independent chaperone with very broad su...	ACCEPT	Summary: PMID:11123922 shows CLU stabilizes stressed proteins in a folding-competent state for subsequent refolding by HSP70. CLU itself does not refold proteins. The annotation to protein folding is appropriate as CLU participates in the protein folding process by preventing irreversible aggregation and maintaining proteins in a refolding-competent state. Reason: CLU participates in the protein folding process as a holdase chaperone that maintains misfolded proteins in a state competent for refolding by downstream ATP-dependent chaperones. Core biological process. Supporting Evidence: PMID:11123922 stabilizes stressed proteins in a state competent for refolding by heat shock protein 70 (HSP70)
GO:0050821 protein stabilization	IDA PMID:11123922 Clusterin is an ATP-independent chaperone with very broad su...	ACCEPT	Summary: PMID:11123922 directly demonstrates that CLU stabilizes stressed proteins by forming soluble high-molecular-weight complexes, preventing irreversible precipitation. This is the core holdase function. Reason: Protein stabilization is the most accurate BP term for CLU's core holdase chaperone function. CLU prevents irreversible aggregation by binding and stabilizing misfolded proteins. Supporting Evidence: PMID:11123922 binds irreversibly via an ATP-independent mechanism to stressed proteins to form solubilized high molecular weight complexes
GO:0051787 misfolded protein binding	IDA PMID:11123922 Clusterin is an ATP-independent chaperone with very broad su...	ACCEPT	Summary: PMID:11123922 demonstrates that CLU binds a very broad range of structurally divergent stressed/misfolded protein substrates via ATP-independent mechanism. This is the core MF of CLU. Reason: Core molecular function. CLU binds misfolded/stressed proteins with very broad substrate specificity. Definitive direct assay evidence. Supporting Evidence: PMID:11123922 In this study, we demonstrate that clusterin (i) inhibits stress-induced precipitation of a very broad range of structurally divergent protein substrates
GO:0005615 extracellular space	IDA PMID:19996109 Identification of human plasma proteins as major clients for...	ACCEPT	Summary: PMID:19996109 identifies major plasma protein clients for CLU by studying CLU-client complexes formed under physiologically relevant shear stress. Confirms CLU functions in the extracellular space (plasma). Reason: Core extracellular localization. CLU forms chaperone-client complexes with plasma proteins under physiological stress conditions.
GO:0051787 misfolded protein binding	IPI PMID:19996109 Identification of human plasma proteins as major clients for...	ACCEPT	Summary: PMID:19996109 identifies ceruloplasmin, fibrinogen, and albumin as major plasma clients for CLU under shear stress. CLU-client complexes were detected by co-purification and sandwich ELISA. Reason: Core MF. Identifies specific plasma protein clients for CLU chaperone activity, demonstrating misfolded protein binding in a physiological context. Supporting Evidence: PMID:19996109 These proteins were identified by mass spectrometry as ceruloplasmin, fibrinogen, and albumin.
GO:0051788 response to misfolded protein	IDA PMID:19996109 Identification of human plasma proteins as major clients for...	ACCEPT	Summary: PMID:19996109 shows CLU responds to misfolded proteins in plasma by forming soluble HMW complexes with stressed clients, preventing their aggregation. This BP captures CLU's role in the cellular/organismal response to misfolded proteins. Reason: Core biological process. CLU is a primary responder to misfolded proteins in the extracellular space, forming complexes to prevent aggregation and facilitate clearance.
GO:0009615 response to virus	IEP PMID:16548883 Transcriptomic and proteomic analyses of rhabdomyosarcoma ce...	MARK AS OVER ANNOTATED	Summary: PMID:16548883 shows CLU is differentially expressed in response to enterovirus 71 infection in rhabdomyosarcoma cells. This is an expression pattern observation (IEP), not a functional demonstration. Reason: IEP evidence showing CLU expression changes during viral infection. CLU is a stress-response protein whose expression changes under many stress conditions. Differential expression during viral infection does not demonstrate a specific role in antiviral response.
GO:0005515 protein binding	IPI PMID:16113678 Clusterin inhibits apoptosis by interacting with activated B...	MARK AS OVER ANNOTATED	Summary: PMID:16113678 shows CLU interacts with activated BAX at mitochondria. Protein binding is uninformative; the specific interaction with BAX is functionally important for CLU's anti-apoptotic activity. Reason: Protein binding is uninformative. The CLU-BAX interaction is specific and functionally important but the generic term adds no value. More specific annotations already capture this activity.
GO:0005615 extracellular space	IDA PMID:16113678 Clusterin inhibits apoptosis by interacting with activated B...	ACCEPT	Summary: PMID:16113678 detects secreted CLU in the extracellular space (culture media) of cancer cells. Confirms core localization. Reason: Core extracellular localization confirmed in cell culture media.
GO:0005739 mitochondrion	IDA PMID:16113678 Clusterin inhibits apoptosis by interacting with activated B...	KEEP AS NON CORE	Summary: PMID:16113678 shows intracellular CLU localizes to mitochondria in response to chemotherapeutic drugs and interacts with activated BAX to inhibit apoptosis. Reason: Mitochondrial localization is stress-induced and relates to the anti-apoptotic function of intracellular CLU. Not the primary extracellular localization. Supporting Evidence: PMID:16113678 intracellular clusterin inhibits apoptosis by interfering with Bax activation in mitochondria
GO:0034366 spherical high-density lipoprotein particle	IDA PMID:16682745 Isolation and characterization of human apolipoprotein M-con...	ACCEPT	Summary: PMID:16682745 identifies apoJ (CLU) among proteins in apoM-containing HDL particles by mass spectrometry. CLU is a well-known component of HDL particles in plasma (PMID:2387851). Reason: CLU is a core component of HDL particles, where it functions as apolipoprotein J. This is a well-established localization consistent with its dual role as chaperone and apolipoprotein. Supporting Evidence: PMID:16682745 Mass spectrometry showed that the apoM-containing lipoproteins also contained apoJ, apoA-I, apoA-II, apoC-I, apoC-II, apoC-III, paraoxonase 1, and apoB.
GO:0043691 reverse cholesterol transport	TAS PMID:16682745 Isolation and characterization of human apolipoprotein M-con...	KEEP AS NON CORE	Summary: PMID:16682745 characterizes apoM-containing HDL particles and their role in cholesterol efflux. CLU is present on HDL particles that stimulate cholesterol efflux from THP-1 foam cells. CLU's role in reverse cholesterol transport is secondary to its primary chaperone function. Reason: CLU associates with HDL particles and may participate in reverse cholesterol transport as an apolipoprotein, but this is a secondary function. CLU's primary role on HDL is likely chaperone-related rather than lipid transport per se.
GO:0006629 lipid metabolic process	NAS PMID:2387851 Purification and characterization of apolipoprotein J.	KEEP AS NON CORE	Summary: PMID:2387851 is the original characterization of apolipoprotein J (CLU) as a component of HDL. CLU is an apolipoprotein that associates with lipid particles, but its primary function is protein chaperoning rather than lipid metabolism. Reason: CLU is an apolipoprotein associated with HDL, but its primary molecular function is as a holdase chaperone, not lipid metabolism. The NAS evidence code reflects a non-traceable statement. Lipid metabolic process is a very broad term.
GO:0006956 complement activation	TAS PMID:1585460 Clusterin: the intriguing guises of a widely expressed glyco...	MODIFY	Summary: PMID:1585460 is the early review describing CLU's participation in the terminal complement reaction. CLU inhibits complement rather than activating it, so the term complement activation is technically inaccurate for CLU's role. More specific terms (GO:0045916 negative regulation of complement activation) are already annotated. Reason: CLU is a complement inhibitor, not an activator. The term complement activation is misleading. While CLU participates in complement biology, its role is inhibitory. The more accurate term GO:0045916 negative regulation of complement activation is already annotated via IDA. Proposed replacements: negative regulation of complement activation Supporting Evidence: PMID:1585460 participates in the terminal complement reaction

Core Functions

CLU (Clusterin/Apolipoprotein J) is a secreted extracellular holdase chaperone that binds a very broad range of structurally divergent stressed and misfolded protein substrates via exposed hydrophobic surfaces. CLU prevents irreversible aggregation by forming soluble high-molecular-weight complexes with its client proteins, maintaining them in a state competent for refolding by downstream ATP-dependent chaperones such as HSP70/HSC70. CLU itself does NOT refold proteins and does NOT require ATP. Recent structural analyses (2024-2025) reveal that two intrinsically disordered hydrophobic tails generated by precursor cleavage are indispensable for this holdase chaperone activity. CLU chaperone activity is enhanced at mildly acidic pH and depends on glycosylation.

Molecular Function:

misfolded protein binding

Directly Involved In:

protein stabilization protein folding negative regulation of amyloid fibril formation negative regulation of amyloid-beta formation

Cellular Locations:

extracellular space

Supporting Evidence:

PMID:11123922
clusterin (i) inhibits stress-induced precipitation of a very broad range of structurally divergent protein substrates, (ii) binds irreversibly via an ATP-independent mechanism to stressed proteins to form solubilized high molecular weight complexes, (iii) lacks detectable ATPase activity, (iv) when acting alone, does not effect refolding of stressed proteins in vitro, and (v) stabilizes stressed proteins in a state competent for refolding by heat shock protein 70 (HSP70).
PMID:12176985
the chaperone action of clusterin is enhanced at mildly acidic pH.
PMID:19996109
These proteins were identified by mass spectrometry as ceruloplasmin, fibrinogen, and albumin as major plasma clients for CLU under shear stress.

CLU functions as a carrier chaperone that binds misfolded proteins (including amyloid-beta) and delivers them to cell surface receptors (LRP2/megalin, TREM2, VLDLR) for receptor-mediated endocytosis and lysosomal degradation. This carrier function is central to extracellular protein quality control, facilitating clearance of damaged proteins from the extracellular space. CLU-Abeta complexes bind LRP-2 with high affinity, promoting cellular uptake and degradation. CLU also acts as a ligand for TREM2 on microglia, facilitating amyloid-beta clearance in the CNS.

Molecular Function:

protein carrier chaperone

Directly Involved In:

amyloid-beta clearance positive regulation of receptor-mediated endocytosis immune complex clearance protein targeting to lysosome involved in chaperone-mediated autophagy

Cellular Locations:

extracellular space

Supporting Evidence:

PMID:9228033
When LRP-2-expressing cells were given 125I-Abeta1-40, cellular uptake of the radiolabeled peptide was promoted by co-incubation with apoJ.
PMID:27477018
identified a set of lipoprotein particles (including LDL) and apolipoproteins (including CLU/APOJ and APOE) as ligands of TREM2.

CLU inhibits the terminal complement pathway by sequestering soluble membrane attack complex (sMAC) precursors and preventing C9 polymerization. Cryo-EM structures show CLU binds a negatively charged surface of sMAC and obstructs the polymerizing face of C9, trapping it in an intermediate conformation. CLU also binds C5b-7 to prevent membrane attachment and binds C5b-8 and C5b-9 to prevent further C9 assembly. At physiological levels, CLU can reduce complement cytolysis of nucleated cells by 10-fold or more.

Molecular Function:

protein sequestering activity

Directly Involved In:

negative regulation of activation of membrane attack complex negative regulation of complement activation negative regulation of complement-dependent cytotoxicity

Cellular Locations:

extracellular space

Supporting Evidence:

PMID:34667172
clusterin recognizes and inhibits polymerizing complement proteins by binding a negatively charged surface of sMAC.
PMID:9200695
Clusterin inhibited C9 assembly on C5b-8 and C5b-9 and also bound to C5b-7 to prevent membrane attachment.
PMID:9200695
the presence of <10% of the circulating clusterin in its heterodimeric, active form could reduce the rate of complement cytolysis of nucleated cells by 10-fold, and under some conditions by 100-fold or more.

References

GO_REF:0000024

Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity

GO_REF:0000033

Annotation inferences using phylogenetic trees

GO_REF:0000043

Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping

GO_REF:0000044

Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt

GO_REF:0000052

Gene Ontology annotation based on curation of immunofluorescence data

GO_REF:0000107

Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara

GO_REF:0000120

Combined Automated Annotation using Multiple IEA Methods

PMID:11123922

Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state.

PMID:12047389

Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin.

PMID:12176985

Mildly acidic pH activates the extracellular molecular chaperone clusterin.

PMID:1585460

Clusterin: the intriguing guises of a widely expressed glycoprotein.

PMID:15857407

Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro.

PMID:15897157

Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain.

PMID:16113678

Clusterin inhibits apoptosis by interacting with activated Bax.

PMID:16502470

Human colostrum: identification of minor proteins in the aqueous phase by proteomics.

PMID:16548883

Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection.

PMID:16682745

Isolation and characterization of human apolipoprotein M-containing lipoproteins.

PMID:17043677

Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia.

PMID:17170699

ERp57 is essential for efficient folding of glycoproteins sharing common structural domains.

PMID:17412999

The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures.

PMID:17567961

Characterization of an eppin protein complex from human semen and spermatozoa.

PMID:17689225

Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer.

PMID:19056867

Large-scale proteomics and phosphoproteomics of urinary exosomes.

PMID:19137541

Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells.

PMID:19199708

Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).

PMID:19996109

Identification of human plasma proteins as major clients for the extracellular chaperone clusterin.

PMID:20005821

Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.

PMID:20068069

Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.

PMID:20195357

A comprehensive resource of interacting protein regions for refining human transcription factor networks.

PMID:20551380

Proteomics characterization of extracellular space components in the human aorta.

PMID:21397462

Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene.

PMID:21543606

Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults.

PMID:21803450

The APP intracellular domain (AICD) potentiates ER stress-induced apoptosis.

PMID:22179788

The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide.

PMID:22516433

Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.

PMID:22528093

Search for amyloid-binding proteins by affinity chromatography.

PMID:22689054

GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.

PMID:23106396

Amyloid-β oligomers are sequestered by both intracellular and extracellular chaperones.

PMID:23164821

Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway.

PMID:23533145

In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

PMID:2387851

Purification and characterization of apolipoprotein J.

PMID:24446231

Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro.

PMID:25051234

Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer's disease.

PMID:25402950

The chaperone activity of clusterin is dependent on glycosylation and redox environment.

PMID:25451228

PACAP inhibits tumor growth and interferes with clusterin in cervical carcinomas.

PMID:26496610

A human interactome in three quantitative dimensions organized by stoichiometries and abundances.

PMID:27068509

Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins.

PMID:27477018

TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia.

PMID:27559042

Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation.

PMID:28887769

α-Synuclein Interacts with Lipoproteins in Plasma.

PMID:30333625

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.

PMID:31270237

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients.

PMID:31413325

HENA, heterogeneous network-based data set for Alzheimer's disease.

PMID:32814053

Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.

PMID:34667172

Structural basis of soluble membrane attack complex packaging for clearance.

PMID:8555189

Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin.

PMID:9200695

Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization.

PMID:9228033

Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide.

PMID:9560017

Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study.

Reactome:R-HSA-481007

Exocytosis of platelet alpha granule contents

Reactome:R-HSA-6810643

EPPIN protein complex binds bacteria

Reactome:R-HSA-8852580

Clusterin binds C5b-C7, C8, C9

📚 Additional Documentation

Deep Research Falcon

(CLU-deep-research-falcon.md)

provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-09T10:05:10.077989'
end_time: '2026-02-09T10:12:04.273786'
duration_seconds: 414.2
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: CLU
gene_symbol: CLU
uniprot_accession: P10909
protein_description: 'RecName: Full=Clusterin; AltName: Full=Aging-associated gene
4 protein {ECO:0000303|Ref.20}; AltName: Full=Apolipoprotein J {ECO:0000303|PubMed:2387851};
Short=Apo-J; AltName: Full=Complement cytolysis inhibitor {ECO:0000303|PubMed:2780565};
Short=CLI {ECO:0000303|PubMed:2780565}; AltName: Full=Complement-associated protein
SP-40,40 {ECO:0000303|PubMed:1903064, ECO:0000303|PubMed:2721499}; AltName: Full=Ku70-binding
protein 1; AltName: Full=NA1/NA2 {ECO:0000303|PubMed:1903064}; AltName: Full=Sulfated
glycoprotein 2 {ECO:0000303|PubMed:1924317}; Short=SGP-2 {ECO:0000303|PubMed:1924317};
AltName: Full=Testosterone-repressed prostate message 2 {ECO:0000250|UniProtKB:P05371};
Short=TRPM-2 {ECO:0000303|PubMed:8181474}; Contains: RecName: Full=Clusterin beta
chain; AltName: Full=ApoJalpha {ECO:0000303|PubMed:1974459, ECO:0000303|PubMed:2387851};
AltName: Full=Complement cytolysis inhibitor a chain {ECO:0000303|PubMed:2780565};
AltName: Full=SP-40,40 beta-chain {ECO:0000303|PubMed:2721499}; Contains: RecName:
Full=Clusterin alpha chain; AltName: Full=ApoJbeta {ECO:0000303|PubMed:1974459,
ECO:0000303|PubMed:2387851}; AltName: Full=Complement cytolysis inhibitor b chain
{ECO:0000303|PubMed:2780565}; AltName: Full=SP-40,40 alpha-chain {ECO:0000303|PubMed:2721499};
Flags: Precursor;'
gene_info: Name=CLU {ECO:0000312|HGNC:HGNC:2095}; Synonyms=APOJ {ECO:0000303|PubMed:2387851},
CLI {ECO:0000303|PubMed:2780565}, KUB1; ORFNames=AAG4;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the clusterin family. .
protein_domains: Clusterin. (IPR016016); Clusterin-like. (IPR000753); Clusterin_C.
(IPR016015); Clusterin_CS. (IPR033986); Clusterin_N. (IPR016014)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 35

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

UniProt Accession: P10909
Protein Description: RecName: Full=Clusterin; AltName: Full=Aging-associated gene 4 protein {ECO:0000303|Ref.20}; AltName: Full=Apolipoprotein J {ECO:0000303|PubMed:2387851}; Short=Apo-J; AltName: Full=Complement cytolysis inhibitor {ECO:0000303|PubMed:2780565}; Short=CLI {ECO:0000303|PubMed:2780565}; AltName: Full=Complement-associated protein SP-40,40 {ECO:0000303|PubMed:1903064, ECO:0000303|PubMed:2721499}; AltName: Full=Ku70-binding protein 1; AltName: Full=NA1/NA2 {ECO:0000303|PubMed:1903064}; AltName: Full=Sulfated glycoprotein 2 {ECO:0000303|PubMed:1924317}; Short=SGP-2 {ECO:0000303|PubMed:1924317}; AltName: Full=Testosterone-repressed prostate message 2 {ECO:0000250|UniProtKB:P05371}; Short=TRPM-2 {ECO:0000303|PubMed:8181474}; Contains: RecName: Full=Clusterin beta chain; AltName: Full=ApoJalpha {ECO:0000303|PubMed:1974459, ECO:0000303|PubMed:2387851}; AltName: Full=Complement cytolysis inhibitor a chain {ECO:0000303|PubMed:2780565}; AltName: Full=SP-40,40 beta-chain {ECO:0000303|PubMed:2721499}; Contains: RecName: Full=Clusterin alpha chain; AltName: Full=ApoJbeta {ECO:0000303|PubMed:1974459, ECO:0000303|PubMed:2387851}; AltName: Full=Complement cytolysis inhibitor b chain {ECO:0000303|PubMed:2780565}; AltName: Full=SP-40,40 alpha-chain {ECO:0000303|PubMed:2721499}; Flags: Precursor;
Gene Information: Name=CLU {ECO:0000312|HGNC:HGNC:2095}; Synonyms=APOJ {ECO:0000303|PubMed:2387851}, CLI {ECO:0000303|PubMed:2780565}, KUB1; ORFNames=AAG4;
Organism (full): Homo sapiens (Human).
Protein Family: Belongs to the clusterin family. .
Key Domains: Clusterin. (IPR016016); Clusterin-like. (IPR000753); Clusterin_C. (IPR016015); Clusterin_CS. (IPR033986); Clusterin_N. (IPR016014)

MANDATORY VERIFICATION STEPS:

Check if the gene symbol "CLU" matches the protein description above
Verify the organism is correct: Homo sapiens (Human).
Check if protein family/domains align with what you find in literature
If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'CLU' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene CLU (gene ID: CLU, UniProt: P10909) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

UniProt Accession: P10909
Protein Description: RecName: Full=Clusterin; AltName: Full=Aging-associated gene 4 protein {ECO:0000303|Ref.20}; AltName: Full=Apolipoprotein J {ECO:0000303|PubMed:2387851}; Short=Apo-J; AltName: Full=Complement cytolysis inhibitor {ECO:0000303|PubMed:2780565}; Short=CLI {ECO:0000303|PubMed:2780565}; AltName: Full=Complement-associated protein SP-40,40 {ECO:0000303|PubMed:1903064, ECO:0000303|PubMed:2721499}; AltName: Full=Ku70-binding protein 1; AltName: Full=NA1/NA2 {ECO:0000303|PubMed:1903064}; AltName: Full=Sulfated glycoprotein 2 {ECO:0000303|PubMed:1924317}; Short=SGP-2 {ECO:0000303|PubMed:1924317}; AltName: Full=Testosterone-repressed prostate message 2 {ECO:0000250|UniProtKB:P05371}; Short=TRPM-2 {ECO:0000303|PubMed:8181474}; Contains: RecName: Full=Clusterin beta chain; AltName: Full=ApoJalpha {ECO:0000303|PubMed:1974459, ECO:0000303|PubMed:2387851}; AltName: Full=Complement cytolysis inhibitor a chain {ECO:0000303|PubMed:2780565}; AltName: Full=SP-40,40 beta-chain {ECO:0000303|PubMed:2721499}; Contains: RecName: Full=Clusterin alpha chain; AltName: Full=ApoJbeta {ECO:0000303|PubMed:1974459, ECO:0000303|PubMed:2387851}; AltName: Full=Complement cytolysis inhibitor b chain {ECO:0000303|PubMed:2780565}; AltName: Full=SP-40,40 alpha-chain {ECO:0000303|PubMed:2721499}; Flags: Precursor;
Gene Information: Name=CLU {ECO:0000312|HGNC:HGNC:2095}; Synonyms=APOJ {ECO:0000303|PubMed:2387851}, CLI {ECO:0000303|PubMed:2780565}, KUB1; ORFNames=AAG4;
Organism (full): Homo sapiens (Human).
Protein Family: Belongs to the clusterin family. .
Key Domains: Clusterin. (IPR016016); Clusterin-like. (IPR000753); Clusterin_C. (IPR016015); Clusterin_CS. (IPR033986); Clusterin_N. (IPR016014)

MANDATORY VERIFICATION STEPS:

Check if the gene symbol "CLU" matches the protein description above
Verify the organism is correct: Homo sapiens (Human).
Check if protein family/domains align with what you find in literature
If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

Research Target:

Please provide a comprehensive research report on the gene CLU (gene ID: CLU, UniProt: P10909) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Research plan
- Verify target identity, organism, and domain family to avoid symbol ambiguity. Completed: CLU encodes human Clusterin/Apolipoprotein J (UniProt P10909), a secreted heterodimeric glycoprotein of the clusterin family with characteristic N-glycosylation and disulfide bonding (see below). (sultana2024clusterinadoubleedged pages 1-3, yustecheca2024hydrophobictailsenable pages 1-4, yustecheca2025structuralanalysesdefine pages 9-10)
- Synthesize current concepts and definitions (structure, processing, localization, molecular functions) from recent primary and review sources (priority 2023–2025). (sultana2024clusterinadoubleedged pages 1-3, milinkeviciute2023clusterinapolipoproteinjits pages 1-2, yustecheca2024hydrophobictailsenable pages 1-4, yustecheca2025structuralanalysesdefine pages 9-10, yustecheca2024hydrophobictailsenable pages 45-46)
- Summarize pathway context and mechanisms (extracellular proteostasis, complement, lipoprotein metabolism) including new structural/biophysical insights. (yustecheca2024hydrophobictailsenable pages 1-4, yustecheca2025structuralanalysesdefine pages 9-10, yustecheca2024hydrophobictailsenable pages 45-46)
- Detail disease relevance with emphasis on 2023–2025 findings (Alzheimer’s disease/CAA, kidney disease, cardiovascular disease, oncology where supported), with statistics. (milinkeviciute2023clusterinapolipoproteinjits pages 1-2, laslo2024pathwaystoalzheimer’s pages 2-3, laslo2024pathwaystoalzheimer’s pages 1-2, yustecheca2024hydrophobictailsenable pages 9-12, yustecheca2025structuralanalysesdefine pages 9-10)
- Document current applications and real-world implementations (plasma/CSF/urine clusterin assays; prognostic/diagnostic performance; interventional implications). (milinkeviciute2023clusterinapolipoproteinjits pages 1-2)
- Compile expert viewpoints and limitations.

Gene/protein identity verification
- Gene symbol and organism: CLU (HGNC:2095) encodes Clusterin/ApoJ in Homo sapiens; UniProt P10909. Multiple recent sources explicitly discuss human secreted clusterin. The protein is synthesized as a glycoprotein precursor and secreted after proteolytic maturation into disulfide‑linked alpha and beta chains (see Molecular identity) (EXCLI Journal 2024: https://doi.org/10.17179/excli2024-7369; bioRxiv 2024: https://doi.org/10.1101/2024.10.30.620894; Nature Structural & Molecular Biology 2025: https://doi.org/10.1038/s41594-025-01631-4). (sultana2024clusterinadoubleedged pages 1-3, yustecheca2024hydrophobictailsenable pages 1-4, yustecheca2025structuralanalysesdefine pages 9-10)
- Family/domains: Belongs to the clusterin family; recent structural work defines a discontinuous three‑domain core stabilized by conserved disulfides and flanked by two intrinsically disordered hydrophobic tails essential for function. (yustecheca2025structuralanalysesdefine pages 9-10, yustecheca2024hydrophobictailsenable pages 1-4)

1) Key concepts and definitions: molecular identity, processing, and isoforms
- Processing and architecture: Clusterin is translated into the ER, N‑glycosylated at multiple sites, and cleaved in the Golgi into alpha and beta chains that remain covalently linked via several conserved disulfide bonds, yielding a mature 75–80 kDa secreted heterodimer. Structural analyses (2024–2025) reveal a three‑domain core plus two disordered, hydrophobic tails generated by the precursor cleavage; these tails are indispensable for ATP‑independent holdase chaperone activity, receptor engagement, and lipoprotein particle formation. URLs: EXCLI Journal 2024 (Jul 2024): https://doi.org/10.17179/excli2024-7369; bioRxiv 2024 (Oct 2024): https://doi.org/10.1101/2024.10.30.620894; NSMB 2025 (Aug 2025): https://doi.org/10.1038/s41594-025-01631-4. (sultana2024clusterinadoubleedged pages 1-3, yustecheca2024hydrophobictailsenable pages 1-4, yustecheca2025structuralanalysesdefine pages 9-10)
- Isoforms: The CLU locus produces multiple mRNA isoforms via alternative splicing; literature reports a predominant secreted isoform (sCLU) and additional intracellular/nuclear forms under stress or alternative translation/splicing contexts. In brain, astrocytes are a dominant source of secreted clusterin. URL: Frontiers in Aging Neuroscience 2023 (Apr 2023): https://doi.org/10.3389/fnagi.2023.1167886; EXCLI Journal 2024: https://doi.org/10.17179/excli2024-7369. (milinkeviciute2023clusterinapolipoproteinjits pages 1-2, sultana2024clusterinadoubleedged pages 1-3)

2) Primary molecular functions with mechanisms
- Extracellular ATP‑independent holdase chaperone: Clusterin binds exposed hydrophobic surfaces on non‑native and amyloidogenic proteins to prevent aggregation and to sequester toxic oligomers. Recent structural work shows the two disordered hydrophobic tails mediate promiscuous client binding (Aβ, tau, α‑synuclein) and are required for chaperone activity; mutational tail deletions or hydrophobic→Ser substitutions abolish function. URL: NSMB 2025: https://doi.org/10.1038/s41594-025-01631-4; bioRxiv 2024: https://doi.org/10.1101/2024.10.30.620894. (yustecheca2025structuralanalysesdefine pages 9-10, yustecheca2024hydrophobictailsenable pages 1-4)
- Lipid transport as ApoJ: Clusterin associates with lipid to form ApoJ‑containing lipoprotein particles in plasma and lipid‑poor ApoJ in CSF; lipid‑bound clusterin retains chaperone function. CSF lipoprotein studies catalog ApoJ among core apolipoproteins of CNS lipoproteins. URLs: Arteriosclerosis, Thrombosis, and Vascular Biology 2024 (May 2024): https://doi.org/10.1161/atvbaha.123.318284; bioRxiv 2024: https://doi.org/10.1101/2024.10.30.620894. (yustecheca2024hydrophobictailsenable pages 9-12)
- Complement regulation (MAC/C5b‑9): Clusterin binds late complement components and has been characterized as an inhibitor of membrane attack complex formation, contributing to extracellular proteostasis and limiting bystander damage; complement pathway reviews note clusterin among common inhibitors of complement activation. URLs: Int J Mol Sci 2024 (Jan 2024): https://doi.org/10.3390/ijms25031566; Int J Mol Sci 2024 (Aug 2024) peritoneal dialysis review referencing MAC regulation: https://doi.org/10.3390/ijms25168607. (, )
- Receptor interactions and clearance: Clusterin and clusterin–cargo complexes interact with LDL receptor–family receptors including LRP2/megalin and VLDLR to mediate cellular uptake and clearance; recent structural analyses mapped tail‑dependent binding determinants for VLDLR. URLs: bioRxiv 2024: https://doi.org/10.1101/2024.10.30.620894. (yustecheca2024hydrophobictailsenable pages 45-46, yustecheca2024hydrophobictailsenable pages 1-4)

3) Subcellular and tissue localization
- Localization: Clusterin is secreted to extracellular fluids (plasma, CSF, urine) and circulates both free and within ApoJ‑lipoproteins; it can bind cell surfaces and extracellular matrices. In the brain, astrocytes secrete clusterin; neurons readily take up extracellular clusterin. Under ER stress or proteostasis challenge, intracellular relocalization and non‑canonical trafficking have been reported. URLs: Frontiers in Aging Neuroscience 2023: https://doi.org/10.3389/fnagi.2023.1167886; EXCLI 2024: https://doi.org/10.17179/excli2024-7369; ATVB 2024: https://doi.org/10.1161/atvbaha.123.318284. (milinkeviciute2023clusterinapolipoproteinjits pages 1-2, sultana2024clusterinadoubleedged pages 1-3)

4) Pathway context and 2023–2025 mechanistic advances
- Extracellular proteostasis: Structural resolution of clusterin’s three‑domain core and functional disordered tails (2024–2025) provides a mechanistic basis for ATP‑independent holdase activity and explains its ability to bind diverse clients and remain chaperone‑competent even when lipid‑bound. URLs: bioRxiv 2024; NSMB 2025. (yustecheca2024hydrophobictailsenable pages 1-4, yustecheca2025structuralanalysesdefine pages 9-10)
- Complement system: Reviews in 2024 emphasize roles of complement regulators, including clusterin, in tempering terminal complement (C5b‑9) assembly across disease contexts. URLs: Int J Mol Sci 2024 (lectin pathway): https://doi.org/10.3390/ijms25031566; peritoneal fibrosis review 2024: https://doi.org/10.3390/ijms25168607. (, )
- Lipoprotein metabolism: New compositional analyses catalog ApoJ among CSF lipoprotein particles and delineate their metabolism in cerebral circulation, consistent with clusterin’s dual apolipoprotein–chaperone role. URL: ATVB 2024: https://doi.org/10.1161/atvbaha.123.318284. ()

5) Disease relevance (emphasis 2023–2025)
- Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA):
• Genetics and pathology: CLU is a replicated late‑onset AD risk locus; clusterin is upregulated in AD brain/CSF, binds Aβ, localizes to plaques and CAA, and modulates Aβ aggregation and clearance. Recent reviews reinforce astrocytic origin and intersection with APOE pathways. URLs: Frontiers in Aging Neuroscience 2023: https://doi.org/10.3389/fnagi.2023.1167886; Pathophysiology 2024: https://doi.org/10.3390/pathophysiology31040040. (milinkeviciute2023clusterinapolipoproteinjits pages 1-2, laslo2024pathwaystoalzheimer’s pages 2-3, laslo2024pathwaystoalzheimer’s pages 1-2)
• Biomarkers and clinical associations: CSF clusterin correlates with canonical AD biomarkers and future cognitive change in MCI; baseline CSF clusterin predicted shifts in MMSE, memory, and executive function in longitudinal ADNI analyses. URL: Frontiers in Aging Neuroscience 2023 (Oct 2023): https://doi.org/10.3389/fnagi.2023.1256389. ()
• Interventional/preclinical modulation: In a CAA‑prone APP23 mouse model, chronic peripheral recombinant human ApoJ reduced cortical microbleeds and larger hemorrhages, improved vascular smooth muscle actin positivity, and modulated circulating inflammatory proteases (e.g., reduced MMP‑12), suggesting protection against BBB leakage independent of brain Aβ burden. Human acute ICH data linked higher plasma MMP‑12 with larger hemorrhage volume. URL: Alzheimer’s Research & Therapy 2024 (Jul 2024): https://doi.org/10.1186/s13195-024-01541-5. ()
• Radiation‑related cognitive decline: In a secondary analysis of a randomized trial in brain metastasis patients, lower baseline serum ApoJ (and ApoE/ApoA1) associated with greater 3‑month neurocognitive decline after stereotactic radiosurgery or WBRT (P<0.05). URL: Neuro‑Oncology 2023 (Dec 2023): https://doi.org/10.1093/neuonc/noac262. ()
• Complement in AD: Plasma studies found increased clusterin and C1q and decreased sCR1 and factor H in AD vs. controls; while C1q was the single best complement biomarker by ROC (AUC 0.655 for LOAD), clusterin increases support complement dysregulation in AD. URL: Journal of Neuroinflammation 2023 (Jul 2023): https://doi.org/10.1186/s12974-023-02850-6. ()

Kidney disease (AKI, CKD, DKD):
• Urinary clusterin as epithelial senescence biomarker and outcome predictor: Multi‑cohort human studies showed urinary clusterin correlates with renal epithelial p21+ senescence (rho >0.5, p<0.001) and predicts CKD progression (ESKD or >40% eGFR decline) independent of eGFR, albuminuria, age and SBP. Spatial transcriptomics colocalized CLU with CDKN1A in CKD kidneys. URL: Kidney International Reports 2025 (Mar 2025; preprint Mar 2024): https://doi.org/10.1101/2024.03.14.24303997. ()
• AKI and CI‑AKI: Reviews highlight clusterin among emerging urinary/serum injury biomarkers that respond earlier than creatinine and aid risk stratification in contrast‑induced AKI and drug nephrotoxicity. URLs: Int J Mol Sci 2024 (Mar 2024): https://doi.org/10.3390/ijms25063438. ()
• Complement engagement in kidney disease progression: Integrated proteomic–metabolomic CKD studies and complement‑focused literature underscore complement activation as a risk axis; clusterin’s MAC‑regulatory function provides a mechanistic link. URLs: JASN 2024 (Apr 2024): https://doi.org/10.1681/ASN.0000000000000343; Int J Mol Sci 2024 (Jan 2024): https://doi.org/10.3390/ijms25031566. (, )
Cardiovascular disease and atherosclerosis:
• Reviews and observational proteomics place ApoJ/clusterin within networks tied to vascular inflammation and lipoprotein biology. Some 2024–2025 studies suggest protective roles (e.g., modulation of macrophage activation/pyroptosis in diabetes‑accelerated atherosclerosis in preclinical models), consistent with anti‑inflammatory and complement‑regulatory properties. URLs: Frontiers in Pharmacology 2025 (Apr 2025): https://doi.org/10.3389/fphar.2025.1536132. ()
• Plasma proteomic links between AD and CVD feature shared biomarker panels that include apolipoproteins and complement, fitting clusterin’s dual apolipoprotein–chaperone role. URL: IJMS 2024 (Oct 2024): https://doi.org/10.3390/ijms251910751. ()
Oncology (brief, where evidence is strong):
• Expert review (2024) summarizes clusterin’s “double‑edged” behavior—neuroprotective in neurodegeneration but associated with tumor survival/therapy resistance in cancer; therapeutic strategies include CLU inhibition in oncology and enhancement in neurodegeneration. URL: EXCLI Journal 2024 (Jul 2024): https://doi.org/10.17179/excli2024-7369. (sultana2024clusterinadoubleedged pages 1-3)

6) Recent quantitative statistics (2023–2025)
- AD complement biomarker ROC: In plasma, C1q AUC 0.655 for LOAD (0.601 for EOAD) as a single complement marker; clusterin increased vs controls but less predictive alone; multi‑marker models marginally improved prediction. (Journal of Neuroinflammation, Jul 2023). ()
- CSF clusterin predicts cognition in MCI: Baseline CSF clusterin associated with subsequent cognitive performance changes (e.g., MMSE β=0.202, p=0.029; memory composite β=0.186, p=0.036; executive function β=0.221, p=0.013) in ADNI. (Frontiers in Aging Neuroscience, Oct 2023). ()
- CAA mouse intervention: rhApoJ reduced cortical microbleeds (50–300 μm diameter, p=0.012) and larger hemorrhages (>300 μm, p=0.002) vs saline in APP23 mice; increased SMA+ vessels (p=0.038) and altered plasma MMP‑12 (decrease, p=0.046). (Alzheimer’s Research & Therapy, Jul 2024). ()
- Radiotherapy cognitive decline: Low baseline serum ApoJ associated with higher odds of 3‑month neurocognitive decline post‑SRS or WBRT (ApoJ, P=0.014 for WBRT; ApoJ/ApoE/ApoA1 P<0.01 for SRS). (Neuro‑Oncology, Dec 2023). ()
- Urinary clusterin and CKD progression: uClusterin correlated with epithelial p21+ senescence (rho >0.5, p<0.001) in paired urine–biopsy cohorts; predicted composite CKD progression independent of eGFR/albuminuria/age/SBP/sex in n=322 cohort. (Kidney International Reports, Mar 2025). ()

7) Current applications and real‑world implementations
- Assay modalities: Clusterin is commonly measured by immunoassays (ELISA) in serum/plasma/CSF and by immunoassays or proteomics in urine. Clinical and trial‑embedded studies have employed longitudinal sampling to relate baseline ApoJ to cognitive outcomes after radiotherapy and to AD/MCI trajectories. URLs: Neuro‑Oncology 2023: https://doi.org/10.1093/neuonc/noac262; Frontiers in Aging Neuroscience 2023: https://doi.org/10.3389/fnagi.2023.1256389. (, )
- AD/CAA: Plasma/CSF ApoJ is integrated in multi‑analyte biomarker panels; preclinical rhApoJ reduces microbleeds in CAA model, supporting translational exploration of peripheral ApoJ augmentation. (Alzheimer’s Research & Therapy 2024). ()
- Nephrology: Urinary clusterin is emerging as a non‑invasive marker of tubular epithelial senescence and a predictor of CKD progression, with potential to enrich senolytic clinical trials; AKI and CI‑AKI reviews include clusterin among early injury markers. URLs: Kidney International Reports 2025; Int J Mol Sci 2024. (, )

Expert opinions, synthesis, and outstanding questions
- Converging evidence positions clusterin as a central node at the intersection of extracellular proteostasis, complement regulation, and lipid transport. Structural breakthroughs (2024–2025) now unify disparate activities—client binding, receptor engagement, and lipoprotein assembly—through the essential disordered hydrophobic tails. This clarifies how clusterin can remain chaperone‑competent when lipid‑bound and suggests tail‑targeted engineering for disease‑specific outcomes (e.g., optimizing anti‑amyloid activity while preserving clearance via VLDLR/LRP2). (yustecheca2025structuralanalysesdefine pages 9-10, yustecheca2024hydrophobictailsenable pages 1-4)
- In AD/CAA, context and dose likely determine whether clusterin is net‑protective (toxic oligomer sequestration and clearance; vascular protection) or pro‑depositing (stabilizing Aβ complexes under certain ratios); rigorous, isoform‑aware assays and in vivo mechanistic readouts remain essential. (milinkeviciute2023clusterinapolipoproteinjits pages 1-2, laslo2024pathwaystoalzheimer’s pages 2-3, laslo2024pathwaystoalzheimer’s pages 1-2)
- In kidney disease, accumulating data support urinary clusterin as a proximal injury/senescence reporter that adds prognostic value beyond established metrics; interventional studies should test whether changes in uClusterin track target‑engagement (e.g., anti‑senescence or anti‑complement therapies). (, )

Conclusion
- Verified target: CLU (P10909), human secreted heterodimeric clusterin/apolipoprotein J with conserved glycosylation and disulfide architecture, member of the clusterin family. (sultana2024clusterinadoubleedged pages 1-3, yustecheca2024hydrophobictailsenable pages 1-4, yustecheca2025structuralanalysesdefine pages 9-10)
- Mechanism: ATP‑independent extracellular holdase chaperone mediated by two essential disordered hydrophobic tails; participates in complement MAC inhibition; forms/associates with ApoJ‑lipoproteins while retaining chaperone competence; engages LDLR‑family receptors to clear clients. (yustecheca2025structuralanalysesdefine pages 9-10, yustecheca2024hydrophobictailsenable pages 1-4)
- Localization: Secreted to plasma/CSF/urine and associates with HDL‑like particles; predominant astrocytic expression in brain with neuronal uptake; stress can alter intracellular trafficking. (milinkeviciute2023clusterinapolipoproteinjits pages 1-2, sultana2024clusterinadoubleedged pages 1-3)
- Disease and applications (2023–2025):
• AD/CAA: CSF clusterin predicts cognitive trajectories; plasma/CSF clusterin elevated in AD; peripheral rhApoJ reduces microbleeds in CAA mice; complement biomarker work shows increased clusterin alongside C1q in AD. (, )
• Kidney: Urinary clusterin tracks epithelial senescence and independently predicts CKD progression; recognized in AKI/CI‑AKI biomarker frameworks. (, )
• Cardiovascular: Emerging preclinical evidence for anti‑inflammatory/anti‑pyroptotic effects in diabetic atherosclerosis; shared plasma proteomic signals with AD/CVD panels. ()
- Quantitative highlights: AD plasma C1q AUC 0.655 (LOAD) with increased plasma clusterin; CSF clusterin β≈0.18–0.22 predicting MCI cognitive outcomes; rhApoJ reduced microbleeds (p=0.012) and large hemorrhages (p=0.002) in APP23 mice; urinary clusterin rho>0.5 with epithelial p21 and independent prediction of CKD progression. (, )

All claims above are supported by and traceable to the cited 2023–2025 sources with URLs and publication dates embedded alongside each section.

References

(sultana2024clusterinadoubleedged pages 1-3): Pinky Sultana and Jiri Novotny. Clusterin: a double-edged sword in cancer and neurological disorders. EXCLI Journal, 23:912-936, Jul 2024. URL: https://doi.org/10.17179/excli2024-7369, doi:10.17179/excli2024-7369. This article has 15 citations and is from a peer-reviewed journal.
(yustecheca2024hydrophobictailsenable pages 1-4): Patricia Yuste-Checa, Alonso I. Carvajal, Chenchen Mi, Sarah Paatz, F. Ulrich Hartl, and Andreas Bracher. Hydrophobic tails enable diverse functions of the extracellular chaperone clusterin. bioRxiv, Oct 2024. URL: https://doi.org/10.1101/2024.10.30.620894, doi:10.1101/2024.10.30.620894. This article has 0 citations and is from a poor quality or predatory journal.
(yustecheca2025structuralanalysesdefine pages 9-10): P. Yuste-Checa, Alonso I Carvajal, Chenchen Mi, Sarah Paatz, F. Hartl, and A. Bracher. Structural analyses define the molecular basis of clusterin chaperone function. Nature structural & molecular biology, Aug 2025. URL: https://doi.org/10.1038/s41594-025-01631-4, doi:10.1038/s41594-025-01631-4. This article has 3 citations and is from a highest quality peer-reviewed journal.
(milinkeviciute2023clusterinapolipoproteinjits pages 1-2): Giedre Milinkeviciute and Kim N. Green. Clusterin/apolipoprotein j, its isoforms and alzheimer's disease. Frontiers in Aging Neuroscience, Apr 2023. URL: https://doi.org/10.3389/fnagi.2023.1167886, doi:10.3389/fnagi.2023.1167886. This article has 19 citations and is from a peer-reviewed journal.
(yustecheca2024hydrophobictailsenable pages 45-46): Patricia Yuste-Checa, Alonso I. Carvajal, Chenchen Mi, Sarah Paatz, F. Ulrich Hartl, and Andreas Bracher. Hydrophobic tails enable diverse functions of the extracellular chaperone clusterin. bioRxiv, Oct 2024. URL: https://doi.org/10.1101/2024.10.30.620894, doi:10.1101/2024.10.30.620894. This article has 0 citations and is from a poor quality or predatory journal.
(laslo2024pathwaystoalzheimer’s pages 2-3): Alexandru Laslo, Laura Laslo, Eliza-Mihaela Arbănași, Alexandru-Andrei Ujlaki-Nagi, Laura Chinezu, Adrian Dumitru Ivănescu, Emil-Marian Arbănași, Roxana Octavia Cărare, Bogdan Andrei Cordoș, Ioana Adriana Popa, and Klara Brînzaniuc. Pathways to alzheimer’s disease: the intersecting roles of clusterin and apolipoprotein e in amyloid-β regulation and neuronal health. Pathophysiology, 31:545-558, Oct 2024. URL: https://doi.org/10.3390/pathophysiology31040040, doi:10.3390/pathophysiology31040040. This article has 9 citations and is from a poor quality or predatory journal.
(laslo2024pathwaystoalzheimer’s pages 1-2): Alexandru Laslo, Laura Laslo, Eliza-Mihaela Arbănași, Alexandru-Andrei Ujlaki-Nagi, Laura Chinezu, Adrian Dumitru Ivănescu, Emil-Marian Arbănași, Roxana Octavia Cărare, Bogdan Andrei Cordoș, Ioana Adriana Popa, and Klara Brînzaniuc. Pathways to alzheimer’s disease: the intersecting roles of clusterin and apolipoprotein e in amyloid-β regulation and neuronal health. Pathophysiology, 31:545-558, Oct 2024. URL: https://doi.org/10.3390/pathophysiology31040040, doi:10.3390/pathophysiology31040040. This article has 9 citations and is from a poor quality or predatory journal.
(yustecheca2024hydrophobictailsenable pages 9-12): Patricia Yuste-Checa, Alonso I. Carvajal, Chenchen Mi, Sarah Paatz, F. Ulrich Hartl, and Andreas Bracher. Hydrophobic tails enable diverse functions of the extracellular chaperone clusterin. bioRxiv, Oct 2024. URL: https://doi.org/10.1101/2024.10.30.620894, doi:10.1101/2024.10.30.620894. This article has 0 citations and is from a poor quality or predatory journal.

Citations

milinkeviciute2023clusterinapolipoproteinjits pages 1-2
yustecheca2024hydrophobictailsenable pages 9-12
sultana2024clusterinadoubleedged pages 1-3
yustecheca2024hydrophobictailsenable pages 1-4
yustecheca2025structuralanalysesdefine pages 9-10
yustecheca2024hydrophobictailsenable pages 45-46
https://doi.org/10.17179/excli2024-7369;
https://doi.org/10.1101/2024.10.30.620894;
https://doi.org/10.1038/s41594-025-01631-4
https://doi.org/10.1038/s41594-025-01631-4.
https://doi.org/10.3389/fnagi.2023.1167886;
https://doi.org/10.17179/excli2024-7369.
https://doi.org/10.1038/s41594-025-01631-4;
https://doi.org/10.1101/2024.10.30.620894.
https://doi.org/10.1161/atvbaha.123.318284;
https://doi.org/10.3390/ijms25031566;
https://doi.org/10.3390/ijms25168607.
https://doi.org/10.1161/atvbaha.123.318284.
https://doi.org/10.3390/pathophysiology31040040.
https://doi.org/10.3389/fnagi.2023.1256389.
https://doi.org/10.1186/s13195-024-01541-5.
https://doi.org/10.1093/neuonc/noac262.
https://doi.org/10.1186/s12974-023-02850-6.
https://doi.org/10.1101/2024.03.14.24303997.
https://doi.org/10.3390/ijms25063438.
https://doi.org/10.1681/ASN.0000000000000343;
https://doi.org/10.3390/ijms25031566.
https://doi.org/10.3389/fphar.2025.1536132.
https://doi.org/10.3390/ijms251910751.
https://doi.org/10.1093/neuonc/noac262;
https://doi.org/10.17179/excli2024-7369,
https://doi.org/10.1101/2024.10.30.620894,
https://doi.org/10.1038/s41594-025-01631-4,
https://doi.org/10.3389/fnagi.2023.1167886,
https://doi.org/10.3390/pathophysiology31040040,

📄 View Raw YAML

id: P10909
gene_symbol: CLU
product_type: PROTEIN
status: IN_PROGRESS
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: >-
  Clusterin (CLU), also known as Apolipoprotein J (ApoJ) and Complement
  Cytolysis Inhibitor (CLI), is a highly glycosylated secreted chaperone that
  functions primarily as an extracellular holdase. The predominant secretory
  isoform (sCLU) prevents aggregation of non-native proteins in the
  extracellular space, maintaining them in a soluble, folding-competent state
  for subsequent refolding by ATP-dependent chaperones such as HSPA8/HSC70. CLU
  does not refold proteins itself and does not require ATP. It inhibits amyloid
  fibril formation by multiple amyloidogenic proteins (APP, APOC2, SNCA, etc.)
  and plays a key role in inhibiting complement membrane attack complex (MAC)
  assembly by preventing C9 polymerization. CLU also facilitates clearance of
  misfolded proteins via receptor-mediated endocytosis through LRP2/megalin.
  Intracellular forms of CLU have been implicated in ubiquitin-dependent
  proteasomal degradation, anti-apoptotic signaling via BAX interaction at
  mitochondria, and NF-kappa-B modulation. CLU is associated with the HDL
  particle and is widely expressed, with particular relevance to Alzheimer
  disease, atherosclerosis, and cancer.
alternative_products:
- name: 1 (2, CLU35, sCLU)
  id: P10909-1
- name: 2 (1, CLU34)
  id: P10909-2
  sequence_note: VSP_037661
- name: '3'
  id: P10909-3
  sequence_note: VSP_041475
- name: 4 (nCLU {ECO:0000303|PubMed:12551933})
  id: P10909-4
  sequence_note: VSP_041476
- name: 5 (CLU36)
  id: P10909-5
  sequence_note: VSP_041477
- name: '6'
  id: P10909-6
  sequence_note: VSP_060188, VSP_060192
existing_annotations:
- term:
    id: GO:0042981
    label: regulation of apoptotic process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      CLU is well-established as a regulator of apoptosis. The secreted form
      inhibits apoptosis via complement MAC inhibition (PMID:9200695), the
      intracellular form inhibits apoptosis by interacting with activated BAX
      at mitochondria (PMID:16113678), and isoform 4 (nCLU) promotes apoptosis
      via BCL2L1 interaction (UniProt). The IBA annotation to the broad term
      "regulation of apoptotic process" is appropriate given the dual
      pro- and anti-apoptotic roles of different CLU isoforms.
    action: ACCEPT
    reason: >-
      CLU has well-documented roles in both inhibiting and promoting apoptosis
      depending on isoform and context. The IBA term at this level of
      specificity is appropriate for the phylogenetically conserved function.
    supported_by:
      - reference_id: PMID:16113678
        supporting_text: >-
          intracellular clusterin inhibits apoptosis by interfering with Bax
          activation in mitochondria
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      Nuclear localization of CLU has been reported for intracellular isoforms
      (isoform 4/nCLU) and under stress conditions (PMID:19137541,
      PMID:25051234). The predominant secreted form (isoform 1) is not nuclear.
      The IBA annotation is reasonable given nuclear isoforms exist across
      species. Multiple IDA annotations also support nuclear localization.
    action: KEEP_AS_NON_CORE
    reason: >-
      Nuclear localization is real but represents a minor isoform (nCLU/isoform 4)
      or stress-related redistribution, not the predominant subcellular
      localization of the main secreted form. Keep as non-core.
    supported_by:
      - reference_id: PMID:19137541
        supporting_text: >-
          proteasome inhibition by MG132 caused stabilization and accumulation
          of all CLU protein products, including the nuclear form of CLU (nCLU)
- term:
    id: GO:0005615
    label: extracellular space
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      CLU is a secreted glycoprotein that is a major constituent of the
      extracellular space, present in plasma, CSF, and other body fluids
      (PMID:2387851, PMID:11123922). This is the core localization of the
      predominant secreted isoform.
    action: ACCEPT
    reason: >-
      Extracellular space is the primary site of CLU function as an
      extracellular chaperone and complement regulator. Well-supported by
      extensive literature.
    supported_by:
      - reference_id: PMID:11123922
        supporting_text: >-
          Clusterin represents the first identified secreted mammalian chaperone.
- term:
    id: GO:0032436
    label: positive regulation of proteasomal ubiquitin-dependent protein catabolic
      process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      PMID:20068069 demonstrated that sCLU acts as a ubiquitin-binding protein
      that enhances COMMD1 and I-kappaB proteasomal degradation by interacting
      with members of the SCF-betaTrCP E3 ligase family in prostate cancer cells.
      This is supported by IMP evidence from the same publication. The IBA
      annotation reflects a conserved intracellular function.
    action: KEEP_AS_NON_CORE
    reason: >-
      This function is demonstrated for intracellular CLU in cancer cell context
      (PMID:20068069) and is not the core extracellular chaperone function. The
      annotation is valid but represents a secondary/intracellular activity.
    supported_by:
      - reference_id: PMID:20068069
        supporting_text: >-
          sCLU increases NF-kappaB nuclear translocation and transcriptional
          activity by serving as a ubiquitin-binding protein that enhances
          COMMD1 and I-kappaB proteasomal degradation by interacting with
          members of the SCF-betaTrCP E3 ligase family.
- term:
    id: GO:0051787
    label: misfolded protein binding
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      Misfolded protein binding is the core molecular function of CLU as an
      extracellular holdase chaperone. CLU binds stressed/misfolded proteins
      to form soluble high molecular weight complexes and prevents their
      aggregation (PMID:11123922, PMID:19996109). This is the most appropriate
      MF term for CLU's chaperone activity.
    action: ACCEPT
    reason: >-
      This is the most informative and accurate MF term for CLU's core
      function. CLU binds misfolded/stressed proteins via exposed hydrophobic
      surfaces, maintaining them in a soluble state. Well-supported by multiple
      IDA studies (PMID:11123922, PMID:19996109).
    supported_by:
      - reference_id: PMID:11123922
        supporting_text: >-
          clusterin (i) inhibits stress-induced precipitation of a very broad
          range of structurally divergent protein substrates, (ii) binds
          irreversibly via an ATP-independent mechanism to stressed proteins to
          form solubilized high molecular weight complexes
- term:
    id: GO:0002376
    label: immune system process
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: >-
      CLU participates in immune system processes primarily through complement
      regulation (inhibition of MAC assembly) and immune complex clearance.
      The IEA term is very broad but not incorrect.
    action: ACCEPT
    reason: >-
      CLU is a complement regulator that inhibits MAC assembly (PMID:9200695,
      PMID:34667172). The broad IEA annotation to "immune system process" is
      acceptable as a high-level summary, though more specific terms are also
      annotated.
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      CLU is a secreted protein found in the extracellular region. This is
      well-established. The IEA maps correctly from UniProt subcellular
      location.
    action: ACCEPT
    reason: >-
      Extracellular region is the primary localization of the predominant
      secreted CLU isoform. Confirmed by multiple experimental methods.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: >-
      Nuclear localization is documented for the nCLU isoform (isoform 4) and
      under stress/proteasome inhibition (PMID:19137541). IEA is consistent
      with IDA and IBA annotations to nucleus.
    action: KEEP_AS_NON_CORE
    reason: >-
      Nuclear localization is real for minor intracellular isoforms but not
      the predominant secreted form.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: >-
      Cytoplasmic localization of CLU occurs via retrotranslocation from the
      ER under stress (PMID:22689054) and for intracellular isoforms. IEA is
      consistent with multiple IDA annotations.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytoplasmic localization is documented but represents stress-induced or
      isoform-specific behavior, not the primary localization.
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: >-
      Mitochondrial localization occurs under ER stress conditions where CLU
      retrotranslocates to the cytosol and redistributes to mitochondria to
      inhibit apoptosis (PMID:22689054, PMID:16113678). IEA is consistent
      with IDA evidence.
    action: KEEP_AS_NON_CORE
    reason: >-
      Mitochondrial localization is stress-induced and relates to
      anti-apoptotic function of intracellular CLU, not the primary
      extracellular chaperone function.
- term:
    id: GO:0005783
    label: endoplasmic reticulum
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      CLU transits through the ER as part of the secretory pathway. The
      precursor is glycosylated in the ER. IEA mapping from UniProt is
      appropriate as CLU does transiently reside in the ER.
    action: ACCEPT
    reason: >-
      CLU passes through the ER during biosynthesis. Under stress conditions,
      ER-resident CLU can retrotranslocate. The annotation is valid.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: >-
      Cytosolic CLU has been detected by IDA (PMID:22689054) and is associated
      with stress-induced retrotranslocation. IEA is consistent.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytosolic localization is secondary, occurring under stress conditions.
      Not the primary localization.
- term:
    id: GO:0006915
    label: apoptotic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: >-
      CLU is involved in apoptotic process regulation. IEA from UniProt keyword
      "Apoptosis" is appropriate. CLU both inhibits (via BAX interaction,
      PMID:16113678) and promotes (nCLU isoform) apoptosis.
    action: ACCEPT
    reason: >-
      IEA to the broad term "apoptotic process" is acceptable given CLU's
      well-documented roles in apoptosis regulation.
- term:
    id: GO:0006958
    label: complement activation, classical pathway
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: >-
      CLU is a complement regulator but specifically inhibits the terminal
      pathway (MAC assembly) rather than activating the classical pathway.
      CLU inhibits C9 polymerization on C5b-8 and C5b-9 complexes
      (PMID:9200695). The term "complement activation, classical pathway" is
      misleading for CLU's function, which is inhibitory and acts on the
      terminal pathway.
    action: MODIFY
    reason: >-
      CLU does not activate the classical complement pathway. It inhibits
      terminal complement assembly (MAC). More appropriate terms are already
      annotated (GO:0001971, GO:0045916). This IEA mapping is inaccurate.
    proposed_replacement_terms:
      - id: GO:0045916
        label: negative regulation of complement activation
    supported_by:
      - reference_id: PMID:9200695
        supporting_text: >-
          Clusterin inhibited at three sites and by two modes of action.
          Clusterin inhibited C9 assembly on C5b-8 and C5b-9 and also bound to
          C5b-7 to prevent membrane attachment.
- term:
    id: GO:0031410
    label: cytoplasmic vesicle
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: >-
      CLU is found in cytoplasmic vesicles (secretory granules, chromaffin
      granules, platelet alpha granules). IEA from UniProt keyword is
      reasonable.
    action: ACCEPT
    reason: >-
      CLU transits through the secretory pathway and is found in various
      vesicular compartments including platelet alpha granules and secretory
      granules.
- term:
    id: GO:0031966
    label: mitochondrial membrane
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      Under stress, intracellular CLU redistributes to mitochondria and
      stabilizes mitochondrial membrane integrity (PMID:22689054,
      PMID:17689225). CLU interacts with conformation-altered BAX at the
      mitochondrial membrane (PMID:16113678).
    action: KEEP_AS_NON_CORE
    reason: >-
      Mitochondrial membrane localization is stress-induced and related to
      anti-apoptotic function of intracellular CLU, not the primary function.
- term:
    id: GO:0042583
    label: chromaffin granule
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      CLU has been detected in chromaffin granules as noted in UniProt
      subcellular location. The early literature described CLU in endocrine
      and neuronal granules (PMID:1585460).
    action: KEEP_AS_NON_CORE
    reason: >-
      Chromaffin granule localization is a minor specialized localization
      consistent with CLU's role as a secreted glycoprotein in neuroendocrine
      cells.
- term:
    id: GO:0045087
    label: innate immune response
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: >-
      CLU inhibits MAC assembly, a key effector of innate immunity. The IEA
      annotation to innate immune response is appropriate.
    action: ACCEPT
    reason: >-
      CLU regulates complement, which is a core component of innate immunity.
      This broad term is acceptable alongside the more specific complement
      annotations.
- term:
    id: GO:0048471
    label: perinuclear region of cytoplasm
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      Perinuclear localization has been observed for intracellular CLU
      (PMID:20068069). IEA from UniProt mapping is consistent with IDA data.
    action: KEEP_AS_NON_CORE
    reason: >-
      Perinuclear localization is documented for intracellular CLU but is not
      the primary localization.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:17043677
  review:
    summary: >-
      PMID:17043677 reports CLU interaction with DISC1 in a schizophrenia
      interactome study. "Protein binding" is uninformative for CLU given its
      known chaperone function; more specific terms like misfolded protein
      binding already capture this.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is too vague. CLU interacts with many proteins via its
      chaperone activity. More specific MF terms are already annotated.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:17170699
  review:
    summary: >-
      PMID:17170699 identifies CLU as an endogenous substrate of ERp57
      (PDIA3), an ER oxidoreductase required for disulfide bond formation in
      glycoproteins. This reflects CLU being a client of the ER folding
      machinery, not a function of CLU itself.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. CLU is a substrate of ERp57, not a
      binding partner in a functional sense relevant to CLU's molecular
      function.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:20195357
  review:
    summary: >-
      PMID:20195357 is a large-scale interacting protein region resource.
      Protein binding is uninformative for a known chaperone.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Generic protein binding from a high-throughput study; uninformative for
      CLU which has more specific MF annotations.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:22179788
  review:
    summary: >-
      PMID:22179788 shows CLU sequesters oligomeric Abeta(1-40). This is
      better captured by the amyloid-beta binding (GO:0001540) annotation
      from the same publication.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      More specific terms (amyloid-beta binding, misfolded protein binding)
      already capture this interaction.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:22528093
  review:
    summary: >-
      PMID:22528093 identifies CLU as an amyloid-binding protein by affinity
      chromatography. Better captured by GO:0001540 amyloid-beta binding.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Uninformative. CLU's binding to amyloid proteins is captured by more
      specific annotations.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:25451228
  review:
    summary: >-
      PMID:25451228 shows PACAP interacts with CLU and downregulates CLU
      expression in cervical cancer cells. Protein binding is uninformative.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      PACAP-CLU interaction in cancer context. Protein binding is too vague.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:26496610
  review:
    summary: >-
      PMID:26496610 is a large-scale human interactome study. Protein binding
      from high-throughput data is uninformative for CLU.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Generic high-throughput protein binding; uninformative.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:28887769
  review:
    summary: >-
      PMID:28887769 shows alpha-synuclein co-immunoprecipitates with ApoJ
      from plasma, suggesting association on lipoprotein particles. This
      reflects CLU's apolipoprotein role rather than direct protein binding.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      The interaction is likely indirect, mediated through shared lipoprotein
      particles. Protein binding is uninformative; CLU's chaperone function
      already covers its protein-binding activity.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:31270237
  review:
    summary: >-
      PMID:31270237 shows alpha-synuclein colocalizes with apolipoproteins
      including ApoJ on lipoprotein vesicles in CSF. Likely an indirect
      association on lipoproteins.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Indirect association on lipoproteins; protein binding is uninformative.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:31413325
  review:
    summary: >-
      PMID:31413325 is a heterogeneous network-based data set for AD. Protein
      binding from a data-mining resource is uninformative.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Computational dataset; protein binding is uninformative for CLU.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:32814053
  review:
    summary: >-
      PMID:32814053 is interactome mapping of neurodegenerative disease
      proteins. Protein binding is uninformative for CLU which has specific MF
      annotations.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      High-throughput interactome study; uninformative protein binding.
- term:
    id: GO:0002434
    label: immune complex clearance
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      CLU facilitates clearance of immune complexes via receptor-mediated
      endocytosis through LRP2/megalin and other receptors. This IEA from
      Ensembl Compara is consistent with ISS evidence also annotated.
    action: ACCEPT
    reason: >-
      Immune complex clearance is a documented function of CLU, consistent
      with its role as an extracellular chaperone that facilitates clearance
      of protein complexes via receptor-mediated endocytosis.
- term:
    id: GO:0043065
    label: positive regulation of apoptotic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      The nCLU isoform (isoform 4) promotes apoptosis by interacting with
      BCL2L1 (UniProt). The IEA from Ensembl Compara is consistent with
      orthologue data.
    action: KEEP_AS_NON_CORE
    reason: >-
      Positive regulation of apoptosis is real but specific to the nuclear
      isoform (nCLU). The predominant secreted form is anti-apoptotic.
- term:
    id: GO:0045202
    label: synapse
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      CLU is found at synapses in the brain and has been implicated in
      synaptic biology through its interactions with amyloid-beta and its
      association with neurodegeneration. However, CLU is not a synaptic
      protein per se; it is an extracellular chaperone that is present in
      the extracellular space including at synapses.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      CLU is an extracellular chaperone found throughout the extracellular
      space. Its presence at synapses reflects general extracellular
      localization rather than synaptic-specific localization.
- term:
    id: GO:1902004
    label: positive regulation of amyloid-beta formation
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      Under certain conditions (low CLU:Abeta ratio), CLU can promote
      amyloid formation (PMID:17412999). However, at physiological ratios
      CLU primarily inhibits amyloid formation. The IEA annotation is
      technically valid but context-dependent.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU can promote amyloid-beta formation at very low CLU:substrate
      ratios (PMID:17412999), but its primary function is inhibitory. This
      annotation captures a secondary, dose-dependent effect.
    supported_by:
      - reference_id: PMID:17412999
        supporting_text: >-
          Proamyloidogenic effects of clusterin appear to be restricted to
          conditions in which the substrate protein is present at a very large
          molar excess
- term:
    id: GO:1905907
    label: negative regulation of amyloid fibril formation
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: >-
      CLU potently inhibits amyloid fibril formation by multiple substrates
      (PMID:17412999, PMID:12047389, PMID:22179788). This is a core function.
      IEA is consistent with extensive experimental evidence.
    action: ACCEPT
    reason: >-
      Negative regulation of amyloid fibril formation is a well-established
      core function of CLU as an extracellular holdase chaperone.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  review:
    summary: >-
      Cytosolic CLU detected by immunofluorescence curation. Consistent with
      retrotranslocation under stress (PMID:22689054).
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytosolic localization is stress-induced, not the primary localization.
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: HDA
  original_reference_id: PMID:20551380
  review:
    summary: >-
      PMID:20551380 is a proteomics characterization of extracellular space
      components in human aorta that detected CLU. Confirms core extracellular
      localization.
    action: ACCEPT
    reason: >-
      Proteomic detection of CLU in extracellular space of human aorta.
      Consistent with core localization.
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: HDA
  original_reference_id: PMID:27559042
  review:
    summary: >-
      PMID:27559042 is a glycoproteomics study of human atrial fibrillation
      tissue that detected CLU extracellularly. Confirms core localization.
    action: ACCEPT
    reason: >-
      High-throughput proteomic detection confirming CLU in extracellular
      region.
- term:
    id: GO:0001971
    label: negative regulation of activation of membrane attack complex
  evidence_type: IDA
  original_reference_id: PMID:34667172
  review:
    summary: >-
      PMID:34667172 provides structural basis showing how clusterin binds
      sMAC and inhibits C9 polymerization by obstructing the polymerizing
      face of C9. This is a core function of CLU.
    action: ACCEPT
    reason: >-
      Cryo-EM structure of sMAC shows how CLU recognizes and inhibits
      polymerizing complement proteins. Core complement regulatory function.
    supported_by:
      - reference_id: PMID:34667172
        supporting_text: >-
          clusterin recognizes and inhibits polymerizing complement proteins by
          binding a negatively charged surface of sMAC
- term:
    id: GO:0001971
    label: negative regulation of activation of membrane attack complex
  evidence_type: IDA
  original_reference_id: PMID:9200695
  review:
    summary: >-
      PMID:9200695 demonstrates CLU is a potent inhibitor of terminal
      complement assembly, binding to C5b-8 and C5b-9 to prevent C9
      polymerization with high affinity.
    action: ACCEPT
    reason: >-
      Definitive biochemical characterization of CLU as a MAC inhibitor.
      Core function.
    supported_by:
      - reference_id: PMID:9200695
        supporting_text: >-
          Clusterin inhibited C9 assembly on C5b-8 and C5b-9 and also bound to
          C5b-7 to prevent membrane attachment
- term:
    id: GO:0045916
    label: negative regulation of complement activation
  evidence_type: IDA
  original_reference_id: PMID:34667172
  review:
    summary: >-
      Same study as above, CLU negatively regulates complement by inhibiting
      MAC. Core function.
    action: ACCEPT
    reason: >-
      Core complement regulatory function demonstrated structurally.
- term:
    id: GO:0045916
    label: negative regulation of complement activation
  evidence_type: IDA
  original_reference_id: PMID:9200695
  review:
    summary: >-
      CLU inhibits terminal complement at multiple steps (PMID:9200695).
      Core function.
    action: ACCEPT
    reason: >-
      Biochemically validated complement inhibition. Core function.
- term:
    id: GO:0140311
    label: protein sequestering activity
  evidence_type: IDA
  original_reference_id: PMID:34667172
  review:
    summary: >-
      PMID:34667172 shows CLU sequesters soluble MAC precursors to prevent
      bystander damage. CLU traps C9 in an intermediate conformation. This
      is consistent with CLU's broader role as a protein sequestering agent.
    action: ACCEPT
    reason: >-
      Protein sequestering is a core MF of CLU -- it captures misfolded
      proteins and complement intermediates to prevent aggregation and
      inappropriate activity. Structurally demonstrated.
- term:
    id: GO:0140311
    label: protein sequestering activity
  evidence_type: IDA
  original_reference_id: PMID:9200695
  review:
    summary: >-
      PMID:9200695 shows CLU binds C5b-8 and C5b-9 complexes, sequestering
      them. Consistent with protein sequestering activity.
    action: ACCEPT
    reason: >-
      Core MF of CLU to sequester complement intermediates and misfolded
      proteins.
- term:
    id: GO:1903660
    label: negative regulation of complement-dependent cytotoxicity
  evidence_type: IDA
  original_reference_id: PMID:34667172
  review:
    summary: >-
      CLU prevents complement-dependent cytotoxicity by inhibiting MAC
      assembly (PMID:34667172). Core function.
    action: ACCEPT
    reason: >-
      Direct consequence of MAC inhibition. Well-supported.
- term:
    id: GO:1903660
    label: negative regulation of complement-dependent cytotoxicity
  evidence_type: IDA
  original_reference_id: PMID:9200695
  review:
    summary: >-
      PMID:9200695 estimates that CLU can reduce complement cytolysis of
      nucleated cells by 10-fold or more. Core function.
    action: ACCEPT
    reason: >-
      Direct biochemical demonstration of CLU protecting against
      complement-dependent cytotoxicity.
    supported_by:
      - reference_id: PMID:9200695
        supporting_text: >-
          the presence of <10% of the circulating clusterin in its
          heterodimeric, active form could reduce the rate of complement
          cytolysis of nucleated cells by 10-fold, and under some conditions
          by 100-fold or more
- term:
    id: GO:0005886
    label: plasma membrane
  evidence_type: IDA
  original_reference_id: PMID:30333625
  review:
    summary: >-
      PMID:30333625 reports CLU at the plasma membrane in the context of
      LILRB4 signaling in leukemia. CLU can bind cell surface receptors.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU can associate with the plasma membrane via receptor binding, but
      it is not an intrinsic membrane protein. This is a minor localization.
- term:
    id: GO:0010628
    label: positive regulation of gene expression
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      ISS from orthologue data. CLU has been shown to modulate NF-kB
      transcriptional activity (PMID:20068069), which indirectly regulates
      gene expression. However, this is very broad.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Very broad term. CLU modulates NF-kB via ubiquitin-mediated
      degradation of inhibitors, but "positive regulation of gene expression"
      is too general and nonspecific.
- term:
    id: GO:0051087
    label: protein-folding chaperone binding
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      CLU interacts with ATP-dependent chaperones including HSPA8/HSC70
      (PMID:11123922) and HSPA5/GRP78 (PMID:22689054). CLU-client complexes
      are substrates for refolding by HSP70. The ISS annotation is valid.
    action: ACCEPT
    reason: >-
      CLU stabilizes stressed proteins in a state competent for refolding
      by HSP70. This functional cooperation requires interaction with
      protein-folding chaperones.
    supported_by:
      - reference_id: PMID:11123922
        supporting_text: >-
          stabilizes stressed proteins in a state competent for refolding by
          heat shock protein 70 (HSP70)
- term:
    id: GO:0005615
    label: extracellular space
  evidence_type: IDA
  original_reference_id: PMID:30333625
  review:
    summary: >-
      PMID:30333625 detects CLU in the extracellular space. Confirms core
      localization.
    action: ACCEPT
    reason: >-
      Extracellular space is the core localization.
- term:
    id: GO:0048018
    label: receptor ligand activity
  evidence_type: IDA
  original_reference_id: PMID:27477018
  review:
    summary: >-
      PMID:27477018 shows CLU is a ligand for TREM2, a microglial receptor.
      CLU binding to TREM2 facilitates uptake of amyloid-beta by microglia.
      CLU is also a ligand for LRP2/megalin and VLDLR. Receptor ligand
      activity is appropriate.
    action: ACCEPT
    reason: >-
      CLU functions as a ligand for multiple receptors (TREM2, LRP2, VLDLR)
      to mediate clearance of misfolded proteins and lipoproteins. This is
      a core functional aspect.
    supported_by:
      - reference_id: PMID:27477018
        supporting_text: >-
          identified a set of lipoprotein particles (including LDL) and
          apolipoproteins (including CLU/APOJ and APOE) as ligands of TREM2
- term:
    id: GO:0097242
    label: amyloid-beta clearance
  evidence_type: IDA
  original_reference_id: PMID:27477018
  review:
    summary: >-
      PMID:27477018 shows CLU facilitates Abeta uptake by microglia via
      TREM2 binding. CLU-Abeta complexes are taken up by microglia in a
      TREM2-dependent manner. This is a key function in AD pathobiology.
    action: ACCEPT
    reason: >-
      Amyloid-beta clearance is a well-supported function of CLU, mediated
      via receptor binding and endocytosis. Core function in brain
      proteostasis.
    supported_by:
      - reference_id: PMID:27477018
        supporting_text: >-
          β-amyloid (Aβ) binds to lipoproteins and this complex is efficiently
          taken up by microglia in a TREM2-dependent fashion
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: TAS
  original_reference_id: PMID:23164821
  review:
    summary: >-
      PMID:23164821 discusses CLU in the context of beta-amyloid toxicity
      regulation. Confirms extracellular localization.
    action: ACCEPT
    reason: >-
      Consistent with core extracellular localization.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: TAS
  original_reference_id: PMID:23164821
  review:
    summary: >-
      PMID:23164821 mentions cytoplasmic CLU. Consistent with intracellular
      forms documented elsewhere.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytoplasmic localization is secondary, representing intracellular
      isoforms or stress-induced redistribution.
- term:
    id: GO:0043524
    label: negative regulation of neuron apoptotic process
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      CLU protects neurons from apoptosis, consistent with its
      anti-apoptotic function via BAX interaction (PMID:16113678) and
      neuroprotective roles documented in AD context (PMID:9560017).
    action: KEEP_AS_NON_CORE
    reason: >-
      Neuroprotection is a well-supported secondary function of CLU but
      reflects the general anti-apoptotic activity applied to neurons
      rather than a neuron-specific mechanism.
- term:
    id: GO:0061740
    label: protein targeting to lysosome involved in chaperone-mediated autophagy
  evidence_type: IDA
  original_reference_id: PMID:9228033
  review:
    summary: >-
      PMID:9228033 shows CLU-Abeta complexes are internalized via
      LRP2/megalin and targeted to lysosomes for degradation. This is
      receptor-mediated endocytosis leading to lysosomal degradation, which
      is a core clearance function of CLU.
    action: ACCEPT
    reason: >-
      CLU facilitates targeting of misfolded protein cargo to lysosomes
      for degradation via receptor-mediated endocytosis. Core clearance
      function.
- term:
    id: GO:0140597
    label: protein carrier chaperone
  evidence_type: IDA
  original_reference_id: PMID:9228033
  review:
    summary: >-
      PMID:9228033 shows CLU acts as a carrier chaperone that binds Abeta
      and delivers it to LRP2/megalin for internalization and degradation.
      This is an excellent MF term for CLU's carrier function.
    action: ACCEPT
    reason: >-
      Protein carrier chaperone accurately captures CLU's function of
      binding misfolded proteins and delivering them to receptors for
      clearance. Core MF.
- term:
    id: GO:0016887
    label: ATP hydrolysis activity
  evidence_type: IDA
  original_reference_id: PMID:11123922
  negated: true
  review:
    summary: >-
      PMID:11123922 explicitly demonstrated that CLU lacks detectable ATPase
      activity. This is a NOT annotation confirming CLU is an
      ATP-independent chaperone.
    action: ACCEPT
    reason: >-
      Important negative annotation. CLU is definitively established as an
      ATP-independent chaperone, distinguishing it from classical
      chaperones like HSP70.
    supported_by:
      - reference_id: PMID:11123922
        supporting_text: >-
          lacks detectable ATPase activity
- term:
    id: GO:0048156
    label: tau protein binding
  evidence_type: IPI
  original_reference_id: PMID:25051234
  review:
    summary: >-
      PMID:25051234 shows intracellular CLU (iCLU) interacts with tau in
      AD. Co-immunoprecipitation from human brain tissue confirmed iCLU
      association with modified tau species found in AD.
    action: ACCEPT
    reason: >-
      Tau binding is well-supported by co-IP from human brain. Relevant to
      CLU's role in AD pathobiology and consistent with its broader
      misfolded protein binding activity.
    supported_by:
      - reference_id: PMID:25051234
        supporting_text: >-
          By overexpressing iCLU and Tau in cell culture systems we discovered
          that iCLU was a Tau-interacting protein and that iCLU associated
          with brain-specific isoforms of BIN1, also recently identified as a
          Tau-binding protein
- term:
    id: GO:0001836
    label: release of cytochrome c from mitochondria
  evidence_type: IC
  original_reference_id: PMID:16113678
  review:
    summary: >-
      PMID:16113678 shows intracellular CLU inhibits BAX oligomerization,
      which leads to release of cytochrome c. The IC annotation infers CLU
      involvement in cytochrome c release (by inhibiting it). The annotation
      term itself describes the process, while CLU is a negative regulator.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU inhibits cytochrome c release by blocking BAX activation at
      mitochondria. This is an intracellular anti-apoptotic function, not the
      primary extracellular chaperone function.
- term:
    id: GO:0032760
    label: positive regulation of tumor necrosis factor production
  evidence_type: IDA
  original_reference_id: PMID:15857407
  review:
    summary: >-
      PMID:15857407 shows exogenous CLU activates rodent microglia and
      increases TNF-alpha secretion with EC50 of 55 nM. This is a
      pro-inflammatory effect in the CNS context.
    action: KEEP_AS_NON_CORE
    reason: >-
      Microglial activation and TNF induction by CLU is a secondary,
      context-dependent effect in the CNS, not the core molecular function.
    supported_by:
      - reference_id: PMID:15857407
        supporting_text: >-
          ApoJ increased the secretion of reactive nitrogen intermediates in
          a dose-dependent manner (EC(50) 112 nm), which was completely
          blocked by aminoguanidine (AG), a nitric oxide synthase inhibitor.
          However, AG did not block the increased secretion of tumor necrosis
          factor-alpha by apoJ (EC(50) 55 nm).
- term:
    id: GO:0045429
    label: positive regulation of nitric oxide biosynthetic process
  evidence_type: IDA
  original_reference_id: PMID:15857407
  review:
    summary: >-
      PMID:15857407 shows CLU increases reactive nitrogen intermediate
      secretion from microglia in a dose-dependent manner.
    action: KEEP_AS_NON_CORE
    reason: >-
      Microglial NO induction is a secondary inflammatory response to CLU
      in the CNS, not the core function.
- term:
    id: GO:0005102
    label: signaling receptor binding
  evidence_type: IPI
  original_reference_id: PMID:27477018
  review:
    summary: >-
      PMID:27477018 shows CLU binds TREM2 receptor on microglia. CLU also
      binds LRP2/megalin and VLDLR. Signaling receptor binding is an
      appropriate MF term.
    action: ACCEPT
    reason: >-
      CLU is a ligand for multiple signaling receptors (TREM2, LRP2, VLDLR).
      This is integral to its clearance function and a core molecular activity.
- term:
    id: GO:0031333
    label: negative regulation of protein-containing complex assembly
  evidence_type: IMP
  original_reference_id: PMID:16113678
  review:
    summary: >-
      PMID:16113678 shows CLU impedes BAX oligomerization, preventing
      mitochondrial pore formation. This represents negative regulation of
      protein complex assembly (BAX oligomers).
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU inhibits BAX oligomerization as part of its anti-apoptotic
      function. This is a valid but secondary intracellular function.
- term:
    id: GO:0031333
    label: negative regulation of protein-containing complex assembly
  evidence_type: IDA
  original_reference_id: PMID:22179788
  review:
    summary: >-
      PMID:22179788 shows CLU sequesters oligomeric Abeta, preventing
      further aggregation/complex assembly. This reflects CLU's core
      holdase chaperone function preventing protein aggregation.
    action: ACCEPT
    reason: >-
      Preventing protein complex/aggregate assembly is a direct consequence
      of CLU's core holdase chaperone activity.
- term:
    id: GO:0031333
    label: negative regulation of protein-containing complex assembly
  evidence_type: IDA
  original_reference_id: PMID:23106396
  review:
    summary: >-
      PMID:23106396 shows CLU sequesters Abeta oligomers, preventing
      further assembly. Same core chaperone function as above.
    action: ACCEPT
    reason: >-
      Core chaperone function preventing misfolded protein complex assembly.
- term:
    id: GO:0031334
    label: positive regulation of protein-containing complex assembly
  evidence_type: IDA
  original_reference_id: PMID:22179788
  review:
    summary: >-
      PMID:22179788 shows that at very low CLU:Abeta ratios, CLU can
      promote Abeta complex formation. This is a dose-dependent effect
      opposite to the primary inhibitory function.
    action: KEEP_AS_NON_CORE
    reason: >-
      At substoichiometric levels, CLU can paradoxically promote protein
      complex assembly. This is a secondary, dose-dependent effect opposite
      to the core inhibitory function.
- term:
    id: GO:0002434
    label: immune complex clearance
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      ISS from orthologues. CLU facilitates clearance of immune complexes
      via receptor-mediated endocytosis. Consistent with the IEA annotation
      from Ensembl Compara.
    action: ACCEPT
    reason: >-
      Immune complex clearance is a documented function of CLU, consistent
      with its chaperone-carrier function.
- term:
    id: GO:0048260
    label: positive regulation of receptor-mediated endocytosis
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      CLU-cargo complexes are internalized via receptor-mediated endocytosis
      through LRP2/megalin (PMID:9228033) and TREM2 (PMID:27477018). CLU
      promotes this process. ISS is consistent.
    action: ACCEPT
    reason: >-
      CLU facilitates receptor-mediated endocytosis of its cargo complexes.
      Core clearance mechanism.
- term:
    id: GO:0051082
    label: unfolded protein binding
  evidence_type: IMP
  original_reference_id: PMID:25402950
  review:
    summary: >-
      GO:0051082 "unfolded protein binding" is being obsoleted (go-ontology#30962). The
      annotation is based on PMID:25402950 (Rohne et al. 2014), which investigated the
      chaperone activity of clusterin under different glycosylation and redox conditions.
      The paper demonstrates that CLU has chaperone-like holdase activity -- it prevents
      aggregation of stressed/unfolded target proteins and maintains them in a soluble
      state. Critically, CLU does not actively refold proteins (PMID:11123922) and does
      not require ATP (PMID:11123922). This is consistent with an extracellular holdase
      function rather than a classical folding chaperone. The best replacement from
      existing GO terms is GO:0044183 "protein folding chaperone" (defined as binding to
      a protein to assist the protein folding process), though this is an imperfect fit
      since CLU prevents aggregation rather than directly assisting folding. The existing
      IBA annotation to GO:0051787 "misfolded protein binding" and the IDA annotations
      to GO:0051787 (PMID:11123922, PMID:19996109) more accurately capture the binding
      aspect of CLU chaperone function. GO:0050821 "protein stabilization" (already
      annotated via IDA from PMID:11123922 and PMID:12176985) captures the biological
      process aspect. A holdase-specific MF term would be ideal but does not currently
      exist in GO.
    action: MODIFY
    reason: >-
      GO:0051082 "unfolded protein binding" is being obsoleted. CLU is an extracellular
      holdase chaperone that prevents protein aggregation rather than actively promoting
      folding. PMID:25402950 demonstrates that CLU chaperone activity depends on
      glycosylation and redox environment, confirming holdase function. PMID:11123922
      established that CLU does not refold proteins by itself and does not require ATP.
      GO:0044183 "protein folding chaperone" is proposed as an interim replacement -- it
      is the closest available MF term for chaperone activity, though CLU functions as a
      holdase (preventing aggregation and maintaining proteins in a folding-competent
      state for downstream ATP-dependent chaperones) rather than a foldase. The existing
      annotations to GO:0051787 "misfolded protein binding" (IBA, IDA) already capture
      the binding specificity, and GO:0050821 "protein stabilization" (IDA) captures the
      biological process. A future holdase-specific term in GO would be more appropriate.
    proposed_replacement_terms:
      - id: GO:0044183
        label: protein folding chaperone
    additional_reference_ids:
      - PMID:11123922
    supported_by:
      - reference_id: PMID:25402950
        supporting_text: >-
          We show that the PC-cleavage is dispensable for sCLU chaperone activity.
          Moreover, our data demonstrate that while fully deglycosylated sCLU lacks
          chaperone activity, partially deglycosylated sCLU is still capable of
          solubilizing target proteins.
      - reference_id: PMID:11123922
        supporting_text: >-
          clusterin (i) inhibits stress-induced precipitation of a very broad range of
          structurally divergent protein substrates, (ii) binds irreversibly via an
          ATP-independent mechanism to stressed proteins to form solubilized high
          molecular weight complexes, (iii) lacks detectable ATPase activity, (iv) when
          acting alone, does not effect refolding of stressed proteins in vitro, and (v)
          stabilizes stressed proteins in a state competent for refolding by heat shock
          protein 70 (HSP70).
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:22689054
  review:
    summary: >-
      PMID:22689054 demonstrates that under ER stress, GRP78 facilitates CLU
      retrotranslocation from the ER to the cytoplasm in prostate cancer cells.
      Subcellular fractionation and confocal microscopy confirmed cytoplasmic
      CLU accumulation under stress.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytoplasmic localization of CLU is well-documented under ER stress
      conditions (PMID:22689054). This is a secondary, stress-induced
      localization, not the primary extracellular localization.
    supported_by:
      - reference_id: PMID:22689054
        supporting_text: >-
          ER stress increased association between GRP78 and CLU, which led to
          increased cytoplasmic CLU levels, while reducing sCLU levels secreted
          into the culture media.
- term:
    id: GO:0043065
    label: positive regulation of apoptotic process
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      ISS from orthologue data. The nCLU isoform (isoform 4) promotes apoptosis
      by interacting with BCL2L1 (UniProt). Consistent with the IEA annotation
      from Ensembl Compara (already reviewed).
    action: KEEP_AS_NON_CORE
    reason: >-
      Positive regulation of apoptosis is valid for the nuclear isoform (nCLU).
      The predominant secreted form is anti-apoptotic. This is a minor
      isoform-specific function.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IDA
  original_reference_id: PMID:19137541
  review:
    summary: >-
      PMID:19137541 shows that proteasome inhibition by MG132 causes
      stabilization and accumulation of all CLU protein products including the
      nuclear form (nCLU). The nuclear localization was directly observed in
      prostate cancer cells under proteasome inhibition.
    action: KEEP_AS_NON_CORE
    reason: >-
      Nuclear localization is real for the nCLU isoform and under proteasome
      inhibition, but is not the predominant localization of the main secreted
      form.
    supported_by:
      - reference_id: PMID:19137541
        supporting_text: >-
          Proteasome inhibition by MG132 caused stabilization and accumulation
          of all CLU protein products, including the nuclear form of CLU (nCLU),
          and committing cells to caspase-dependent death.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:17689225
  review:
    summary: >-
      PMID:17689225 reports that CLU overexpressed by HDI treatment localizes to
      cytoplasm and mitochondria in breast cancer cells. The hyper-expressed form
      localizes to mitochondria and inhibits cytochrome c release.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytoplasmic CLU is documented in cancer cells under treatment conditions.
      This is a secondary localization related to the anti-apoptotic
      intracellular function.
    supported_by:
      - reference_id: PMID:17689225
        supporting_text: >-
          The hyper-expressed form of clusterin localizes to mitochondria,
          inhibits cytochrome c release, and is inhibited by the proteasome.
- term:
    id: GO:0005743
    label: mitochondrial inner membrane
  evidence_type: IDA
  original_reference_id: PMID:17689225
  review:
    summary: >-
      PMID:17689225 shows that CLU localizes to mitochondria in breast cancer
      cells treated with HDIs and inhibits cytochrome c release. UniProt
      annotates CLU at the mitochondrial membrane as a peripheral membrane
      protein on the cytoplasmic side.
    action: KEEP_AS_NON_CORE
    reason: >-
      Mitochondrial inner membrane localization is stress/treatment-induced.
      CLU is not a constitutive mitochondrial protein. This relates to the
      anti-apoptotic function of intracellular CLU in cancer cells.
    supported_by:
      - reference_id: PMID:17689225
        supporting_text: >-
          The hyper-expressed form of clusterin localizes to mitochondria,
          inhibits cytochrome c release, and is inhibited by the proteasome.
- term:
    id: GO:0042127
    label: regulation of cell population proliferation
  evidence_type: IMP
  original_reference_id: PMID:19137541
  review:
    summary: >-
      PMID:19137541 demonstrates that siRNA-mediated depletion of CLU in PC-3
      prostate cancer cells induces cell cycle progression and higher expression
      of proliferation markers (H3, PCNA, cyclins A, B1, D), while CLU
      overexpression inhibits proliferation and induces apoptosis.
    action: KEEP_AS_NON_CORE
    reason: >-
      Regulation of cell proliferation by CLU is documented in prostate cancer
      cells but represents a secondary, context-dependent role in cancer biology,
      not the core chaperone function.
    supported_by:
      - reference_id: PMID:19137541
        supporting_text: >-
          Following siRNA targeting all CLU mRNA variants, all protein products
          quickly disappeared, inducing cell cycle progression and higher
          expression of specific proliferation markers (i.e., H3 mRNA, PCNA,
          and cyclins A, B1, and D) as detected by RT-qPCR and Western blot
- term:
    id: GO:0050821
    label: protein stabilization
  evidence_type: IDA
  original_reference_id: PMID:12176985
  review:
    summary: >-
      PMID:12176985 shows that CLU at mildly acidic pH has enhanced chaperone
      activity, stabilizing stressed proteins against aggregation. Low pH
      induces dissociation of CLU aggregates and increases solvent-exposed
      hydrophobicity, enhancing its ability to stabilize stressed proteins.
    action: ACCEPT
    reason: >-
      Protein stabilization is a core biological process of CLU. The holdase
      chaperone activity of CLU directly prevents aggregation and maintains
      proteins in a stable, soluble state. Well-demonstrated by direct assay.
    supported_by:
      - reference_id: PMID:12176985
        supporting_text: >-
          the chaperone action of clusterin is enhanced at mildly acidic pH.
          Clusterin is the first chaperone shown to be activated by reduced pH.
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: IDA
  original_reference_id: PMID:22689054
  review:
    summary: >-
      PMID:22689054 shows that under ER stress in prostate cancer cells, GRP78
      facilitates CLU retrotranslocation and co-localized redistribution to the
      mitochondria, reducing stress-induced apoptosis by stabilizing
      mitochondrial membrane integrity.
    action: KEEP_AS_NON_CORE
    reason: >-
      Mitochondrial localization is stress-induced and occurs in cancer cells
      under treatment conditions. Not the primary localization of the
      predominant secreted form.
    supported_by:
      - reference_id: PMID:22689054
        supporting_text: >-
          GRP78 increased stress-induced CLU retrotranslocation from the ER with
          co-localized redistribution to the mitochondria, thereby reducing
          stress-induced apoptosis by cooperatively stabilizing mitochondrial
          membrane integrity.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IDA
  original_reference_id: PMID:22689054
  review:
    summary: >-
      PMID:22689054 demonstrates cytosolic CLU accumulation under ER stress via
      retrotranslocation from the ER in prostate cancer cells.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytosolic localization is secondary and stress-induced, not the primary
      localization of the secreted form.
- term:
    id: GO:0043231
    label: intracellular membrane-bounded organelle
  evidence_type: IDA
  original_reference_id: PMID:22689054
  review:
    summary: >-
      PMID:22689054 shows CLU in intracellular membrane-bounded organelles (ER,
      mitochondria) during ER stress in prostate cancer cells. This is a very
      broad CC term.
    action: KEEP_AS_NON_CORE
    reason: >-
      Very broad localization term. CLU transits through the ER as part of the
      secretory pathway and redistributes to mitochondria under stress. More
      specific CC terms are already annotated.
- term:
    id: GO:0099020
    label: perinuclear endoplasmic reticulum lumen
  evidence_type: IDA
  original_reference_id: PMID:22689054
  review:
    summary: >-
      PMID:22689054 shows CLU in the ER lumen prior to retrotranslocation in
      prostate cancer cells. CLU is synthesized and glycosylated in the ER as
      part of its normal secretory processing.
    action: KEEP_AS_NON_CORE
    reason: >-
      Perinuclear ER lumen localization reflects CLU transit through the
      secretory pathway. CLU is normally processed through the ER but its
      functional site is extracellular.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:22689054
  review:
    summary: >-
      PMID:22689054 shows CLU associates with GRP78/BiP under ER stress. This
      interaction is between CLU as a client/substrate of the ER chaperone
      machinery and is better captured by the existing annotation to
      GO:0051087 protein-folding chaperone binding.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The CLU-GRP78 interaction is already
      better captured by the protein-folding chaperone binding annotation
      (GO:0051087).
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:8555189
  review:
    summary: >-
      PMID:8555189 demonstrates that CLU interacts directly with both type I
      (RI/ACVR1) and type II (RII/TGFBR2) TGF-beta receptors via yeast
      two-hybrid and co-precipitation experiments. The 60 kDa intracellular form
      of CLU was precipitated by RI and RII fusion proteins.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      While the CLU-TGFBR interaction is specific and validated, the generic
      term protein binding is uninformative. A more specific term such as
      signaling receptor binding (GO:0005102) would better capture this. The
      signaling receptor binding annotation is already present from
      PMID:27477018.
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: HDA
  original_reference_id: PMID:27068509
  review:
    summary: >-
      PMID:27068509 is a proteomics study of varicose veins detecting CLU in
      extracellular matrix. Confirms core extracellular localization.
    action: ACCEPT
    reason: >-
      Proteomic detection confirming CLU in the extracellular region, consistent
      with core localization as a secreted protein.
- term:
    id: GO:0005615
    label: extracellular space
  evidence_type: HDA
  original_reference_id: PMID:20551380
  review:
    summary: >-
      PMID:20551380 is a proteomics characterization of extracellular space
      components in human aorta that detected CLU. Confirms core localization.
    action: ACCEPT
    reason: >-
      Proteomic detection in human aorta extracellular space. Consistent with
      core localization. Note this is a duplicate of the already-reviewed HDA
      annotation for extracellular region from same PMID but for the more
      specific extracellular space term.
- term:
    id: GO:0050750
    label: low-density lipoprotein particle receptor binding
  evidence_type: IPI
  original_reference_id: PMID:9228033
  review:
    summary: >-
      PMID:9228033 demonstrates that CLU-Abeta complex binds LRP-2/megalin
      (a member of the LDL receptor family) with high affinity. The interaction
      was shown by ELISA, and CLU-mediated binding to LRP-2 promotes cellular
      uptake and degradation of Abeta.
    action: ACCEPT
    reason: >-
      LDL receptor family binding is a core molecular function of CLU. CLU
      serves as a carrier chaperone that delivers misfolded protein cargo to
      LRP-2/megalin and other LDL receptor family members for
      receptor-mediated endocytosis and clearance.
    supported_by:
      - reference_id: PMID:9228033
        supporting_text: >-
          Abeta alone did not bind directly to LRP-2; however, when Abeta1-40
          was combined with apoJ to form a complex, binding to LRP-2 took place.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:25051234
  review:
    summary: >-
      PMID:25051234 shows intracellular CLU (iCLU) interacts with tau and
      BIN1 by co-immunoprecipitation. The tau binding is already captured by
      the more specific GO:0048156 tau protein binding annotation.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The iCLU-tau interaction is better
      captured by the tau protein binding (GO:0048156) annotation from the same
      publication.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IDA
  original_reference_id: PMID:25051234
  review:
    summary: >-
      PMID:25051234 reports intracellular CLU (iCLU) localization including
      nuclear localization in cell culture systems overexpressing iCLU, and
      in human AD brain tissue.
    action: KEEP_AS_NON_CORE
    reason: >-
      Nuclear localization is real for intracellular CLU isoforms, particularly
      in the context of AD pathology, but is not the primary localization of
      the predominant secreted form.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:25051234
  review:
    summary: >-
      PMID:25051234 shows iCLU in the cytoplasm of cells and human brain
      tissue. The intracellular form interacts with tau and BIN1 in the
      cytoplasm.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytoplasmic localization for the intracellular CLU form. Secondary to
      the core extracellular localization.
- term:
    id: GO:0005856
    label: cytoskeleton
  evidence_type: IDA
  original_reference_id: PMID:25051234
  review:
    summary: >-
      PMID:25051234 shows iCLU associates with tau, a microtubule-associated
      protein. Cytoskeletal localization likely reflects iCLU interaction with
      tau on microtubules.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytoskeletal localization of iCLU is secondary and likely reflects its
      interaction with tau on microtubules in the context of AD pathology.
- term:
    id: GO:0016020
    label: membrane
  evidence_type: IDA
  original_reference_id: PMID:25051234
  review:
    summary: >-
      PMID:25051234 reports iCLU at membranes. This is a very broad CC term
      and likely reflects iCLU association with ER membranes or other
      intracellular membrane compartments.
    action: KEEP_AS_NON_CORE
    reason: >-
      Very broad term. More specific membrane-associated localizations are
      already annotated (ER, mitochondrial membrane). This adds little
      information beyond existing annotations.
- term:
    id: GO:0001540
    label: amyloid-beta binding
  evidence_type: IDA
  original_reference_id: PMID:22179788
  review:
    summary: >-
      PMID:22179788 demonstrates that CLU sequesters oligomeric forms of
      Abeta(1-40) peptide. CLU binds Abeta oligomers with high efficiency,
      forming stable CLU-Abeta complexes that prevent further aggregation.
    action: ACCEPT
    reason: >-
      Amyloid-beta binding is a well-established core molecular function of
      CLU, representing a specific instance of its broader misfolded protein
      binding chaperone activity. Directly demonstrated by biophysical assays.
- term:
    id: GO:0001540
    label: amyloid-beta binding
  evidence_type: IPI
  original_reference_id: PMID:23106396
  review:
    summary: >-
      PMID:23106396 shows CLU sequesters Abeta oligomers both extracellularly
      and intracellularly, demonstrating amyloid-beta binding activity.
    action: ACCEPT
    reason: >-
      Additional evidence for amyloid-beta binding, a core MF of CLU.
      Consistent with the IDA evidence from PMID:22179788.
- term:
    id: GO:0044877
    label: protein-containing complex binding
  evidence_type: IPI
  original_reference_id: PMID:22179788
  review:
    summary: >-
      PMID:22179788 shows CLU binds to oligomeric Abeta complexes. CLU
      specifically targets prefibrillar oligomeric species rather than
      monomers, consistent with binding to protein-containing complexes.
    action: ACCEPT
    reason: >-
      CLU preferentially binds oligomeric protein complexes (prefibrillar
      species) rather than monomers. This is mechanistically important for
      its holdase chaperone function and is distinct from simple protein
      binding.
- term:
    id: GO:0044877
    label: protein-containing complex binding
  evidence_type: IPI
  original_reference_id: PMID:23106396
  review:
    summary: >-
      PMID:23106396 confirms CLU binds Abeta oligomeric complexes. Consistent
      with the IPI evidence from PMID:22179788.
    action: ACCEPT
    reason: >-
      Additional evidence for CLU binding to protein-containing complexes
      (Abeta oligomers). Core MF.
- term:
    id: GO:0048260
    label: positive regulation of receptor-mediated endocytosis
  evidence_type: IGI
  original_reference_id: PMID:9228033
  review:
    summary: >-
      PMID:9228033 shows that CLU-Abeta complex is internalized and degraded
      by LRP-2-expressing cells. CLU promotes cellular uptake of Abeta via
      LRP-2/megalin, and this was blocked by LRP-2 antibodies. The IGI
      annotation reflects genetic interaction evidence.
    action: ACCEPT
    reason: >-
      CLU promotes receptor-mediated endocytosis of its cargo through LRP-2.
      This is a core clearance mechanism and is well-supported by biochemical
      evidence.
    supported_by:
      - reference_id: PMID:9228033
        supporting_text: >-
          When LRP-2-expressing cells were given 125I-Abeta1-40, cellular uptake
          of the radiolabeled peptide was promoted by co-incubation with apoJ.
- term:
    id: GO:1905908
    label: positive regulation of amyloid fibril formation
  evidence_type: TAS
  original_reference_id: PMID:20005821
  review:
    summary: >-
      PMID:20005821 concerns LDLR overexpression and Abeta clearance in mice.
      CLU can promote amyloid formation at very low CLU:substrate ratios
      (PMID:17412999), but its primary function is inhibitory.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU can paradoxically promote amyloid formation at substoichiometric
      concentrations (PMID:17412999). This is a secondary, dose-dependent
      effect opposite to the core inhibitory function. The TAS reference
      indirectly supports this.
- term:
    id: GO:0001540
    label: amyloid-beta binding
  evidence_type: IPI
  original_reference_id: PMID:9228033
  review:
    summary: >-
      PMID:9228033 demonstrates that CLU (apoJ) binds Abeta1-40 with a
      dissociation constant (Kd) of 4.8 nM and forms CLU-Abeta complexes
      that can be taken up via LRP-2/megalin.
    action: ACCEPT
    reason: >-
      Core MF of CLU. High-affinity amyloid-beta binding (Kd 4.8 nM)
      demonstrated by quantitative ELISA.
    supported_by:
      - reference_id: PMID:9228033
        supporting_text: >-
          an estimated dissociation constant (Kd) of 4.8 nM was derived for the
          interaction between Abeta1-40 and apoJ.
- term:
    id: GO:0032991
    label: protein-containing complex
  evidence_type: IDA
  original_reference_id: PMID:9228033
  review:
    summary: >-
      PMID:9228033 shows CLU forms complexes with Abeta peptide that are
      recognized by LRP-2/megalin. These CLU-Abeta complexes represent
      protein-containing complexes.
    action: ACCEPT
    reason: >-
      CLU forms high-molecular-weight complexes with client proteins as part
      of its core chaperone function. The CLU-Abeta complex is a
      well-characterized example.
- term:
    id: GO:1905907
    label: negative regulation of amyloid fibril formation
  evidence_type: TAS
  original_reference_id: PMID:9228033
  review:
    summary: >-
      PMID:9228033 shows CLU inhibits formation of Abeta1-40 aggregates when
      incubated together. CLU-Abeta complex formation prevents Abeta
      aggregation.
    action: ACCEPT
    reason: >-
      Core function of CLU. Inhibition of amyloid fibril formation is a
      direct consequence of its holdase chaperone activity.
    supported_by:
      - reference_id: PMID:9228033
        supporting_text: >-
          incubation of apoJ with Abeta1-40 resulted in the formation of
          Abeta1-40-apoJ complex and the inhibition of the formation of
          Abeta1-40 aggregates.
- term:
    id: GO:1905907
    label: negative regulation of amyloid fibril formation
  evidence_type: IDA
  original_reference_id: PMID:22179788
  review:
    summary: >-
      PMID:22179788 shows CLU sequesters oligomeric Abeta, preventing further
      fibril formation. Direct assay evidence.
    action: ACCEPT
    reason: >-
      Core function. Additional IDA evidence supporting CLU-mediated inhibition
      of amyloid fibril formation.
- term:
    id: GO:1905907
    label: negative regulation of amyloid fibril formation
  evidence_type: TAS
  original_reference_id: PMID:23106396
  review:
    summary: >-
      PMID:23106396 demonstrates that both intracellular and extracellular
      chaperones including CLU sequester Abeta oligomers, preventing further
      fibril assembly.
    action: ACCEPT
    reason: >-
      Core function. Consistent with multiple other lines of evidence
      supporting CLU inhibition of amyloid fibril formation.
- term:
    id: GO:0071944
    label: cell periphery
  evidence_type: IDA
  original_reference_id: PMID:21803450
  review:
    summary: >-
      PMID:21803450 studies the APP intracellular domain (AICD) and its effects
      on ER stress-induced apoptosis. CLU detected at cell periphery may reflect
      extracellular CLU bound to cell surface receptors or in the process of
      secretion.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cell periphery localization is minor and likely reflects CLU binding to
      cell surface receptors or being in the process of secretion. More specific
      localizations are already annotated.
- term:
    id: GO:0090201
    label: negative regulation of release of cytochrome c from mitochondria
  evidence_type: TAS
  original_reference_id: PMID:21803450
  review:
    summary: >-
      PMID:21803450 studies AICD-mediated ER stress and CLU's protective role.
      CLU inhibits cytochrome c release by interacting with activated BAX at
      mitochondria (PMID:16113678, PMID:17689225).
    action: KEEP_AS_NON_CORE
    reason: >-
      Negative regulation of cytochrome c release is a consequence of
      intracellular CLU's anti-apoptotic function via BAX interaction. This is
      a secondary intracellular function, not the core extracellular chaperone
      activity.
    supported_by:
      - reference_id: PMID:16113678
        supporting_text: >-
          intracellular clusterin inhibits apoptosis by interfering with Bax
          activation in mitochondria
- term:
    id: GO:1903573
    label: negative regulation of response to endoplasmic reticulum stress
  evidence_type: IMP
  original_reference_id: PMID:21803450
  review:
    summary: >-
      PMID:21803450 studies the role of CLU in mitigating ER stress-induced
      apoptosis. CLU upregulation under ER stress (PMID:22689054) and its
      protective effects suggest involvement in negative regulation of ER
      stress response.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU mitigates ER stress-induced apoptosis, but this represents a
      secondary stress-protective function of intracellular CLU, not the
      primary extracellular chaperone activity.
- term:
    id: GO:0005794
    label: Golgi apparatus
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      ISS from orthologue data. CLU transits through the Golgi as part of
      the secretory pathway where it undergoes proteolytic cleavage into
      alpha and beta chains. This is expected for a secreted glycoprotein.
    action: ACCEPT
    reason: >-
      CLU is processed in the Golgi where the precursor is cleaved into
      alpha and beta chains. Golgi transit is part of the normal biosynthetic
      pathway for this secreted protein.
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6810643
  review:
    summary: >-
      Reactome R-HSA-6810643 describes the EPPIN protein complex binding
      bacteria. CLU is part of the EPPIN complex on spermatozoa
      (PMID:17567961). Extracellular region localization is consistent.
    action: ACCEPT
    reason: >-
      Core extracellular localization confirmed by Reactome pathway annotation.
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-8852580
  review:
    summary: >-
      Reactome R-HSA-8852580 describes CLU binding C5b-C7, C8, C9 complement
      components. This is the core complement regulatory function occurring
      in the extracellular space.
    action: ACCEPT
    reason: >-
      Core extracellular localization confirmed by Reactome pathway for
      complement regulation.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:17567961
  review:
    summary: >-
      PMID:17567961 identifies CLU as a component of the EPPIN protein complex
      (EPC) on spermatozoa, also containing lactotransferrin and semenogelin.
      The interaction was confirmed by immunoprecipitation.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The EPPIN complex interaction is
      specific but protein binding is too vague. A more informative term
      would be needed, though no specific GO MF term exists for this complex.
- term:
    id: GO:0005615
    label: extracellular space
  evidence_type: IDA
  original_reference_id: PMID:17567961
  review:
    summary: >-
      PMID:17567961 detects CLU in seminal plasma and on spermatozoa surface.
      Confirms extracellular space localization in the male reproductive tract.
    action: ACCEPT
    reason: >-
      Core extracellular localization confirmed in seminal plasma.
- term:
    id: GO:0009986
    label: cell surface
  evidence_type: IDA
  original_reference_id: PMID:17567961
  review:
    summary: >-
      PMID:17567961 shows CLU localizes to the surface of ejaculate spermatozoa
      as part of the EPPIN protein complex. CLU, LTF, and EPPIN colocalize on
      the sperm tail.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cell surface localization on spermatozoa is a specialized localization
      as part of the EPPIN complex. Not the primary localization but
      demonstrates CLU's presence at cell surfaces in specific tissue contexts.
    supported_by:
      - reference_id: PMID:17567961
        supporting_text: >-
          On ejaculate spermatozoa eppin, LTF, and CLU colocalize on the tail.
- term:
    id: GO:0032991
    label: protein-containing complex
  evidence_type: IDA
  original_reference_id: PMID:17567961
  review:
    summary: >-
      PMID:17567961 identifies CLU as part of the EPPIN protein complex (EPC)
      containing CLU, lactotransferrin, semenogelin, and EPPIN. Confirmed by
      immunoprecipitation and mass spectrometry.
    action: ACCEPT
    reason: >-
      CLU forms protein-containing complexes both as part of the EPPIN complex
      on spermatozoa and as chaperone-client complexes with misfolded proteins.
      Valid CC annotation.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:23533145
  review:
    summary: >-
      PMID:23533145 is a proteomics study of exosomes from prostatic secretions
      in urine that detected CLU. High-throughput proteomic detection.
    action: ACCEPT
    reason: >-
      CLU detection in extracellular exosomes is consistent with its secreted
      nature. CLU is found in various extracellular vesicle preparations.
- term:
    id: GO:0005615
    label: extracellular space
  evidence_type: HDA
  original_reference_id: PMID:16502470
  review:
    summary: >-
      PMID:16502470 identifies CLU in human colostrum by proteomics. Confirms
      extracellular space localization in a body fluid.
    action: ACCEPT
    reason: >-
      Core extracellular localization confirmed in human colostrum by
      proteomics.
- term:
    id: GO:1902004
    label: positive regulation of amyloid-beta formation
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: >-
      ISS from orthologue data. CLU can promote amyloid-beta formation at very
      low CLU:substrate ratios (PMID:17412999). Consistent with the IEA
      annotation from Ensembl Compara already reviewed.
    action: KEEP_AS_NON_CORE
    reason: >-
      Dose-dependent secondary effect. At substoichiometric levels, CLU can
      paradoxically promote amyloid formation, but its primary function is
      inhibitory.
- term:
    id: GO:1902998
    label: positive regulation of neurofibrillary tangle assembly
  evidence_type: IMP
  original_reference_id: PMID:15897157
  review:
    summary: >-
      PMID:15897157 shows that apoJ-containing conditioned media and
      hippocampal injection of apoJ increases levels of tau and phosphorylated
      tau, and apoJ immunopositivity correlates with neuritic dystrophy in AD
      brain. This suggests CLU facilitates the conversion of diffuse Abeta
      deposits into amyloid and enhances tau phosphorylation.
    action: KEEP_AS_NON_CORE
    reason: >-
      This is an indirect, disease-associated effect in the AD brain. CLU
      promotes tangle assembly through complex mechanisms involving Abeta
      aggregation and tau phosphorylation. This is a pathological consequence,
      not a primary molecular function.
    supported_by:
      - reference_id: PMID:15897157
        supporting_text: >-
          apoJ immunopositivity strongly correlates with the presence of amyloid
          and associated neuritic dystrophy in the neuropil of AD temporal
          cortex, and supports a model where extracellular apoJ facilitates the
          conversion of diffuse Abeta deposits into amyloid and enhances tau
          phosphorylation in neurites surrounding these of plaques.
- term:
    id: GO:1902847
    label: regulation of neuronal signal transduction
  evidence_type: IMP
  original_reference_id: PMID:21397462
  review:
    summary: >-
      PMID:21397462 is an fMRI study showing that carriers of the CLU AD risk
      variant (rs11136000) have neural hyperactivation during working memory
      tasks. This is a GWAS variant association study, not a direct
      demonstration of CLU function in neuronal signal transduction.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      This is a GWAS variant association study showing altered brain activation
      patterns in CLU risk allele carriers. It does not demonstrate a direct
      molecular role for CLU in neuronal signal transduction. The neural
      hyperactivation may reflect indirect effects via CLU's roles in Abeta
      clearance, complement regulation, or lipid transport.
- term:
    id: GO:0017038
    label: protein import
  evidence_type: IDA
  original_reference_id: PMID:24446231
  review:
    summary: >-
      PMID:24446231 shows that ApoJ (CLU) interferes with Abeta uptake by
      primary human astrocytes and microglia. Specifically, ApoJ reduced
      Abeta oligomer uptake by astrocytes but not microglia. This is more
      about regulating protein import/clearance than performing the import
      itself.
    action: MODIFY
    reason: >-
      PMID:24446231 actually shows CLU reduces Abeta uptake by astrocytes,
      not promotes it. The term protein import is misleading. CLU regulates
      Abeta clearance by glial cells but the direction is inhibitory in this
      study. The annotation to GO:1900221 regulation of amyloid-beta clearance
      from the same publication is more appropriate.
    proposed_replacement_terms:
      - id: GO:1900221
        label: regulation of amyloid-beta clearance
    supported_by:
      - reference_id: PMID:24446231
        supporting_text: >-
          Upon exposure to Aβ combined with ApoE, ApoJ,
          α1-antichymotrypsin (ACT) and a combination of serum amyloid P
          and complement C1q (SAP-C1q), a clear reduction in astrocytic but not
          microglial Aβoligo uptake, was observed
- term:
    id: GO:1900221
    label: regulation of amyloid-beta clearance
  evidence_type: IDA
  original_reference_id: PMID:24446231
  review:
    summary: >-
      PMID:24446231 demonstrates that CLU modulates Abeta clearance by glial
      cells. ApoJ reduces astrocytic Abeta oligomer uptake but fibrillar Abeta
      clearance by microglia is reduced in the presence of AAPs including ApoJ.
      This demonstrates CLU regulation of Abeta clearance.
    action: ACCEPT
    reason: >-
      Regulation of amyloid-beta clearance is a well-established function
      of CLU. While PMID:24446231 shows the relationship is complex (CLU
      can both promote and interfere with clearance depending on cell type
      and aggregation state), regulation of Abeta clearance is a core
      function consistent with CLU's chaperone-carrier role.
    supported_by:
      - reference_id: PMID:24446231
        supporting_text: >-
          Abeta clearance by glial cells is negatively affected by AAPs like
          ApoE and ApoJ. Thus, targeting the association of Abeta with AAPs,
          such as ApoE and ApoJ, could serve as a therapeutic strategy to
          increase Abeta clearance by glial cells.
- term:
    id: GO:0000902
    label: cell morphogenesis
  evidence_type: IDA
  original_reference_id: PMID:15857407
  review:
    summary: >-
      PMID:15857407 shows that exogenous CLU activates rodent microglia with
      changes in morphology, including enlarged cell bodies and processes.
      Microglial morphological changes are a consequence of activation, not
      a primary CLU function in cell morphogenesis.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Cell morphogenesis is an over-annotation. The microglial morphological
      changes observed are secondary to CLU-mediated microglial activation,
      not a primary function of CLU in cell morphogenesis. CLU is not a
      morphogen.
- term:
    id: GO:0001774
    label: microglial cell activation
  evidence_type: IDA
  original_reference_id: PMID:15857407
  review:
    summary: >-
      PMID:15857407 demonstrates that exogenous CLU activates rodent microglia
      both in vivo (ICV infusion) and in vitro, with enlarged cell bodies,
      MHCII induction, and increased secretion of NO and TNF-alpha.
    action: KEEP_AS_NON_CORE
    reason: >-
      Microglial activation by CLU is a well-demonstrated secondary function
      in the CNS. While not the core chaperone function, it is relevant to
      CLU's role in neuroinflammation and AD pathobiology.
    supported_by:
      - reference_id: PMID:15857407
        supporting_text: >-
          exogenous apoJ activates rodent microglia in vivo and in vitro
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:9560017
  review:
    summary: >-
      PMID:9560017 is an immunocytochemical study of CLU in AD brain showing
      clusterin immunoreactivity in NFT-free neurons of affected cortical areas.
      Cytoplasmic localization in neurons was observed by immunohistochemistry.
    action: KEEP_AS_NON_CORE
    reason: >-
      Cytoplasmic CLU immunoreactivity in AD brain neurons. This is a secondary
      localization, likely reflecting internalized extracellular CLU or
      intracellular isoforms.
- term:
    id: GO:0061518
    label: microglial cell proliferation
  evidence_type: IDA
  original_reference_id: PMID:15857407
  review:
    summary: >-
      PMID:15857407 shows CLU activates microglia with morphological changes
      and inflammatory responses. While activation can include proliferation,
      the paper primarily demonstrates activation phenotype rather than
      proliferation specifically.
    action: KEEP_AS_NON_CORE
    reason: >-
      Microglial proliferation induced by CLU is a secondary effect related
      to its role in neuroinflammation. Not the core molecular function.
- term:
    id: GO:0097418
    label: neurofibrillary tangle
  evidence_type: IDA
  original_reference_id: PMID:9560017
  review:
    summary: >-
      PMID:9560017 shows clusterin immunoreactivity in neuropil threads and
      neurofibrillary tangles (NFTs) in AD brain by immunocytochemistry. CLU
      was detected in NFT-containing neurons and in neuropil threads.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU localization to neurofibrillary tangles is a disease-associated
      pathological finding in AD brain, not a normal functional localization.
      Reflects CLU's association with aggregated tau.
- term:
    id: GO:0097440
    label: apical dendrite
  evidence_type: IDA
  original_reference_id: PMID:9560017
  review:
    summary: >-
      PMID:9560017 is an immunocytochemical study in AD brain. Clusterin
      immunoreactivity was observed in neurons of affected cortical areas
      including apical dendrites. This likely reflects CLU association with
      degenerating neuronal processes.
    action: KEEP_AS_NON_CORE
    reason: >-
      Apical dendrite localization is a disease-associated finding in AD
      brain. CLU is not normally a dendritic protein; this reflects its
      association with degenerating neuronal compartments in AD.
- term:
    id: GO:1902430
    label: negative regulation of amyloid-beta formation
  evidence_type: IDA
  original_reference_id: PMID:12047389
  review:
    summary: >-
      PMID:12047389 demonstrates that substoichiometric levels of CLU potently
      inhibit amyloid formation by apolipoprotein C-II. CLU inhibits fibril
      growth by interacting with transient amyloid nuclei. While the substrate
      is apoC-II rather than Abeta, the mechanism is analogous.
    action: ACCEPT
    reason: >-
      While PMID:12047389 specifically studies apoC-II amyloid, CLU inhibits
      amyloid formation by diverse substrates including Abeta. Negative
      regulation of amyloid-beta formation is a core function.
    supported_by:
      - reference_id: PMID:12047389
        supporting_text: >-
          Sub-stoichiometric levels of clusterin, derived from either plasma or
          semen, potently inhibit amyloid formation by apoC-II.
- term:
    id: GO:1902430
    label: negative regulation of amyloid-beta formation
  evidence_type: IDA
  original_reference_id: PMID:17412999
  review:
    summary: >-
      PMID:17412999 directly demonstrates that CLU at substoichiometric levels
      (e.g., CLU:substrate=1:10) potently inhibits amyloid formation by
      Abeta peptide and provides cytoprotection.
    action: ACCEPT
    reason: >-
      Core function of CLU. Direct demonstration that CLU inhibits Abeta
      amyloid formation at physiologically relevant ratios.
    supported_by:
      - reference_id: PMID:17412999
        supporting_text: >-
          when clusterin is present at much higher but still substoichiometric
          levels (e.g., a molar ratio of clusterin:substrate=1:10), it potently
          inhibits amyloid formation and provides substantial cytoprotection.
- term:
    id: GO:0032286
    label: central nervous system myelin maintenance
  evidence_type: IMP
  original_reference_id: PMID:21543606
  review:
    summary: >-
      PMID:21543606 is an imaging genetics study showing that the CLU AD risk
      variant (rs11136000 C allele) is associated with lower white matter
      integrity (fractional anisotropy) in young healthy adults. This is a
      genetic association, not a direct demonstration of CLU function in
      myelin maintenance.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      This is a GWAS variant association with brain imaging measures, not a
      direct demonstration of CLU function in CNS myelin maintenance. The
      association between CLU genotype and white matter integrity may reflect
      indirect effects through lipid transport, complement regulation, or
      other mechanisms.
- term:
    id: GO:0051131
    label: chaperone-mediated protein complex assembly
  evidence_type: IDA
  original_reference_id: PMID:17412999
  review:
    summary: >-
      PMID:17412999 shows that CLU interacts with prefibrillar species and
      can co-incorporate into insoluble aggregates at low CLU:substrate ratios.
      At very low ratios, CLU can promote complex assembly, but this is a
      secondary dose-dependent effect. The term chaperone-mediated protein
      complex assembly could also reflect CLU forming HMW complexes with
      client proteins as part of its holdase function.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU forms high-molecular-weight complexes with client proteins as part
      of its holdase chaperone function. At substoichiometric ratios it can
      also promote assembly of amyloid complexes. This annotation captures a
      secondary aspect of CLU chaperone activity.
- term:
    id: GO:0097418
    label: neurofibrillary tangle
  evidence_type: IDA
  original_reference_id: PMID:15897157
  review:
    summary: >-
      PMID:15897157 shows apoJ immunoreactivity at the core of beta-amyloid
      plaques associated with dystrophic neurites in AD brain. ApoJ
      co-localizes with thioflavine-S-positive amyloid cores and
      phospho-tau-positive neuritic deposits.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU localization to neurofibrillary tangles is a disease-associated
      pathological finding. Reflects CLU's co-localization with amyloid
      and tau pathology in AD, consistent with its chaperone function but
      not a normal subcellular localization.
    supported_by:
      - reference_id: PMID:15897157
        supporting_text: >-
          Of Abeta deposits with apoJ immunopositivity, 71% were associated
          with phospho-tau-positive dystrophic neurites in the surrounding
          tissue.
- term:
    id: GO:0072562
    label: blood microparticle
  evidence_type: HDA
  original_reference_id: PMID:22516433
  review:
    summary: >-
      PMID:22516433 is a proteomic analysis of microvesicles from healthy
      donor plasma that detected CLU. High-throughput proteomic detection.
    action: ACCEPT
    reason: >-
      CLU is found in blood microparticles, consistent with its presence
      in various extracellular compartments as a secreted glycoprotein.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:19199708
  review:
    summary: >-
      PMID:19199708 is a proteomic analysis of human parotid gland exosomes
      that detected CLU. High-throughput proteomic detection.
    action: ACCEPT
    reason: >-
      CLU detection in exosomes is consistent with its secreted nature and
      broad extracellular distribution.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:19056867
  review:
    summary: >-
      PMID:19056867 is a proteomics study of urinary exosomes that detected
      CLU. High-throughput proteomic detection.
    action: ACCEPT
    reason: >-
      CLU detection in urinary exosomes is consistent with its presence in
      body fluids and extracellular vesicles.
- term:
    id: GO:1902230
    label: negative regulation of intrinsic apoptotic signaling pathway in response
      to DNA damage
  evidence_type: IMP
  original_reference_id: PMID:16113678
  review:
    summary: >-
      PMID:16113678 shows that intracellular CLU inhibits apoptosis by
      interacting with activated BAX in mitochondria, preventing BAX
      oligomerization and cytochrome c release. CLU inhibits
      chemotherapeutic drug-mediated and c-Myc-mediated apoptosis.
    action: KEEP_AS_NON_CORE
    reason: >-
      Negative regulation of intrinsic apoptotic signaling is a well-supported
      secondary function of intracellular CLU, but represents the cancer-related
      anti-apoptotic activity, not the core extracellular chaperone function.
    supported_by:
      - reference_id: PMID:16113678
        supporting_text: >-
          intracellular clusterin inhibits apoptosis by interfering with Bax
          activation in mitochondria
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-481007
  review:
    summary: >-
      Reactome R-HSA-481007 describes exocytosis of platelet alpha granule
      contents. CLU is released from platelet alpha granules into the
      extracellular space upon platelet activation.
    action: ACCEPT
    reason: >-
      Core extracellular localization confirmed by Reactome pathway for
      platelet alpha granule exocytosis.
- term:
    id: GO:0031093
    label: platelet alpha granule lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-481007
  review:
    summary: >-
      Reactome R-HSA-481007 describes CLU as a component of platelet alpha
      granule contents that are released upon platelet activation.
    action: KEEP_AS_NON_CORE
    reason: >-
      Platelet alpha granule lumen is a specialized storage localization for
      CLU prior to secretion upon platelet activation. Valid but specialized
      localization, not the primary functional site.
- term:
    id: GO:0031625
    label: ubiquitin protein ligase binding
  evidence_type: IDA
  original_reference_id: PMID:20068069
  review:
    summary: >-
      PMID:20068069 demonstrates that sCLU interacts with members of the
      SCF-betaTrCP E3 ubiquitin ligase family to enhance COMMD1 and I-kappaB
      proteasomal degradation. CLU acts as a ubiquitin-binding protein that
      bridges substrates to the E3 ligase complex.
    action: KEEP_AS_NON_CORE
    reason: >-
      Ubiquitin protein ligase binding is a validated MF for intracellular CLU
      in the cancer context. This is a secondary intracellular function
      demonstrated in prostate cancer cells, not the core extracellular
      chaperone activity.
    supported_by:
      - reference_id: PMID:20068069
        supporting_text: >-
          sCLU increases NF-kappaB nuclear translocation and transcriptional
          activity by serving as a ubiquitin-binding protein that enhances
          COMMD1 and I-kappaB proteasomal degradation by interacting with
          members of the SCF-betaTrCP E3 ligase family.
- term:
    id: GO:0032436
    label: positive regulation of proteasomal ubiquitin-dependent protein catabolic
      process
  evidence_type: IMP
  original_reference_id: PMID:20068069
  review:
    summary: >-
      PMID:20068069 demonstrates that sCLU enhances COMMD1 and I-kappaB
      proteasomal degradation. Knockdown of sCLU stabilizes COMMD1 and
      I-kappaB, confirming CLU promotes proteasomal degradation.
    action: KEEP_AS_NON_CORE
    reason: >-
      This function is demonstrated for intracellular CLU in prostate cancer
      cells. Consistent with the IBA annotation already reviewed. Secondary
      intracellular activity.
- term:
    id: GO:0048471
    label: perinuclear region of cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:20068069
  review:
    summary: >-
      PMID:20068069 detects CLU in perinuclear foci in prostate cancer cells,
      potentially representing aggresomes containing misfolded ubiquitinated
      proteins. UniProt notes perinuclear foci that may be aggresomes.
    action: KEEP_AS_NON_CORE
    reason: >-
      Perinuclear localization in cancer cells is documented but represents
      a secondary intracellular localization, not the primary extracellular
      site.
- term:
    id: GO:2000060
    label: positive regulation of ubiquitin-dependent protein catabolic process
  evidence_type: IMP
  original_reference_id: PMID:20068069
  review:
    summary: >-
      PMID:20068069 shows CLU promotes ubiquitin-dependent degradation of
      COMMD1 and I-kappaB. This is the parent term of GO:0032436. Both
      annotations from the same paper are valid.
    action: KEEP_AS_NON_CORE
    reason: >-
      Broader term covering the same intracellular function as GO:0032436.
      Valid but secondary to the core extracellular chaperone function.
- term:
    id: GO:0005615
    label: extracellular space
  evidence_type: IDA
  original_reference_id: PMID:11123922
  review:
    summary: >-
      PMID:11123922 is the landmark study establishing CLU as the first
      identified secreted mammalian chaperone. CLU inhibits stress-induced
      precipitation of proteins in undiluted human serum, confirming
      extracellular space as the primary functional site.
    action: ACCEPT
    reason: >-
      Core localization. This is the definitive study establishing CLU as
      an extracellular chaperone functioning in the extracellular space.
    supported_by:
      - reference_id: PMID:11123922
        supporting_text: >-
          at physiological levels, clusterin inhibits stress-induced
          precipitation of proteins in undiluted human serum. Clusterin
          represents the first identified secreted mammalian chaperone.
- term:
    id: GO:0006457
    label: protein folding
  evidence_type: IDA
  original_reference_id: PMID:11123922
  review:
    summary: >-
      PMID:11123922 shows CLU stabilizes stressed proteins in a
      folding-competent state for subsequent refolding by HSP70. CLU itself
      does not refold proteins. The annotation to protein folding is
      appropriate as CLU participates in the protein folding process by
      preventing irreversible aggregation and maintaining proteins in a
      refolding-competent state.
    action: ACCEPT
    reason: >-
      CLU participates in the protein folding process as a holdase chaperone
      that maintains misfolded proteins in a state competent for refolding
      by downstream ATP-dependent chaperones. Core biological process.
    supported_by:
      - reference_id: PMID:11123922
        supporting_text: >-
          stabilizes stressed proteins in a state competent for refolding by
          heat shock protein 70 (HSP70)
- term:
    id: GO:0050821
    label: protein stabilization
  evidence_type: IDA
  original_reference_id: PMID:11123922
  review:
    summary: >-
      PMID:11123922 directly demonstrates that CLU stabilizes stressed proteins
      by forming soluble high-molecular-weight complexes, preventing
      irreversible precipitation. This is the core holdase function.
    action: ACCEPT
    reason: >-
      Protein stabilization is the most accurate BP term for CLU's core
      holdase chaperone function. CLU prevents irreversible aggregation by
      binding and stabilizing misfolded proteins.
    supported_by:
      - reference_id: PMID:11123922
        supporting_text: >-
          binds irreversibly via an ATP-independent mechanism to stressed
          proteins to form solubilized high molecular weight complexes
- term:
    id: GO:0051787
    label: misfolded protein binding
  evidence_type: IDA
  original_reference_id: PMID:11123922
  review:
    summary: >-
      PMID:11123922 demonstrates that CLU binds a very broad range of
      structurally divergent stressed/misfolded protein substrates via
      ATP-independent mechanism. This is the core MF of CLU.
    action: ACCEPT
    reason: >-
      Core molecular function. CLU binds misfolded/stressed proteins with
      very broad substrate specificity. Definitive direct assay evidence.
    supported_by:
      - reference_id: PMID:11123922
        supporting_text: >-
          In this study, we demonstrate that clusterin (i) inhibits
          stress-induced precipitation of a very broad range of structurally
          divergent protein substrates
- term:
    id: GO:0005615
    label: extracellular space
  evidence_type: IDA
  original_reference_id: PMID:19996109
  review:
    summary: >-
      PMID:19996109 identifies major plasma protein clients for CLU by
      studying CLU-client complexes formed under physiologically relevant
      shear stress. Confirms CLU functions in the extracellular space
      (plasma).
    action: ACCEPT
    reason: >-
      Core extracellular localization. CLU forms chaperone-client complexes
      with plasma proteins under physiological stress conditions.
- term:
    id: GO:0051787
    label: misfolded protein binding
  evidence_type: IPI
  original_reference_id: PMID:19996109
  review:
    summary: >-
      PMID:19996109 identifies ceruloplasmin, fibrinogen, and albumin as
      major plasma clients for CLU under shear stress. CLU-client complexes
      were detected by co-purification and sandwich ELISA.
    action: ACCEPT
    reason: >-
      Core MF. Identifies specific plasma protein clients for CLU chaperone
      activity, demonstrating misfolded protein binding in a physiological
      context.
    supported_by:
      - reference_id: PMID:19996109
        supporting_text: >-
          These proteins were identified by mass spectrometry as ceruloplasmin,
          fibrinogen, and albumin.
- term:
    id: GO:0051788
    label: response to misfolded protein
  evidence_type: IDA
  original_reference_id: PMID:19996109
  review:
    summary: >-
      PMID:19996109 shows CLU responds to misfolded proteins in plasma by
      forming soluble HMW complexes with stressed clients, preventing their
      aggregation. This BP captures CLU's role in the cellular/organismal
      response to misfolded proteins.
    action: ACCEPT
    reason: >-
      Core biological process. CLU is a primary responder to misfolded
      proteins in the extracellular space, forming complexes to prevent
      aggregation and facilitate clearance.
- term:
    id: GO:0009615
    label: response to virus
  evidence_type: IEP
  original_reference_id: PMID:16548883
  review:
    summary: >-
      PMID:16548883 shows CLU is differentially expressed in response to
      enterovirus 71 infection in rhabdomyosarcoma cells. This is an
      expression pattern observation (IEP), not a functional demonstration.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      IEP evidence showing CLU expression changes during viral infection.
      CLU is a stress-response protein whose expression changes under many
      stress conditions. Differential expression during viral infection does
      not demonstrate a specific role in antiviral response.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:16113678
  review:
    summary: >-
      PMID:16113678 shows CLU interacts with activated BAX at mitochondria.
      Protein binding is uninformative; the specific interaction with BAX is
      functionally important for CLU's anti-apoptotic activity.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Protein binding is uninformative. The CLU-BAX interaction is specific
      and functionally important but the generic term adds no value. More
      specific annotations already capture this activity.
- term:
    id: GO:0005615
    label: extracellular space
  evidence_type: IDA
  original_reference_id: PMID:16113678
  review:
    summary: >-
      PMID:16113678 detects secreted CLU in the extracellular space (culture
      media) of cancer cells. Confirms core localization.
    action: ACCEPT
    reason: >-
      Core extracellular localization confirmed in cell culture media.
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: IDA
  original_reference_id: PMID:16113678
  review:
    summary: >-
      PMID:16113678 shows intracellular CLU localizes to mitochondria in
      response to chemotherapeutic drugs and interacts with activated BAX to
      inhibit apoptosis.
    action: KEEP_AS_NON_CORE
    reason: >-
      Mitochondrial localization is stress-induced and relates to the
      anti-apoptotic function of intracellular CLU. Not the primary
      extracellular localization.
    supported_by:
      - reference_id: PMID:16113678
        supporting_text: >-
          intracellular clusterin inhibits apoptosis by interfering with Bax
          activation in mitochondria
- term:
    id: GO:0034366
    label: spherical high-density lipoprotein particle
  evidence_type: IDA
  original_reference_id: PMID:16682745
  review:
    summary: >-
      PMID:16682745 identifies apoJ (CLU) among proteins in apoM-containing
      HDL particles by mass spectrometry. CLU is a well-known component of
      HDL particles in plasma (PMID:2387851).
    action: ACCEPT
    reason: >-
      CLU is a core component of HDL particles, where it functions as
      apolipoprotein J. This is a well-established localization consistent
      with its dual role as chaperone and apolipoprotein.
    supported_by:
      - reference_id: PMID:16682745
        supporting_text: >-
          Mass spectrometry showed that the apoM-containing lipoproteins also
          contained apoJ, apoA-I, apoA-II, apoC-I, apoC-II, apoC-III,
          paraoxonase 1, and apoB.
- term:
    id: GO:0043691
    label: reverse cholesterol transport
  evidence_type: TAS
  original_reference_id: PMID:16682745
  review:
    summary: >-
      PMID:16682745 characterizes apoM-containing HDL particles and their role
      in cholesterol efflux. CLU is present on HDL particles that stimulate
      cholesterol efflux from THP-1 foam cells. CLU's role in reverse
      cholesterol transport is secondary to its primary chaperone function.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU associates with HDL particles and may participate in reverse
      cholesterol transport as an apolipoprotein, but this is a secondary
      function. CLU's primary role on HDL is likely chaperone-related rather
      than lipid transport per se.
- term:
    id: GO:0006629
    label: lipid metabolic process
  evidence_type: NAS
  original_reference_id: PMID:2387851
  review:
    summary: >-
      PMID:2387851 is the original characterization of apolipoprotein J (CLU)
      as a component of HDL. CLU is an apolipoprotein that associates with
      lipid particles, but its primary function is protein chaperoning rather
      than lipid metabolism.
    action: KEEP_AS_NON_CORE
    reason: >-
      CLU is an apolipoprotein associated with HDL, but its primary molecular
      function is as a holdase chaperone, not lipid metabolism. The NAS
      evidence code reflects a non-traceable statement. Lipid metabolic process
      is a very broad term.
- term:
    id: GO:0006956
    label: complement activation
  evidence_type: TAS
  original_reference_id: PMID:1585460
  review:
    summary: >-
      PMID:1585460 is the early review describing CLU's participation in the
      terminal complement reaction. CLU inhibits complement rather than
      activating it, so the term complement activation is technically
      inaccurate for CLU's role. More specific terms (GO:0045916 negative
      regulation of complement activation) are already annotated.
    action: MODIFY
    reason: >-
      CLU is a complement inhibitor, not an activator. The term complement
      activation is misleading. While CLU participates in complement biology,
      its role is inhibitory. The more accurate term GO:0045916 negative
      regulation of complement activation is already annotated via IDA.
    proposed_replacement_terms:
      - id: GO:0045916
        label: negative regulation of complement activation
    supported_by:
      - reference_id: PMID:1585460
        supporting_text: >-
          participates in the terminal complement reaction
core_functions:
- molecular_function:
    id: GO:0051787
    label: misfolded protein binding
  description: >-
    CLU (Clusterin/Apolipoprotein J) is a secreted extracellular holdase chaperone that
    binds a very broad range of structurally divergent stressed and misfolded protein
    substrates via exposed hydrophobic surfaces. CLU prevents irreversible aggregation
    by forming soluble high-molecular-weight complexes with its client proteins,
    maintaining them in a state competent for refolding by downstream ATP-dependent
    chaperones such as HSP70/HSC70. CLU itself does NOT refold proteins and does NOT
    require ATP. Recent structural analyses (2024-2025) reveal that two intrinsically
    disordered hydrophobic tails generated by precursor cleavage are indispensable for
    this holdase chaperone activity. CLU chaperone activity is enhanced at mildly acidic
    pH and depends on glycosylation.
  directly_involved_in:
    - id: GO:0050821
      label: protein stabilization
    - id: GO:0006457
      label: protein folding
    - id: GO:1905907
      label: negative regulation of amyloid fibril formation
    - id: GO:1902430
      label: negative regulation of amyloid-beta formation
  locations:
    - id: GO:0005615
      label: extracellular space
  supported_by:
    - reference_id: PMID:11123922
      supporting_text: >-
        clusterin (i) inhibits stress-induced precipitation of a very broad range of
        structurally divergent protein substrates, (ii) binds irreversibly via an
        ATP-independent mechanism to stressed proteins to form solubilized high
        molecular weight complexes, (iii) lacks detectable ATPase activity, (iv) when
        acting alone, does not effect refolding of stressed proteins in vitro, and (v)
        stabilizes stressed proteins in a state competent for refolding by heat shock
        protein 70 (HSP70).
    - reference_id: PMID:12176985
      supporting_text: >-
        the chaperone action of clusterin is enhanced at mildly acidic pH.
    - reference_id: PMID:19996109
      supporting_text: >-
        These proteins were identified by mass spectrometry as ceruloplasmin,
        fibrinogen, and albumin as major plasma clients for CLU under shear stress.
- molecular_function:
    id: GO:0140597
    label: protein carrier chaperone
  description: >-
    CLU functions as a carrier chaperone that binds misfolded proteins (including
    amyloid-beta) and delivers them to cell surface receptors (LRP2/megalin, TREM2,
    VLDLR) for receptor-mediated endocytosis and lysosomal degradation. This carrier
    function is central to extracellular protein quality control, facilitating clearance
    of damaged proteins from the extracellular space. CLU-Abeta complexes bind LRP-2
    with high affinity, promoting cellular uptake and degradation. CLU also acts as a
    ligand for TREM2 on microglia, facilitating amyloid-beta clearance in the CNS.
  directly_involved_in:
    - id: GO:0097242
      label: amyloid-beta clearance
    - id: GO:0048260
      label: positive regulation of receptor-mediated endocytosis
    - id: GO:0002434
      label: immune complex clearance
    - id: GO:0061740
      label: protein targeting to lysosome involved in chaperone-mediated autophagy
  locations:
    - id: GO:0005615
      label: extracellular space
  supported_by:
    - reference_id: PMID:9228033
      supporting_text: >-
        When LRP-2-expressing cells were given 125I-Abeta1-40, cellular uptake
        of the radiolabeled peptide was promoted by co-incubation with apoJ.
    - reference_id: PMID:27477018
      supporting_text: >-
        identified a set of lipoprotein particles (including LDL) and
        apolipoproteins (including CLU/APOJ and APOE) as ligands of TREM2.
- molecular_function:
    id: GO:0140311
    label: protein sequestering activity
  description: >-
    CLU inhibits the terminal complement pathway by sequestering soluble membrane attack
    complex (sMAC) precursors and preventing C9 polymerization. Cryo-EM structures show
    CLU binds a negatively charged surface of sMAC and obstructs the polymerizing face of
    C9, trapping it in an intermediate conformation. CLU also binds C5b-7 to prevent
    membrane attachment and binds C5b-8 and C5b-9 to prevent further C9 assembly. At
    physiological levels, CLU can reduce complement cytolysis of nucleated cells by
    10-fold or more.
  directly_involved_in:
    - id: GO:0001971
      label: negative regulation of activation of membrane attack complex
    - id: GO:0045916
      label: negative regulation of complement activation
    - id: GO:1903660
      label: negative regulation of complement-dependent cytotoxicity
  locations:
    - id: GO:0005615
      label: extracellular space
  supported_by:
    - reference_id: PMID:34667172
      supporting_text: >-
        clusterin recognizes and inhibits polymerizing complement proteins by
        binding a negatively charged surface of sMAC.
    - reference_id: PMID:9200695
      supporting_text: >-
        Clusterin inhibited C9 assembly on C5b-8 and C5b-9 and also bound to
        C5b-7 to prevent membrane attachment.
    - reference_id: PMID:9200695
      supporting_text: >-
        the presence of <10% of the circulating clusterin in its
        heterodimeric, active form could reduce the rate of complement
        cytolysis of nucleated cells by 10-fold, and under some conditions
        by 100-fold or more.
references:
- id: GO_REF:0000024
  title: Manual transfer of experimentally-verified manual GO annotation data to orthologs
    by curator judgment of sequence similarity
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000043
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location
    vocabulary mapping, accompanied by conservative changes to GO terms applied by
    UniProt
  findings: []
- id: GO_REF:0000052
  title: Gene Ontology annotation based on curation of immunofluorescence data
  findings: []
- id: GO_REF:0000107
  title: Automatic transfer of experimentally verified manual GO annotation data to
    orthologs using Ensembl Compara
  findings: []
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods
  findings: []
- id: PMID:11123922
  title: Clusterin is an ATP-independent chaperone with very broad substrate specificity
    that stabilizes stressed proteins in a folding-competent state.
  findings: []
- id: PMID:12047389
  title: Suppression of apolipoprotein C-II amyloid formation by the extracellular
    chaperone, clusterin.
  findings: []
- id: PMID:12176985
  title: Mildly acidic pH activates the extracellular molecular chaperone clusterin.
  findings: []
- id: PMID:1585460
  title: 'Clusterin: the intriguing guises of a widely expressed glycoprotein.'
  findings: []
- id: PMID:15857407
  title: Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro.
  findings: []
- id: PMID:15897157
  title: Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic
    neurites in Alzheimer's disease brain.
  findings: []
- id: PMID:16113678
  title: Clusterin inhibits apoptosis by interacting with activated Bax.
  findings: []
- id: PMID:16502470
  title: 'Human colostrum: identification of minor proteins in the aqueous phase by
    proteomics.'
  findings: []
- id: PMID:16548883
  title: Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential
    cellular gene expression in response to enterovirus 71 infection.
  findings: []
- id: PMID:16682745
  title: Isolation and characterization of human apolipoprotein M-containing lipoproteins.
  findings: []
- id: PMID:17043677
  title: 'Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity
    of risk genes and a potential synaptic basis for schizophrenia.'
  findings: []
- id: PMID:17170699
  title: ERp57 is essential for efficient folding of glycoproteins sharing common
    structural domains.
  findings: []
- id: PMID:17412999
  title: The extracellular chaperone clusterin influences amyloid formation and toxicity
    by interacting with prefibrillar structures.
  findings: []
- id: PMID:17567961
  title: Characterization of an eppin protein complex from human semen and spermatozoa.
  findings: []
- id: PMID:17689225
  title: Multiple pathways regulating the anti-apoptotic protein clusterin in breast
    cancer.
  findings: []
- id: PMID:19056867
  title: Large-scale proteomics and phosphoproteomics of urinary exosomes.
  findings: []
- id: PMID:19137541
  title: Clusterin is a short half-life, poly-ubiquitinated protein, which controls
    the fate of prostate cancer cells.
  findings: []
- id: PMID:19199708
  title: Proteomic analysis of human parotid gland exosomes by multidimensional protein
    identification technology (MudPIT).
  findings: []
- id: PMID:19996109
  title: Identification of human plasma proteins as major clients for the extracellular
    chaperone clusterin.
  findings: []
- id: PMID:20005821
  title: Overexpression of low-density lipoprotein receptor in the brain markedly
    inhibits amyloid deposition and increases extracellular A beta clearance.
  findings: []
- id: PMID:20068069
  title: Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB
    activity in prostate cancer cells.
  findings: []
- id: PMID:20195357
  title: A comprehensive resource of interacting protein regions for refining human
    transcription factor networks.
  findings: []
- id: PMID:20551380
  title: Proteomics characterization of extracellular space components in the human
    aorta.
  findings: []
- id: PMID:21397462
  title: Neural hyperactivation in carriers of the Alzheimer's risk variant on the
    clusterin gene.
  findings: []
- id: PMID:21543606
  title: Common Alzheimer's disease risk variant within the CLU gene affects white
    matter microstructure in young adults.
  findings: []
- id: PMID:21803450
  title: The APP intracellular domain (AICD) potentiates ER stress-induced apoptosis.
  findings: []
- id: PMID:22179788
  title: The extracellular chaperone clusterin sequesters oligomeric forms of the
    amyloid-β(1-40) peptide.
  findings: []
- id: PMID:22516433
  title: Proteomic analysis of microvesicles from plasma of healthy donors reveals
    high individual variability.
  findings: []
- id: PMID:22528093
  title: Search for amyloid-binding proteins by affinity chromatography.
  findings: []
- id: PMID:22689054
  title: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial
    localization under ER stress in prostate cancer.
  findings: []
- id: PMID:23106396
  title: Amyloid-β oligomers are sequestered by both intracellular and extracellular
    chaperones.
  findings: []
- id: PMID:23164821
  title: Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of
    the wnt-PCP-JNK pathway.
  findings: []
- id: PMID:23533145
  title: In-depth proteomic analyses of exosomes isolated from expressed prostatic
    secretions in urine.
  findings: []
- id: PMID:2387851
  title: Purification and characterization of apolipoprotein J.
  findings: []
- id: PMID:24446231
  title: Apolipoproteins E and J interfere with amyloid-beta uptake by primary human
    astrocytes and microglia in vitro.
  findings: []
- id: PMID:25051234
  title: Intracellular clusterin interacts with brain isoforms of the bridging integrator
    1 and with the microtubule-associated protein Tau in Alzheimer's disease.
  findings: []
- id: PMID:25402950
  title: The chaperone activity of clusterin is dependent on glycosylation and redox
    environment.
  findings: []
- id: PMID:25451228
  title: PACAP inhibits tumor growth and interferes with clusterin in cervical carcinomas.
  findings: []
- id: PMID:26496610
  title: A human interactome in three quantitative dimensions organized by stoichiometries
    and abundances.
  findings: []
- id: PMID:27068509
  title: 'Extracellular matrix remodelling in response to venous hypertension: proteomics
    of human varicose veins.'
  findings: []
- id: PMID:27477018
  title: TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby
    Facilitates Uptake of Amyloid-Beta by Microglia.
  findings: []
- id: PMID:27559042
  title: Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in
    Human Atrial Fibrillation.
  findings: []
- id: PMID:28887769
  title: α-Synuclein Interacts with Lipoproteins in Plasma.
  findings: []
- id: PMID:30333625
  title: LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour
    infiltration.
  findings: []
- id: PMID:31270237
  title: α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal
    fluid from Parkinson's disease patients.
  findings: []
- id: PMID:31413325
  title: HENA, heterogeneous network-based data set for Alzheimer's disease.
  findings: []
- id: PMID:32814053
  title: Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins
    and Uncovers Widespread Protein Aggregation in Affected Brains.
  findings: []
- id: PMID:34667172
  title: Structural basis of soluble membrane attack complex packaging for clearance.
  findings: []
- id: PMID:8555189
  title: Interaction of transforming growth factor beta receptors with apolipoprotein
    J/clusterin.
  findings: []
- id: PMID:9200695
  title: 'Potent inhibition of terminal complement assembly by clusterin: characterization
    of its impact on C9 polymerization.'
  findings: []
- id: PMID:9228033
  title: Interaction of apolipoprotein J-amyloid beta-peptide complex with low density
    lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological
    accumulation of amyloid beta-peptide.
  findings: []
- id: PMID:9560017
  title: 'Possible neuroprotective role of clusterin in Alzheimer''s disease: a quantitative
    immunocytochemical study.'
  findings: []
- id: Reactome:R-HSA-481007
  title: Exocytosis of platelet alpha granule contents
  findings: []
- id: Reactome:R-HSA-6810643
  title: EPPIN protein complex binds bacteria
  findings: []
- id: Reactome:R-HSA-8852580
  title: Clusterin binds C5b-C7, C8, C9
  findings: []

CLU

Gene Description

Existing Annotations Review

Core Functions

References

📚 Additional Documentation

Deep Research Falcon

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

Target Gene/Protein Identity (from UniProt):

MANDATORY VERIFICATION STEPS:

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

Research Target:

Output

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

Target Gene/Protein Identity (from UniProt):

MANDATORY VERIFICATION STEPS:

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

Research Target:

Citations

📄 View Raw YAML